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Abstract
There are three theories of cancer development analyzed in this review. The first theory is the immunological theory, which states 
that cancer is a result of the immune system failing to detect a cancerous cell in which results in uncontrolled cell growth. The second 
theory is the somatic mutation theory, which states that genetic mutations are a direct cause cancer. The third theory is the stem 
cell theory which states that cancer results from an uncontrolled stem cell. The difference in each theory helps guide a clinician’s 
judgment in how to treat cancer. If a clinician believes in the immunological theory, he/she will view the best route of treatment as 
being by targeting the patient’s immune system. One who believes somatic mutation theory would say that the patient’s genetic 
makeup of the patient is the ideal target for treatment. One who believes in the stem cell theory would say that the only method of 
treatment is to remove the cancer entirely as any residual cancer will return. Based on all the evidence it appears that there is not 
one individual factor that causes cancer development, rather it is a combination of several factors that result in cancer.
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Introduction
In 2013 cancer was reported to affect over 1.6 million 
people (Siegel, et al., 2013). Despite cancer being such a 
highly discussed and researched disease there are many 
things that remain unknown. One of the major debates is 
how cancer develops; there are three major schools of 
thought: the immunological theory, the somatic mutation 
theory, and the stem cell theory.
The immunological theory postulates that cancer de-
velops as a result of the immune system failing to detect 
the cancerous cell. As a result of an undetected cell the 
cancer grows at an uncontrolled and dangerous rate, 
thereby damaging the host. If this is the sole etiology of 
cancer, the immune system could be harnessed to treat 
a person who had developed cancer. For example, a new 
cancer vaccine has been developed for prostate cancer 
patients. This vaccine was developed for two reasons. 
Firstly, prostate cancer cells have several tumor-associat-
ed antigens. Secondly, because the prostate is a nonessen-
tial organ, annihilation of any normal prostate tissue that 
comes about because of the immune response has no 
clinical consequence (Singh & Gulley, 2014). While not all 
cancers have these qualifications that make them suscep-
tible to a vaccine, other forms of immunotherapies are in 
development to try and take advantage of the specifics of 
each cancer to attack it immunologically.
The somatic mutation theory postulates cancer devel-
ops due to a genetic mutation leading to uncontrolled 
growth. A study showed that there are specific gene mu-
tations involved in breast and ovarian cancer. These are 
mutations of either the BRCA1 or BRCA2 gene (Miki, 
et al., 1994). More specifically, it has been shown that 
women with BRCA1 mutation by age 80 have a 72 per-
cent chance of developing breast cancer. While women 
who have the BRCA 2 mutation have a 69 percent chance 
of developing breast cancer (Kuchenbaecker, et al., 2017). 
Treatments based on this theory focuses more on the 
genetics of a person and using that field as a method to 
control or treat the cancer.
The stem cell theory of cancer assumes that cancer de-
velops because there is an uncontrolled stem cell in the 
body. All humans develop from stem cells that multiply 
repeatedly. However, during human development stem 
cells become specialized and eventually stop multiplying. 
This theory of cancer development says that cancer re-
sults from a stem cell that has not “turned off”, resulting 
in uncontrolled growth to the point of being detrimental 
to the host. This theory has many implications. Some cli-
nicians evaluate a cancer treatment based on how much 
it causes the tumor to shrink, but without removing the 
source the tumor will come back very quickly because 
the stem cells are still there. Physicians and Oncologists 
who subscribe to the stem cell theory may treat cancers 
differently than those who believe in the immunological 
theory or the somatic mutation theory.
The significance of each theory is that the information 
regarding how the disease develops can help determine 
the best course of treatment. Evidence seems to point to 
all three of these theories, hence there is no conclusive 
explanation. This review will examine all the evidence in 
order to determine which hypothesis best explains the 
development of cancer.
Methods
The articles and journals used in this review were found 
on PubMed, Ebsco, and Google Scholar. These articles 
were carefully reviewed in order to determine their rel-
evance to the thesis.
Discussion 
Immunological Theory of Cancer
This theory has been associated with three general steps 
the body constantly goes through: elimination, equilibrium 
and escape. The elimination step consists of the immune 
system surveying for all cancerous cells and destroying 
them. However, there are times when tumorous cells re-
main undetected while remaining dormant. This period is 
defined as equilibrium because there are cancerous cells 
in the body, but they are not doing any harm. The final 
step is escape in which the tumor gains dominance over 
the immune system and starts spreading (Lopez, et al., 
2016). This implies that the immune system’s activity and 
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ability to detect cancerous cells is important before the 
cancer gets out of hand.
To try to determine how immune activity affects cancer, 
residents of Japan, mostly above 40, were given a ques-
tionnaire that covered 90 lifestyle factors. People who 
participated in the study gave a peripheral blood sam-
ple after fasting for over 12 hours. A follow-up was per-
formed 11 years later where cancer incidence and death 
totals were gathered. Based on the questionnaire, each 
patient was assessed for cancer risk at one of three levels, 
low, medium, or high. Of the 8552 individuals who took 
the survey, 211 of the 3625 whose blood was sampled 
were identified as cancer cases. A number of the cases 
had to be excluded based on age, blood samples being 
inaccessible, etc. The total number of cases remaining was 
154, 92 men and 62 women. Accounting for age, it was 
found that patients with lower cytotoxicity activity, were 
at a significantly higher risk for developing cancer when 
compared to those with medium or high activity (Imai, 
et al., 2000). This study points to the fact that cytotoxic 
activity can help a person fight cancer, further illustrating 
that the immune system plays a role in cancer treatment.
A specific type of immunotherapy is currently being 
developed in which some of the patient’s T-cells are 
extracted and modified to become chimeric antigen re-
ceptor t-Cells (CAR-T cells). These T-cells are then given 
artificial receptors that are from monoclonal antibodies 
which allow the CAR-T cell to bind to the cancer cells. 
The patient is then treated with chemotherapy to elim-
inate any immunosuppressant activity in the body. The 
CAR-T cells are then injected and are free to attack the 
cancer cells. This treatment sounds perfect but there are 
some complications that arise. Cytokine release syn-
drome (CRS) is a life-threatening complication in which 
the immune system goes into a state of being overly ac-
tive and releases an excessive number of cytokines which 
results in organ toxicity. CRS is manageable but one has 
to be conscious of it when treating a patient with CAR-T. 
Another complication that can arise is CAR-T cell related 
encephalopathy syndrome. This syndrome can result in 
some patients feeling slightly disoriented while others can 
have seizures (Graham, et al., 2018). This methodology of 
cancer treatment is new but is showing great promise. It 
shows that the immune system, under careful monitoring, 
can be harnessed to fight cancers. 
A person’s immune system doesn’t allow cancer cells 
to grow because the natural killer cells, or NK cells de-
tect the cancers and kill them. These cells can identify a 
cancerous cell because they identify which cells are “not 
self” cells by searching for specific receptors that only 
one’s own cells have. Therefore, they find the cancer cell 
and kill it before it starts growing. Although some cancer 
cells go undetected, there are researchers who believe 
that the NK cells can be used to kill an active cancer. 
A new treatment is being studied in which NK cells are 
being combined with the concept of CAR-T cells cre-
ating CAR-NK cells. These cells have several advantages 
over CAR-T cells. Firstly, because NK cells have natural 
receptors for tumors, they have an easier time identi-
fying cancer cells even if the CAR portion of the cell is 
downregulated by the cancer. Secondly, CAR-NK cells do 
not undergo clonal expansion or immune rejection thus 
eliminating the issue of cytokine release syndrome that 
is present with CAR-T cells. Lastly, HLA matching is not 
necessary for CAR-NK cells, which means the graph-ver-
sus-host disease is not an issue when it comes to CAR-
NK cell treatment. Currently there is not enough clinical 
data to fully implement the treatment, however, there are 
studies being performed to help investigate new treat-
ment options. For example, CAR-NK cells are being re-
searched to help determine their ability to fight hemato-
logical and solid tumors, including glioblastoma, prostate 
cancer, and ovarian cancer (Hu, et al., 2019). While this 
treatment is in very early stages it has had great results 
thus far. If this treatment can prove to be effective it can 
have massive implications in the successful treatment of 
cancers because there are few side-effects. 
Dendritic cells are another one of the immune cells 
being used to fight cancer. Dendritic cells function as an 
antigen presenting cell meaning, when it recognizes an 
antigen it alerts the body to produce antibodies. There 
are vaccines that have been proven to work that are pre-
pared by removing a patient’s dendritic cells and “teach-
ing” them to recognize cancer cells, then reinjecting them 
into the patient. Once these dendritic cells are in the 
bloodstream, they can identify the cancer cells and initiate 
a T-Cell response to them. However, there were several 
issues when the dendritic cells were taken from ex vivo 
and put inside patients. Firstly, some patients experienced 
a T-cell response from the injection, but it did not result 
in significant improvement. This alteration in functional-
ity could be a result of the cells being transferred from 
an in vivo environment to an ex vivo environment, then 
returned to in vivo. Another issue with the vaccine is 
that the process is very time-consuming and expensive. 
Lastly, the dendritic cell vaccine is reliant on the patient’s 
immune system and its function. Because of this, in vivo 
preparation of the dendritic cell is still being perfected 
(Le Gall, et al., 2018). This technique can be very helpful to 
cancer patients as often the cancer proliferates because 
the immune system fails to recognize the cancer cells. 
With this treatment the incidents of cancer cells going 
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undetected can be virtually eliminated resulting in the 
body halting the cancer cells growth.
Another form of immunotherapy using dendritic cells 
is called dendritic-cell cytokine induced killer cells (DC-
CIK). In the study, there were several criteria that had to 
be met when determining who was an appropriate can-
didate. The first requirement was that the patients had to 
have advanced cancer (stages 3-5). Secondly, prior to this 
study, patients had to have received first-line treatment, 
including surgery, adjuvant chemotherapy and/or radio-
therapy. The study examined a total of 142 patients with 
histologically confirmed colorectal carcinoma, 71 were 
treated with DC-CIK and 71 were not. Patients were ex-
amined at three separate times, after 1, 3 and 5 years. The 
retrospective study found that patients who were treated 
with DC-CIK had 1,3 and 5-year prolonged progression 
free survival and overall survival versus those who were 
not treated. Minor side-effects were experienced by the 
patients treated with DC-CIK such as mild fever, chills, 
fatigue, while three also developed a headache and one 
developed chest tightness and hypotension. While these 
symptoms cannot be ignored, in the grand scheme of can-
cer treatment these side-effects are very mild. This study 
shows the effectiveness of DC-CIK and its ability to com-
bat colorectal cancer in patients who were treated with 
first-line treatments (Xie, et al., 2017). While this study 
has its limitations because it required first line treatment 
such as surgery, it does provide a powerful tool for pa-
tients who have already gone through or may require first 
line treatments.
The examples listed above all seem to point to the ac-
curacy of the immunological theory of cancer. Perhaps the 
most indicative proof that cancer prevention is a function 
of the immune system is from a study performed several 
years ago which analyzed 12 patients with glioblastoma 
who received regular course of immunotherapy (a den-
dritic cell vaccine). However, a few patients were also 
given a tetanus vaccine. The patients who were given the 
immunotherapy and the tetanus vaccine lived between 
four to eight years after their treatment. The patients who 
received the immunotherapy with another placebo drug 
lived only 11 months following their treatment (Mitchell, 
et al., 2015). The reason the tetanus shot impacts the can-
cer defense is because once given, the body begins to 
create t-cells as a typical reaction to a vaccine. Due to this 
additional t-cell production the body was more prepared 
to fight the cancer as well (Haelle, 2015). While this study 
was performed on a small sample size the results point to 
the same conclusion as the previous studies; it illustrates 
the role the immune system plays when fighting cancer.
These are just some of the treatments in development, 
all working under the assumption of the immunological 
theory of cancer being correct. As it stands, the treat-
ments appear promising and with further research they 
can hopefully be perfected and cancer patients can be 
cured with minimal side effects. All the studies cited point 
to the immunological theory of cancer as a very real and 
likely explanation for cancer development.
Somatic Mutation Theory of Cancer
The somatic mutation theory analyzes the development 
of cancer by looking at genetic factors. The specific ge-
netic variances in squamous cell carcinoma (SCC), adeno-
carcinoma (AC), and adenosquamous carcinoma (ASC), 3 
types of cervical cancers, were analyzed. Three hundred 
and one patients with SCC, AC, or ASC who were all 
treated with radical hysterectomy with lymphadenec-
tomy as their primary treatment were analyzed. All fol-
low-up data was obtained 5 years after primary treat-
ment. One hundred and sixty-six (55%) of the patients 
had SCC, fifty-five (18%) had AC and eighty (27%) had 
ASC. In 103 of the tumors there were 123 somatic muta-
tions detected as roughly 4% of the tumors had multiple 
mutations. The specific mutations were identified for each 
cancer. The PIK3CA was most common in SCC and ASC 
while KRAS was most common in AC. However, in each 
type of cervical cancer there was not only one mutation 
rather there were several mutations found across multi-
ple genes such as, PTEN, PPP2R1A, CTNNB1, CDKN2A, 
FBXW7, FGFR3, NRAS, and HRAS. The KRAS mutation 
is not exclusive to cervical cancers as it has also been 
linked to colorectal, lung and pancreatic cancers. KRAS 
and PIK3CA mutations were both not associated with 
survival; however a clear trend of lower survival rate was 
in patients carrying a PIK3CA mutation (Spaans, et al., 
2015). This study points to a connection between specific 
cancers and mutations that result in them. If an unknown 
cancer’s genetic sequence could be inspected it could give 
a clinician a clear idea of what cancer he/she is dealing 
with and how to properly treat that patient.
Cervical cancers are not the only cancers to have a 
gene associated with them as prostate cancers were also 
found to have specific genes connected to them. These 
genes were identified by looking at a prostate specific 
antigen (PSA) a protease produced in the prostate, as 
well as prostatic acid phosphatase (PAP). By looking at 
these two markers the researchers used the technique of 
guilt-by-association which works based on combinatoric 
measure of association. Forty-thousand different genes 
were analyzed, and each gene was determined to be 
present in prostate cancers if the cDNA corresponding 
to that gene is detected in the library. Upon analysis of all 
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40,000 genes most of them were determined to not be 
related to prostate cancer. However, eight of the genes 
were identified as being associated with it (Walker, et al., 
1999). The extent of their association is difficult to prove 
because correlation is more provable than causality, but 
the association is significant none the less.
Certain genes have been identified as being related to 
breast cancer that is metastatic to bone. One hundred 
and seven breast cancer patients who had developed 
metastasis had their negative-lymph nodes biopsied. 
Sixty-nine of the relapses were categorized as bone 
while 38 were labeled as not bone. Upon analysis, 69 sig-
nificantly unique gene sets were discovered across bone 
and non-bone samples. The five most common genes in 
bone cancer were TFF1, TFF3, AGR2, NAT1, and CRIP1. 
TFF1 was studied in 122 independent breast tumors in 
node-negative patients which indicates it is the most 
prevalent mutation. The researches then attempted to 
predict a correlation between a cancer’s gene sets and 
that cancer spreading to the bone. The samples were di-
vided into a test set and a training set. Five hundred and 
eighty-eight genes were selected and subjected to PAM 
analysis. A 31-gene predictor was selected after 10-fold 
cross validation that could identify relapse to the bone 
at 100% sensitivity and 50% specificity. The predictor 
showed 79.3% positive predictive value and TIFF1 was 
present in the gene list. Two random gene sets of 50 
and 100 genes were analyzed to test the validity of this 
method. Twenty-nine of the 50 random genes showed 
100% sensitivity and of these 29, the average specificity 
is 13.2% which indicates that the 50% specificity found 
by the earlier gene list is significantly higher than a ran-
dom gene set. Based on SAM sets the researchers de-
termined that the most common genes associated with 
the cancer metastases were TFF1 and TFF3. TFF3 was 
also found as overexpressed in some metastatic pros-
tate cancers, while TFF1 was found to induce cellular 
invasion of kidney and colon cancer (Smid, et al., 2006). 
This further proves that there is a strong tie between 
cancer and genetics. 
In high-grade serous ovarian cancers, triple-nega-
tive breast cancers, esophageal cancers, small-cell lung 
cancers, and squamous cell lung cancers, the p53 gene 
is mutated in at least 80% of patients’ tissue samples 
(Duffy, et al., 2017). P53 has two major functions in the 
cell cycle thereby linking it to cancer. P53 serves as a 
cell cycle regulator, so if the cell no longer needs to go 
through the cell cycle p53 will stop the cycle. Another 
function is that a normal p53 protein stops a cell that 
has already grown too much and is technically cancer-
ous by initiating apoptosis for that cell (Zilfou & Lowe, 
2009). When p53 is mutated the cells experience un-
controlled growth either because its cell cycle is not 
arrested or because a cell that is already out of control 
is not sent to apoptosis. 
Because of the prevalence of mutant p53 in cancer 
patient’s researchers have looked into a way to stabilize 
these mutant forms of p53. They analyzed mice whose 
p53 proteins were removed by one of several methods. 
One method was that the mice were injected with an 
anti-p53 antibody in which the p53 proteins in the mice 
underwent ubiquitination. Another method was by using 
an adenovirus, either Ad/GFP (green fluorescent pro-
tein) or Ad/His. They found that when these mice were 
exposed to a drug called CP-31398, not only was the 
DNA binding activity of mutant p53 restored thus al-
lowing cell cycle arrest and induction of apoptosis, but it 
can also increase the steady-state levels of wild type p53 
(Takimoto, et al., 2002). Another study showed that CP-
31398 also inhibited the ubiquitination of p53 proteins. 
A non-small-cell lung carcinoma cell, H460, was exposed 
to CP-31398 for an hour, it was then exposed to ALLN, 
a proteasome inhibitor, for four hours. Another group 
of cells was exposed to ALLN alone and both were 
analyzed. The results showed that the cells that had 
just been exposed to ALLN showed a typical pattern 
of ubiquitinated p53 ladders. However, the cells treated 
with a mixture of CP-31398 and ALLN or just CP-31398 
alone showed no ubiquitinated p53 ladders (Wang, et al., 
2003). These two applications of CP-31398 demonstrate 
how useful it can be in preventing cancer because of the 
prevalence of p53 mutations in cancer patients.
Another protein that has been a target for treatment 
is p21, a cell cycle inhibitor, cell proliferation effector, 
and apoptosis regulator. As with p53, many cancer 
patients have been shown to have their p21 proteins 
mutated. Gene editing techniques such as CRISPR, 
TALEN’s, ZFN’s and rAAV have all been used to change 
p21 expression and have been shown to suppress tu-
morigenesis phenotypes and reduce drug resistance. 
Several chemical treatments target p21 as well. Histone 
deacetylase inhibitors help increase the expression of 
p21. Trichostatin A, PAC-320, and HDAC inhibitor com-
bined with bortezomib or doxorubicin, have shown to 
enhance p21 expression in pancreatic cancer, prostate 
cancer and ovarian cancer respectively (Shamloo & 
Usluer, 2019). All these treatments targeting p21 can 
have massive ramifications because of p21’s effect on 
cell cycle arrest.
Specific genetic mutations are directly linked to spe-
cific cancers which seemingly indicates that certain 
genetic mutations are linked to specific cancers, thus 
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legitimizing the claim that cancers have genetic compo-
nents to them.
Stem Cell Theory of Cancer
This theory assumes that cancer is a result of a stem cell 
that is unregulated and grows uncontrollably. Because of 
several unique characteristics of prostate cancer such as 
histological heterogeneity, metastatic growth, drug resis-
tance, and distant relapse after effective primary treat-
ment, the stem cell theory was proposed as a possible 
explanation for prostate cancer. It was tested by search-
ing for stem cell markers in the cancerous tissue. While 
there is not one marker specific for prostate cancer stem 
cells, there are a few methods used to help identify the 
stem cells such as: β1 integrins, CD133, CD44, stem cell 
antigen 1 and the ABCG2-associated drug-resistance 
proteins. β1 is a marker for “stemness” because it is es-
sential for sustaining a functional stem cell population and 
establishing asymmetric division. β1 is also important to 
stem cell maintenance. CD133 is a marker because it is 
generally found in progenitor stem cells, linking it to a 
stem cell. CD133+ prostate cells use their stem cell like 
features developing prostatic-like acini in immunocom-
promised male mice. CD44 is a cell surface protein in-
volved in cell-to-cell interaction, migration and adhesion. 
Stem cell antigen 1 is expressed in the tissue of several 
stem and progenitor stem cells including, cardiac mam-
mary, hematopoietic, testicular, integumentary and mus-
cular. These markers have been found in prostate cancers 
thus giving credence to this theory (Tu & Lin, 2012). It was 
also found that cancers that had CD44 were much more 
tumorigenic and metastatic than cancers without CD44. 
This further proves that these markers have relevance 
when it comes to identifying cancers (Patrawala, et al., 
2007). These two studies indicate these classic stem cell 
markers are present in cancers and furthermore they 
enhance the growth and metastasis of the cancer when 
they’re present.
Breast cancer was also examined for these markers. 
The researchers analyzed surgically removed breast can-
cer tissue in 47 cases of only invasive duct carcinoma 
(IDC), 135 cases of IDC with ductal carcinoma in situ 
(DCIS), 35 cases of DCIS with microinvasion, 58 cases 
of pure DCIS and 73 cases of IDCs with adjacent DCIS. 
Four major subtypes of breast cancer were looked for in 
this analysis: luminal A, luminal B, HER2+, and basal-like. 
Each subtype was defined based on certain characters, 
luminal A (ER+ and/or PR+, HER2−), luminal B (ER+ and/
or PR+, HER2+), HER2+ (ER−, PR−, HER2+), basal-like 
(ER−, PR−, HER2−, basal cytokeratin+, and EGFR+/−). 
CD44+/CD24− and CD44−/CD24+ cells were found by 
way of double immunohistochemistry. It was found that 
luminal A tumors were least common in DCIS with mi-
croinvasion, luminal B tumors were least common in IDC 
alone, and basal-like tumors were least common in pure 
DCIS groups. CD44, CD24 and ALDH-1 markers were 
analyzed in normal breast tissue they were then com-
pared to cancerous breast tissue. In normal breast tissue 
CD44 was localized to the basal, myoepithelial, and a sub-
set of luminal epithelial cells. CD24 was found on the 
apical membranes of luminal cells while ALDH1 was het-
erogeneously expressed in luminal and basal cells. CD44 
was expressed in 57% of IDC only samples, 59% IDCs 
with DCIS samples, 62% of DCIS with microinvasion sam-
ples, and 85% of DCIS samples. CD24 was not nearly as 
prevalent as it was present in 24% IDC only tumors, 38% 
of IDC with DCIS tumors, 59% of DCIS with microin-
vasion tumors and 62% of DICS tumors. While ALDH1 
was not commonlyf ound in any of the four subtypes, it 
was far more common in IDC alone and IDC with DCIS 
than the other two subtypes of DCIS with microinvasion 
and DCIS alone, 9%, 6%, 3%, 3%, respectively (Park, et al., 
2010). These figures point to the fact that there is an as-
sociation between stem cell markers and breast cancer, 
further legitimizing the stem cell cancer theory.
Head and neck squamous cell carcinoma (HNSCC) 
such as cancers of the oral cavity, pharynx, larynx, pa-
ranasal sinuses, nasal cavity, salivary glands, or head and 
neck lymph nodes were studied to aid in further proving 
stem cell theory. Multi-modality therapy including surgery, 
has been emphasized as the method of treatment, yet 
the five-year survival rate for HNSCC is 0-40%, with no 
significant improvements in the past 30 years. A study 
was done using tissue specimens of cervical lymph nodes, 
primary tumors, and normal mucosa of patients under-
going surgical treatment of squamous cell carcinomas of 
multiple sites in the upper aerodigestive tract. A total of 
82 primary tumors and 24 metastatic lymph nodes from 
82 patients were analyzed. Several variants of CD44 were 
tested for: CD44s, CD44 v3, CD44 v6, and CD44 v10. It 
was found that a majority of the cells from both the prima-
ry tumors and lymph nodes presented strong expression 
of all 4 variants. CD44v3, v6 and v10 had a higher propor-
tion of being strongly expressed in lymph nodes than they 
did in primary tumors. Strong expression of CD44 v3 in 
primary tumors was also proven to have association with 
lymph node metastasis. Strong expression of CD44 v10 
in primary tumors showed association with radiation fail-
ure and with distant metastasis. The expression of CD44 
v6 was significantly associated with perineural invasion. 
Next, an analysis was performed with regard to disease 
free survival and overall survival. Overall tumor stage was 
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found to be correlated with shorter disease-free interval. 
Non-oropharyngeal primary site, positive cervical lymph 
nodes, distant metastasis, CD44 v6 and CD44 v10 ex-
pression, in primary tumors, were all significantly asso-
ciated with worse disease-free survival. Prior radiation 
therapy, expression of CD44s and, both the standard and 
variant form of CD44, in metastatic lymph nodes, were 
all not significantly associated with disease free interval 
or overall survival. Expression of CD44s, v3, v6, v10 were 
all associated with advanced primary tumor stage, treat-
ment failure, reduced disease-free interval, and metastasis 
(Wang, et al., 2009). These stem cell markers are all indic-
ative of very poor prognosis in HNCSS patients.
Researchers analyzed two cell groups of one patient 
who suffered from colon cancer, the primary tumor cell 
(SW480) and the metastatic lymph node (SW620). These 
cells were analyzed by phase contrast microscopy and 
were revealed as having two separate morphologies. 
SW480 was shown to have 80% of its fully adhered cells 
to be irregularly shaped, while 20% were spindle-like. 
SW620 displayed a more mixed morphology amongst 
its cells with 53% of its adhered cells as elongated spin-
dle-shaped and the remaining 47% were either more 
rounded spindles or irregularly shaped. The two cell lines 
displayed similar measures of cell growth normal to their 
respective cell line’s. When measuring migratory poten-
tial, SW480 cells were found to have a significantly higher 
migratory potential than SW620 cells. Several stem cell 
markers were analyzed in each cell line including, CD338, 
CD44, CD133, CD24 and CD49f. SW620 revealed a 
50.6% proportion of CD44+/CD133+ cells and SW480 
displayed 28.6%. But the proportion of CD44+/CD133- 
cells favored SW480 over SW620 with 54.3% and 20.7% 
respectively. CD44+/CD24- cells were abundant in both 
cell lines with SW480 having 62.7% and SW620 having 
75.3%. The presence of CD49f+/CD338- was the highest 
with SW480 and SW620 expressing it at 98 and 99%. 
Because of the prevalence in both groups of cell lines, 
it was deemed that these stem cell markers were not 
significant enough to differentiate between SW480 and 
SW620 in vitro cells (Slater, et al., 2018). While utilizing 
stem cells did not prove to be a method to differentiate 
between colon and metastatic tumors, it does prove the 
presence of these stem cell markers in cancers.
Utilizing the stem cell theory, researchers have devel-
oped a new treatment for leukemic stem cells (LSCs) 
that reside mainly in the bone marrow. Chronic myeloid 
leukemia (CML) and acute myeloid leukemia (AML) 
were analyzed. CML is categorized as a clonal hemato-
poietic stem cell that is caused by a translocation of a 
fusion of two parts of two separate chromosomes, ALB1 
(chromosome 9) and BCR (chromosome 22). AML is the 
most common form of adult leukemia and is categorized 
by infiltration of leukemic cells into the bone marrow 
and blood. The current therapies have an overall surviv-
al of roughly 40% in patients under 60 and decline by 
5-15% in older patients. AML is very difficult to treat be-
cause of how drug resistant the disease is. While CML 
and AML are both considered to have leukemia stem 
cells, the environment of the bone marrow that contains 
many growth factors only expedites the growth process. 
The markers used to indicate CML LSCs are CD25 IL-1 
and CD26 have been suggested as markers that are 
specific to this disease as opposed to other stem cells. 
CML LSCs vary from ALM LSC in that CML LSCs are 
defined as CD34+/CD38- fraction whereas AML LSCs 
are composed of heterogenous populations and aside 
from CD34+/CD38- they also are in CD34+/CD38+ and 
CD34-. The treatment method for these cancers is to 
disconnect the cancer from the growth promoting bone 
marrow environment thus making them more sensitive 
to conventional therapy. There are several compounds 
being studied as possible ways to disconnect the AML or 
CML from the bone marrow such as: BL-8040, CAR-LMC, 
Ruxolitinib, AMD3100, TH-302, Aflibercept, AS101, AMG 
386, SRF231, TTI-621, CC90002 Hu5F9-G4, LY3039478. 
These compounds all have different target cites but are 
all designed to disconnect the cancer from the growth 
advances provided by the bone marrow. IL-1RAP has also 
been shown as a good marker to target CML LSCs in a 
more selective manor because of its specific expression 
in CML LSCs. Inducing apoptosis is a common approach 
to AML treatment (Houshmand, et al., 2019).
Antibodies targeting IL-1RAP were thought as a pos-
sible way to treat CML LSCs without harming normal 
stem cells. The antibodies mAb81.2 and mAb3F8 were 
used and generated by the hybridoma technique. The cell 
cultures were bone marrow and peripheral blood from 
healthy volunteers and CML patients. The CML cells were 
stimulated with IL-1B, IL-33, IL-36 or SCF. IL-1B and SCF 
resulted in a slight expansion of CD34- CML progeni-
tor cells. The stimulation as a result IL-1B on CD34+/
CD38- cells resulted in a 30-fold increase in cell numbers 
as opposed to normal cells that responded weakly. In vivo 
samples were studied to show the therapeutic effects of 
IL-1RAP antibodies. Mice who expressed IL-1RAP were 
treated with mAb81.2 which resulted in prolonged sur-
vival. The treatment proved to be very effective to the 
point where the treatment was stopped after 45 days, yet 
the mice survived an additional 12 days with 2 mice living 
until day 101. Several of these mice displayed significantly 
lower bone marrow leukemic cell levels compared with 
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control mice. These antibodies are effective because they 
block the signals of IL-1 as well as initiating effector cells 
to kill tumor cells. This treatment does not affect normal 
human stem cells because normal stem cells do not ex-
press IL1RAP (Agerstam, et al., 2016). This study shows 
tremendous promise of utilizing the stem cell theory’s 
principles as a route of treatment.
Conclusion
While there is a lot of data supporting each understand-
ing of cancer development, there seems to be one correct 
approach to cancer; it appears that the correct answer is 
not one of these three theories rather a combination 
of the immunological theory and the somatic mutation 
theory. The immunological theory seems almost entirely 
correct based on the utilization of CAR-T and CAR-NK, 
DC-CIK as successful methods of treatment as well as the 
case-report of a tetanus shot proving to increase cancer 
prognosis. The issue with solely using the immunological 
theory is that it better explains the treatment of cancer 
and what should happen to prevent cancers from devel-
oping (NK cells) but it does not address why a cancer 
cell forms. Rather it only states once a cancer forms the 
immune system should prevent it from developing. The 
somatic mutation theory explains why a cancer starts 
to develop but the immunological theory explains how 
to prevent it from continual growth. These theories, in 
tandem, are the best explanation of cancer development.
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Dentistry is a continuously evolving field with new materials and technologies constantly innovated. The oral cavity presents a 
harsh environment in which restorative and implant materials must be able to withstand. Aside for meeting the appropriate physi-
cal and chemical standards, it is important that dental materials be biocompatible. Biocompatibility relates to the material’s ability 
to function in the body without causing harm to living tissue. It is necessary to analyze the materials being used and determine 
whether they interact with the body in a detrimental manner. This will enable dental professionals to choose the most beneficial 
material to utilize for patient safety and overall health.
The Biocompatibility of Various Dental Materials
Amy Noble
Amy Noble graduated with a Bachelor of Science degree in Biology in January 2020 and is currently enrolled in 
the Touro College of Dentistry
Introduction
Tooth decay is a prevalent health issue faced by the gen-
eral population. In fact, according to the National Institute 
of Dental and Craniofacial Research, 92% of adults be-
tween the ages of 20 to 64 have had dental caries in their 
permanent teeth. Our teeth are comprised of four tissue 
layers. Enamel, dentin, and cementum, are the three outer 
layers of hard tissue, which surround the soft pulp tissue 
layer containing nerves, blood vessels, and connective 
tissue. Cavities form when bacteria and food debris com-
bine with saliva to create a layer of plaque which sticks to 
the teeth. Plaque contains acid which begins to dissolve 
the enamel of our teeth and cause dental caries when the 
plaque layer is not removed. Tooth decay is an active pro-
cess that will continue to progress through the multiple 
layers of tooth structure if left untreated. 
There are various restorative treatment options that 
exist to treat damaged teeth. Choosing the right material 
is important considering that our teeth are exposed 
to constant wear and tear. At times, teeth can regress 
beyond the ability to be repaired. Fortunately, implant 
replacement has become a viable option, with the use of 
various metals and synthetic materials. Materials must be 
durable as well as viable in an aqueous environment. 
Amalgam and composite resin fillings are the two most 
common materials used to fill cavities. Amalgam is com-
posed of liquid mercury combined with an alloy made of 
silver, tin, and copper solid particles. Dental amalgam is in-
expensive and easy to work with, making it a convenient 
option for dental restorations. Composite resin material 
is made of a ceramic and plastic compound which makes 
it a good tooth colored alternative. At present, titanium is 
the gold standard in implant dentistry. On the other hand, 
there are other materials being explored in cases where 
titanium may present issues of biocompatibility. 
However, when introducing any foreign substances 
into the human body there is always the risk of detrimen-
tal side effects. Some of the components in these filling 
materials can be cause for concern. For example, the use 
of dental amalgam gives rise to mercury vapor exposure. 
In contrast, composite resin fillings may release bisphenol 
A (BPA) and other monomers into the blood stream. 
Both of these restorative materials contain components 
that can have toxic effects on the human organ systems 
and may be hazardous to our health. 
This review will explore the biocompatibility of these 
restorative and replacement materials and analyze the 
possible long-term side effects that they may have on 
one’s overall health. 
Material and Methods
Research was done by studying original research articles 
and scientific papers found on the Touro College online 
library. Specific scientific databases such as ProQuest and 
EBSCO were utilized, and additional information was ob-
tained by analyzing articles found. 
Discussion: Amalgam
Amalgam fillings, also known as silver fillings because of 
their appearance, are one of the oldest used materials in 
restoring decayed teeth. The low cost, ease of placement, 
and durability make amalgam a great option for dental 
fillings. The material is composed of a powdered alloy of 
silver, tin, copper, zinc, and elemental mercury. Directly 
prior to placement, the components are mixed together 
to activate the filling, which makes it soft and pliable for 
easy placement. It is not necessary for the area receiving 
the amalgam to be completely dry, which makes it a good 
choice in locations that are difficult to isolate from saliva. 
With a composition of about 50% elemental mercury 
by weight, there is a concern regarding the toxicity of 
this material. Interestingly, although it has been in use 
for over one hundred years, dental amalgam has not 
undergone the regulatory proof of safety testing required 
of materials intended to be implanted into the human 
body. Therefore, the question remains as to whether the 
components of this material interact with the body in a 
harmful way. 
Inhaled mercury vapor can cause damage to the brain, 
kidneys, and other major organs. After being inhaled into 
the lungs, it is transported through the blood to the 
brain. Liquid mercury is dangerous because it vaporizes 
at room temperature and can easily be inhaled. Although 
amalgam fillings harden rapidly and remain in the solid 
metallic form once placed in the tooth, studies have 
shown elevated levels of mercury in the blood and urine 
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following restorative procedures utilizing amalgam as the 
material of choice (Nicolae, et. al., 2013). This indicates 
that there is some inhalation of mercury vapor prior to 
the material hardening. 
Aside for the inhalation upon initial placement of 
amalgam fillings, low levels of elemental mercury vapor 
are released when amalgam filled teeth are subject to 
stress due to chewing, brushing, bruxism, and ingesting 
hot foods. Measuring urinary mercury concentration is 
a good method of analyzing the long-term influence due 
to the presence of such fillings. A comprehensive study 
utilizing this method of analysis was conducted within 
the Canadian population (Nicolae et. al., 2013). Factors 
considered included age, gender, and the number of filled 
surfaces. Of all groups, 95.42 – 98.23 % of participants 
had mean urinary mercury levels below 5 ug Hg/L. When 
compared to a normal range of up to 20 ug Hg/L, these 
concentrations do not seem to be cause for concern. 
Overall, less than 5% of participants had mean urinary 
mercury levels that qualified for possible reevaluation. 
Although amalgam seems safe to use in the mouth, 
there is a potential concern for dental professionals who 
experience daily exposure (Jamil et. al., 2016). A recent 
study demonstrated that people working in the dental 
environment who handle amalgam do have increased 
levels of mercury concentrations in their blood. Mean 
concentrations in both dentists and dental assistants 
were above the normal range of 20 ug/ L, with dentists 
at a mean concentration if 29.835 ug/L and assistants at 
22.798 ug/L.  Also, the study demonstrated a correlation 
between dentists who had more years of experience 
with greater increases in mercury levels in the blood. This 
seems to indicate that there is somewhat of a cumulative 
effect. In addition, working longer shifts was associated 
with higher concentration of mercury in the blood (Jamil 
et. al., 2016). 
With the phase down of amalgam fillings, this should 
be less of a concern. Although dental professionals are 
still utilizing amalgam fillings sporadically, other fillings 
have become more popular. This would suggest that the 
occasional use of amalgam for a filling would not contrib-
ute significantly to an increase in mercury concentration 
in the blood. A possible method of preventing increased 
mercury concentration in the blood of dentists would 
be to implement appropriate regulatory safety measures, 
such as wearing protective masks and gloves. 
The New Zealand children’s amalgam trial (CAT) was 
a study that explored the impact of exposure to mercury 
from amalgam fillings on neuropsychological and renal 
function, focusing specifically on children as the popula-
tion (Bellinger et. al., 2007). The randomized sample size 
was 534 participants, and at baseline there were no amal-
gam restorations present. Over a five year period, there 
was an average of 15 tooth surfaces restored per patient. 
When measured, the group with amalgam as the dental 
material of choice for restorations had significantly higher 
mercury levels in the blood. However, this did not trans-
late into impaired neuropsychological and renal function. 
A possible explanation can be that this was a study 
conducted with children as the participants. Increased 
mercury levels may have a cumulative effect. Perhaps 
adverse health effects would not appear until later in life. 
For this reason, it would be appropriate to take precau-
tions with pregnant women and children who are still 
developing. In fact, studies have shown that mercury easily 
crosses the placenta as well as the blood brain barrier 
(Magos, Clarkson, 2006). 
Furthermore, with the increase of exposure to elec-
tromagnetic fields due to common sources such as Wi Fi 
routers, laptops, mobile devices, and MRI, there is a new 
aspect to consider regarding the safety of amalgam fillings. 
Although fillings have been shown to release mercury 
vapor even after being placed, countless studies have 
demonstrated that the release is generally at extremely 
low dosages which is not a cause for concern. However, 
the presence of electromagnetic fields increases the re-
lease of toxic mercury from amalgam fillings (Mortazavi 
et. al., 2015). This creates an extra concern specifically 
for pregnant women who have amalgam fillings.  Mercury 
circulating in the blood easily crosses the blood brain 
barrier, as well as the placenta (Magos, Clarkson, 2006). 
An in vitro study was conducted to examine this new 
concern regarding amalgam toxicity. The goal was to test 
the effect of electromagnetic fields on the release of 
mercury from amalgam fillings. The study included twenty 
healthy premolar teeth that had been removed for ortho-
dontic treatment. The teeth were all prepared to be filled 
in an identical way, by the same dentist. They were then 
restored using amalgam and placed into artificial saliva. 
The control group was stored in an environment away 
from any exposure to electromagnetic fields. The experi-
mental group was placed in the vicinity of a Wi-Fi router 
that was actively exchanging data with a nearby laptop. 
Following electromagnetic exposure, the mean con-
centration of mercury in the artificial saliva was tested. 
The concentration in the saliva containing teeth that 
had been exposed was .056 mg/L, in contrast to the 
unexposed control group that had a mean concentration 
of .026 mg/L. The results clearly indicate that the radiofre-
quency radiation given off via Wi-Fi devices can increase 
mercury release from amalgam fillings (Paknahad et. al., 
2016). Being that it is one of the first studies exploring 
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this concern, it would be necessary to conduct further 
studies before stating that it is a concern. 
There are people who remain concerned with the 
presence of amalgam fillings, and even desire to have such 
fillings removed. However, removing such filling for no 
other dental related reason may cause more harm than 
benefit. This is because drilling old fillings would cause the 
release of additional mercury vapor and would cause the 
patient to unnecessarily inhale additional mercury vapor. 
A study was conducted to determine whether the 
removal of amalgam fillings alleviated symptoms of health 
issues attributed to the presence of mercury. The pres-
ence of these symptoms had no other medical or psy-
chological explanation. The study consisted of 90 patients 
between the ages of 20 -50 who reported 10 symptoms 
of health problems that were suspected to be due to 
amalgam. There were three groups; a group whose fillings 
were removed, another group that underwent biological 
detoxification therapy in addition to filling removal, and a 
final group that did not remove fillings but participated in 
a lifestyle improvement regimen. 
To begin, baseline mercury levels were taken to be 
compared to the end results. In addition, all participants 
were given a 50 item symptom list to complete, ranking 
each item 0-3, and combining the scores for a weighted 
sum score. The amalgam fillings were removed and re-
placed by other materials over a period of time, in the 
two groups chosen to have fillings removed. The fillings 
were removed one quadrant at a time with a wait period 
of one week between treatments. The group undergoing 
biological detoxification therapy, took vitamin supple-
ments in addition to filling removal. 
Mercury levels measured in the blood and urine were 
significantly lower in the two groups to have their fillings 
removed as compared to the group that did not have any 
fillings removed. The 50 item symptom list was completed 
by all participants at 6, 12, and 18 months following initial 
treatment.  All groups showed a decrease in the main 
complaint sum score, with a slightly larger decrease for 
the two groups to have the amalgam removed (Melchart 
et. al., 2008). 
It is difficult to demonstrate a correlation between 
the amalgam fillings and attributed symptoms of health 
issues. The results of this study indicate that although the 
presence of amalgam fillings increase levels of mercury in 
the blood, they are not the source of any known adverse 
health effects.  Therefore, it would be unwise to have such 
fillings removed if not deemed necessary for improved 
oral health.
Amalgam continues to be used as a great option in 
restorative dentistry. Research thus far has demonstrated 
that amalgam remains a biocompatible material that does 
not cause harm to the human body. Although it does 
increase mercury levels, the concentration is too slight to 
be considered significant. Specifically in the case of poste-
rior teeth where aesthetics are not as much of a concern, 
it may actually be a preferable option. This is because it 
can withstand stronger chewing forces. 
On the other hand, being that it is not the only source 
of environmental exposure to mercury, there is a move-
ment to utilize other available materials in cases where 
it will not compromise treatment outcomes. In addition, 
appropriate protective safety measures should be taken 
to protect dental personnel who are more frequently 
exposed. Thus far the use of amalgam has not been linked 
with adverse health effects. Further studies are necessary 
to determine the association between electromagnetic 
fields and the release of mercury from amalgam fillings. 
Resin-Based Composite
Resin-based composites (RBC) are a more recent inno-
vation in restorative dentistry. These fillings are made 
up of a mixture of ceramics and plastics.  RBC are often 
preferred, as they match the color of teeth and have a 
nicer esthetic appearance. However, these fillings may 
contain Bisphenol A (BPA), and other components that 
are toxic when released as monomers. BPA is used to 
synthesize various monomers that make up RBC, such as 
BPA–glycidyl methacrylate (BisGMA). Often, residues of 
BPA remain in the process of synthesizing RBC material 
(Luo, et. al., 2016). 
BPA is in the class of xenoestrogens. Xenoestrogens 
are chemicals that are known to be endocrine disrupters, 
and they inhibit normal hormone function (Zimmerman-
Downs, et. al., 2010). BPA is thought to be related to 
various diseases including diabetes, heart disease, obe-
sity, as well as immune and reproductive disorders. The 
European Food Safety Authority has established a tolera-
ble daily intake of no more than 4 ug/ kg of body weight 
per day.
Most of the BPA that humans are exposed to comes 
from people’s diet. Upon entering the body and passing 
through the digestive tract, BPA passes through the liver 
and is detoxified. The liver converts most of the BPA 
from its free unconjugated form to a non-estrogenic 
conjugated form. This prevents it from interacting with 
the body in a harmful way. However, research has shown 
that even after fasting, the concentration of unconjugated 
BPA is higher than predicted (Stalhut, et. al., 2009). This 
demonstrates that it is not metabolized immediately, but 
remains in the body for some time. 
In addition, BPA entering the body via the skin, as well 
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as oral or respiratory mucosa, bypasses initial liver me-
tabolism and circulates in the blood for a longer period 
of time in its unconjugated form. This presents a concern 
specifically when dealing with dental treatment. Materials 
that contain BPA or precursor molecules may leech these 
harmful chemicals into saliva and enter the blood stream. 
Various studies have been conducted both in vitro and 
clinically to determine if the use of these materials in 
dental fillings negatively impacts overall health. 
A study was done to test whether the presence of 
composite fillings was related to increased levels of BPA 
in saliva. The study consisted of 40 volunteer participants 
between the ages of 20 -35 who were patients of dental 
clinics in Bergen, Norway. All of the participants under-
went a comprehensive dental evaluation and were given a 
score between 1 and 3 based on the number of existing 
composite restorations. The experimental group consist-
ed of twenty individuals with at least 6 tooth surfaces 
restored with RBC. The control group was made up of 
twenty people without any composite fillings. Five ml. of 
saliva was collected from all participants and stored in 
BPA free test tubes. 
The collected saliva samples were then tested using a 
liquid chromatography technique. Both the unconjugated, 
as well as total BPA concentrations were measured. In the 
experimental group, eight out of the twenty were found 
to have saliva BPA concentrations above the detectable 
limit of .1 ng/mL. Within the control group there were 
3 participants with concentrations above the detectable 
limit. However, in both cases the concentration was still 
very low (Berge et.al. 2017). This study seems to indicate 
that the presence of RBC alone is not the cause of BPA 
related health concerns. However, there are factors that 
limit this study (i.e. sample size), and further studies are 
necessary to explore this issue. 
An in vitro study was done to test cytotoxicity of resin 
based composite fillings. The harmful effects of these ma-
terials are decreased once placed in dentin, but not com-
pletely eliminated. The release of toxic materials from 
composite materials was previously thought to be a con-
cern only within the first 24 hours following placement. 
Therefore, many studies were designed focusing on the 
potential harm caused only following initial placement. 
This study aimed to test whether or not there is a long-
term release of toxic materials into our body systems. 
Various common composite materials used were pre-
pared in lab dishes and light cured. The specimens were 
then split into three groups; a control group stored as is, 
a second group aged in lab simulated artificial saliva for 
seven days, and a final group also in saliva for 14 days. 
High- pressure liquid chromatography was used to test 
the components of the artificial saliva for presence of 
harmful substances. The results indicated that although 
the release of these substances decreased after 24 hours, 
a cytotoxic effect on cell activity remained even after a 
two week wait period. This study suggests that further 
clinical testing should be designed with a focus over more 
than a 24 hour release period (Al-Hiyasat, et. al., 2005).  
Composite fillings require a bonding agent, which as-
sists the material in adhering to a prepared tooth struc-
ture. 2-hydroxyethyl methacrylate (HEMA) and BPA are 
components contained in bonding agents that can be 
cytotoxic to human gingival fibroblast (HGF). In a recent 
study, cell cultures were grown using healthy human gingi-
val tissue to test various bonding agents. It demonstrated 
that both HEMA and BPA negatively impact cell viability 
of HGF although they exhibit different patterns of cyto-
toxicity. Although the cytotoxic effect was reduced after 
24 hours, this is a matter of concern that requires further 
study being that all of the bonding agents displayed some 
level of cytotoxic activity on HGF (Reddy, 2017). The 
study was important as it displayed that different bonding 
systems had varying effects, with some being more harm-
ful to HGF cells than others. Until an improved method 
is developed it is necessary to evaluate and choose a low 
risk bonding agent. 
When using RBC, the technique for placing them var-
ies. Composite fillings are soft and pliable for placement, 
and then cured with a blue light to harden the material 
into a strong durable filling. These fillings are available in 
flowable, paste like, and bulk consistencies. Interestingly, 
studies have demonstrated that the method used for 
placement is related to the degree of release of toxic 
monomers and BPA into circulation (Pongprueksa et. 
al, 2015). They are generally placed in 2 mm increments 
to ensure adequate polymerization and reduce polym-
erization shrinkage stress. For deep fillings, a bulk fill 
composite has been developed that can be cured in 4 
mm increments. Fillings that are not cured completely 
can result in monomers leeching into the oral cavity and 
reaching pulp tissue. 
The efficiency of polymerization is important, as com-
posites with low degree of polymerization release more 
monomers. The degree of conversion (DC) can be mea-
sured by means of spectroscopy. A study was conducted 
with the objective of determining how the DC varied 
based on the consistency of RBC used, and how it re-
lated to monomer elution. It also analyzed the change in 
release of monomers over time. Cylindrical samples were 
prepared using three types of RBC. They were filled in 
two 2 mm thick layers or one 4 mm bulk layer, and light 
cured to polymerize. 
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For all of the composites, there was a mean DC be-
tween 60 and 70%. There was a significant difference in 
total monomer release depending on the composite type. 
The paste-like composite showed the lowest monomer 
elution. This can be attributed to the fact that it has a 
lower resin content to begin with. In addition, it is admin-
istered in layers allowing for better curing. Four mm bulk 
placement resulted in a lower DC and higher monomer 
release. Evidently, curing through a thicker layer of com-
posite material is not as effective in complete polymeriza-
tion of the material. This results in greater release of toxic 
monomers. In addition, fillings that are not fully cured can 
lead to gaps forming between the filling and the tooth 
structure. This can lead to secondary caries. 
The study demonstrated that monomer release is de-
pendent on both the composite type and the method of 
application. Therefore, the usage of paste-like composite 
and a layered placement technique seem to be the prefera-
ble method of treatment. This would limit the unnecessary 
release of monomers and BPA. In addition, it was found 
that rinsing and scrubbing fillings following placement fur-
ther reduces the escape of harmful monomers. This extra 
step should be implemented for a safer procedure. 
During the placement of RBC, composite dust par-
ticles are released into the surrounding environment. 
These nano sized particles become airborne and upon 
inhalation can travel deep into the lungs. This may present 
a concern for patients, and for dental personnel who per-
form multiple such procedures daily. RBC are composed 
of methacrylate monomers, which have been shown to 
provoke allergic reactions. It is important to investigate 
whether the composite dust that escapes into the atmo-
sphere releases methacrylate monomers. 
A recent study analyzed the dust particles released 
from four common composites used in dentistry. Samples 
of composite were light cured and polished in an enclosed 
chamber using a diamond bur. The dust was collected by 
means of a cyclone vacuum for analysis. The particles 
collected underwent various examinations by means of 
microscopy and spectroscopy. They were shown to re-
lease unpolymerized methacrylate monomers (Cokic, et. 
al., 2017). This poses a respiratory risk to those in the 
surrounding environment. Interestingly, dental workers 
are prone to developing asthma and other respiratory is-
sues, although the cause has not been verified. Composite 
dust particles released in the air may be the culprit of 
this observed phenomenon. Further measures should be 
taken to reduce the inhalation of composite dust. Perhaps 
better safety masks should be implemented to reduce the 
inhalation of unhealthy composite dust.
Amalgam vs. Composite: Which to Choose?
The biocompatibility of materials used in restorative den-
tistry relates to how well it can interact with living tissue. 
According to the above data both amalgam and compos-
ite fillings contain components that can create issues of 
biocompatibility. However, although studies indicate the 
presence of toxic materials circulating in the body follow-
ing dental procedures, the concentrations generally remain 
below levels that are harmful. Therefore, the question re-
mains as to which material is preferred for treatment. 
With the increased focus on esthetics, many patients 
opt for composite fillings. Particularly when dealing with 
anterior teeth, it definitely seems to be a better option. 
However, when considering which material to use for 
posterior teeth, amalgam does have some advantages. 
This is because the back molars bear a lot of stress from 
chewing forces. Amalgam has been shown to withstand 
more strain and is less prone to cracking or needing 
to be replaced. In addition, composite fillings are sensi-
tive to temperature, and shrink upon exposure to heat, 
which can cause increased tooth sensitivity. Furthermore, 
shrinkage of composite material creates a gap between 
the tooth and the filling. This is known as leakage, and is 
a big cause of secondary caries formation. However, with 
proper oral hygiene much of this can be avoided. 
Implants
Prosthetic implant devices are an evolving field in dentist-
ry, and choosing the right materials are key to a success-
ful procedure. Implants provide an excellent replacement 
option for teeth that are no longer restorable and need 
to be removed. Titanium is often the material of choice, 
as its osteophilic nature makes it highly biocompatible. 
Titanium is very reactive, and will rapidly form a layer 
of titanium oxide when exposed to an aqueous environ-
ment (such as the mouth) or air. This forms a boundary at 
the interface between the implant material and biological 
environment, which protects the material from corrosion. 
Therefore, the metal ion release into the body is limited 
and generally unreactive (Kumar et. al, 2016). 
Although less prevalent than other metal allergies, 
titanium allergies do exist (Lahori et. al., 2015). An allergic 
reaction can create a rift in this oxide layer formation and 
may impair the biocompatible function. Allergic reaction 
to titanium is caused by the release of ions interacting 
with native proteins in the nearby environment. This may 
cause a hypersensitive reaction and rejection of the im-
plant.  Determining the presence of titanium allergies and 
working with alternative materials is an area of continued 
research. Titanium allergies may be the culprit to other-
wise unexplainable implant failures. 
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Another potential issue of this otherwise successful 
material is its elasticity. Young’s modulus is a mechanical 
property which measures the stiffness of a solid materi-
al. It is a measurement determined by the slope of the 
stress-strain curve of a material. At 113.8 GPa, the elastic 
modulus of titanium is significantly higher than bone (18.6 
GPa). This makes it less flexible than bone and can result in 
strain upon implant insertion and subsequent implant fail-
ure (El Hajje et. al., 2014). The implant material will act to 
shield the bone from stress, which eventually can lead to it 
loosening and losing contact with the surrounding tissue. 
Zirconium has been introduced as a possible alter-
native implant material. Clinically, it has demonstrated 
success similar to traditional titanium implants. Studies 
have shown little difference in osseo-integration between 
the two materials. In addition, zirconium implants actually 
display reduced microbial growth as compared to titani-
um. This decreases plaque formation on the implant and 
surrounding tissue, which is important for the long-term 
success of an implant.
Peri-implantitis is the inflammation of the gum and 
bone structure in the area of a dental implant. It is caused 
by the buildup of trapped bacteria and can lead to bone 
loss. An in-vitro study was conducted to explore the ad-
hesion of oral bacteria to different implant materials. It 
included both titanium and zirconium, as well as a combi-
nation of both. The results displayed that oral bacteria have 
less of an affinity for zirconia (Al- Radha et. al., 2012). This 
suggests that zirconia implants can lead to better implant 
results and more successfully prevent the development of 
peri-implantitis. 
Over time, recession of soft tissue surrounding im-
plants can occur. This can lead to exposure of implant 
parts and is a particular concern when dealing with anteri-
or teeth. Also, titanium implants can result in discoloration 
of gingival tissue. In patients with a thin gingival biotype 
or high smile line, such discoloration is readily apparent. 
Zirconium implants may provide a solution to this issue 
as they result in a more esthetic appearance (Bhasin, et. 
al., 2015).
Polyetheretherketone, or PEEK, is a new material being 
explored as a possible alternative implant material. This 
may be an effective way to circumvent the titanium allergy, 
as well as provide a more esthetic option. In addition, with 
a low elastic modulus it can prevent issues of stress-strain 
distribution. This is in contrast to both titanium and zirco-
nium, which possess higher elastic modulus (El Hajje et. al., 
2014). However, being that its elastic modulus is actually 
lower than that of bone it is necessary to reinforce the ma-
terial in order to use it successfully (Schwitalla et. al., 2015. 
A finite element analysis technique, which is commonly 
used to test dental materials in vitro, was used to study 
the stress distribution on the jaw following implant place-
ment. It focused on titanium vs PEEK as the materials to 
be analyzed. A 3D model of the left mandibular jawbone 
was produced and an implant screw and abutment was 
inserted. Three different implant materials were used in 
the study to be compared, including titanium, and two 
different forms of commercial PEEK. 
Circular contact areas were used for the purpose 
of testing the degree of stress caused to the different 
implant materials. Force was applied to the occlusion 
areas of the simulated implant via a specialized device, 
and the stress, deformations, and contact pressure were 
measured. The results of the study indicated that PEEK 
reinforced with 60% vertical carbon fibers was similar in 
stress distribution as titanium. Pure PEEK displayed high-
er stress damage. Perhaps this can be attributed to the 
fact that the elastic modulus of pure peek is lower than 
that of cortical bone. Reinforcing it with vertical carbon 
fibers makes it strong enough to withstand more stress, 
yet still maintain a lower elastic modulus than titanium 
(Schwitalla et. al., 2015).
The characteristics of PEEK suggests that it possess-
es the potential to be a good alternative to titanium. 
However, long term studies regarding clinical success are 
lacking. Further research is necessary before implement-
ing the use of this synthetic material as a final abutment 
for implants. 
For the most part, titanium implants have a track re-
cord of success and continue to be used as an excellent 
replacement option. It is a highly biocompatible material 
that generally integrates into the bone well. In the case 
of allergies or hypersensitivity, there are other options 
being explored. Zirconia is a good alternative as it has 
shown similar clinical success and may even have higher 
antimicrobial properties. In addition, it seems to be a 
preferred option in the case of anterior teeth and thin 
gingival biotypes. 
Conclusion
The above studies indicate that the field of biomaterial 
compatibility requires further attention. It is necessary 
take a closer look, even though they are already being 
utilized in the dental field. Amalgam as an older material 
is less of a concern. However, in regard to composites, 
future studies focusing on the long term and cumulative 
effect should be designed. This information is important 
in being able to further improve the biocompatibility of 
dental materials. On the other hand, with both of these 
materials, the release of toxic components is shown to 
be below baseline levels of what is harmful to the body. 
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Therefore, in terms of clinical applications the decision 
of which material to utilize can be made by practicing 
dentists. The choice can be made based on the individual 
needs of each patient and situation. 
When dealing with implants, titanium remains an ex-
cellent option. Although it is a small percentage, there are 
some people who experience hypersensitivity or allergies 
to this material. There are other materials being explored 
with similar success rates. Some of these materials have 
shown good potential experimentally, yet clinical case 
studies are lacking. Further studies are necessary before 
implementing the widespread use of such materials. 
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The management of Venous Thromboembolism in terms of treatments and prevention has been well researched for patients 
who have been discovered as positive for Factor V Leiden genetic clotting disorder, in either the homozygous or the heterozy-
gous genotype. In fact, the research and development of new agents called Direct oral anticoagulants aim to treat and prevent 
clotting events while minimizing the risks of bleeding. Although several risk factors have been identified in relation to VTE, Factor 
V Leiden mutation presents a seemingly higher risk due to its unpredictable incidences of clotting events, even in patients with 
optimal health characteristics. Yet, we haven’t transitioned to routine testing of the common population for the Factor V Leiden 
as a preventative measure, rather the focus has been on those at risk due to family history of VTE or if clinical decisions might 
depend on it, such as the proper choice of contraception for female patients. Additionally, the increased risk of thrombophilia 
during pregnancy raises concern for proper medical management that would benefit the mother, without harming the baby, at 
any point of the pregnancy.
What are the Most Appropriate Treatments, Preventions and 
Family Planning Options for Patients with Factor V Leiden?
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Introduction 
For many people, the thought of having a blood clot is 
terrifying and rightfully so because it is potentially fatal 
and essentially invisible. A blood clot can appear in the leg, 
in the lungs or even in the brain. Also called a thrombus, a 
clot represents an accumulation of blood in a solid state, 
essentially caused by coagulation processes. Although 
coagulation is an important and vital function of homeo-
stasis, the resultant clot formation may obstruct blood 
vessels enough to limit perfusion of their field of supply. 
Medicine has shown that many risk factors for developing 
thrombi are acquired and depend on a patient’s physi-
cal or medical conditions such as obesity, hypertension, 
atherosclerosis, or even pregnancy. However, different 
genetic mutations appear to be linked to increased risk 
of thrombosis, such as Factor V Leiden, named after the 
city of Leiden in the Netherlands, where it was first iden-
tified while researching links between oral contraceptives 
and increased cases of thrombosis (Vandenbroucke et 
al., 1994). Factor V Leiden is the most common genetic 
mutation causing increased risk of  thrombophilia, or ab-
normal coagulation, therefore treatment options should 
be carefully considered for patients with clotting histo-
ry, as well as preventative measures for those who have 
not presented with thrombi. In view of the association of 
blood clots with family planning measures, this review will 
focus on women with Factor V Leiden, considering female 
individuals with or without a history of thrombophilia.
Background: 
Pathophysiology of Factor V Leiden
The factor V Leiden thrombophilia, also called Activated 
Protein C resistance, stems from a genetic mutation that 
affects parts of the clotting cascade, a physiological pro-
cess necessary for proper regulation of coagulation (Van 
Cott et. al, 2016). More specifically, Activated Protein C 
(APC), along with a cofactor Protein S, normally inacti-
vates some coagulation factors, hence acting as an an-
ticoagulant system. The mutation results in a decline in 
that inactivation, which has the potential to increase the 
coagulation activity. As for all genetic mutations, they can 
be present as heterozygous with one abnormal copy of 
the gene, or homozygous, for which both copies of the 
gene are mutated, the latter increasing the risk for throm-
bophilia by 80-fold. Regarding the population distribution 
of the Factor V Leiden mutation, it appears to be more 
prevalent in Europe, followed by Africa, and less prevalent 
in America (Rees, Cox, 1995). 
Methods
To complete this review, multiple scientific scholar da-
tabases and peer-reviewed articles mainly found on the 
Touro College online library were used. The Proquest, 
Browzine, Google scholar, and Dynamed databases were 
utilized with specific associations of key words in order 
to optimize the research and the results necessary to 
complete this study.
Discussion
When exploring the Factor V Leiden mutation and its 
relation to increased risk of venous thrombosis, it is first 
essential to make the distinction between individuals who 
have had a previous clotting event such as a deep vein 
thrombosis or a pulmonary embolism and those who 
have not. In fact, treatment options, preventative measures 
and family planning possibilities may be affected by a pos-
itive history of thrombophilia, regardless of the presence 
of any physiological risk factors, not to be dismissed, but 
to be utilized in conjunction with factor Factor V Leiden 
mutation at the time of medical management (Anderson, 
2003). Those risk factors should be touched upon for ref-
erence and comparison throughout this review.
Non-genetic Risk Factors of Venous Thrombosis
The risk factors for VTE (venous thromboembolism) 
mainly consist of obesity, long periods of immobility, 
surgery, smoking, age, pregnancy and use of oral contra-
ceptive pills, according to the NYU VTEC center and the 
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Cornell center for blood disorders, both specializing in 
venous thrombosis. Although common knowledge sup-
ports their statement, others might argue about the true 
character of “risk factor” for some of the elements above 
mentioned. For instance, obesity appears as a weak link 
to increased VTE, based on multiple studies, therefore it 
should be carefully analyzed when considering treatment 
or even prophylaxis (Anderson, 2003). Similarly, although 
age seems to count as a risk factor for many diseases or 
medical complications, its direct connection to increased 
VTE is questionable, especially due to the variety of eth-
nicities throughout the world and their life standards, as 
described by an epidemiology review with respect to 
China presenting an impressively low rate of DVT per 
year (Cushman, 2007). Therefore, we should denote the 
importance of evaluating an association of physiological 
and potentially genetic risk factors when treating or pre-
venting venous thrombosis.
Treatments and Preventions of Venous 
Thromboembolism
It is essential to distinguish between patients who have 
had a VTE event and those who haven’t, as it may affect 
their treatment approach, even if they are positive for fac-
tor V Leiden. Additionally, this section will analyze wheth-
er treatments and preventions will be influenced by the 
homozygous vs heterozygous factor V Leiden status. 
When discussing treatment options, we refer to pa-
tients who have actually had a DVT or a pulmonary embo-
lism and require treatment with anticoagulant. Although 
the review focuses on patients with Factor V Leiden, it is 
important to make the comparison with patients who do 
not have any genetic mutation that would favor VTE, in 
order to better understand the rationale for treatment 
and prophylaxis.
Duration of Treatment
A minimum of 3-6 months of anticoagulation therapy is 
recommended for all patients who suffered a VTE, regard-
less of physiological or genetic risk factors (Kearon, Akl, 
2014). However, if a VTE is unprovoked, meaning without 
obvious risk factor, it is highly recommended to pursue 
anticoagulation for at least 12 months, or perhaps in-
definitely to avoid recurrence, as highlighted by multiple 
studies compiled in one of the articles on UPTODATE, 
an online medical reference, that strongly emphasized the 
reduction in rates of VTE recurrences in patients who 
had been on anticoagulation long term (Lip, Russell, 2019). 
Moreover, it is debatable whether a genetic mutation 
causes unprovoked VTE or if it is provoked by the mu-
tation. Even if provoked, opinions about the duration of 
treatment vary widely, especially if the patient’s genotype 
is heterozygous for factor V Leiden; in fact, many provid-
ers will not treat indefinitely for a VTE provoked by a 
genetic factor, (Lip, Russell, 2019). More surprisingly, the 
actual difference in VTE incidence between both Factor 
V Leiden genotypes seems questionable. Indeed, when 
analyzing the number of actual cases and the percentage 
of recurrence after a first event, only a slim difference 
between homozygous and heterozygous percentages in 
VTE events (Perez Botero, Ormsby, 2016). Therefore, we 
can argue that the Factor V Leiden genotype shouldn’t be 
used alone to distinguish between lengths of treatment. 
On a separate note, it is essential to take into con-
sideration the bleeding risk associated with taking anti-
coagulant agents, commonly named “blood thinners”. As 
a matter of fact, all anticoagulants increase the bleeding 
risk to some extent and require vital risk versus benefit 
assessment when initiating treatment for VTE and deter-
mining duration of treatment. Bleeding associated with 
anticoagulation can range from a simple  hematoma or 
easy bruising, to life threatening gastrointestinal or intra-
cranial hemorrhage (Garcia, Crowther, 2019). Evidently, 
the longer a patient is on anticoagulation treatment, the 
higher chances he/she has of developing internal bleeding 
events, and those shouldn’t be taken lightly, therefore 
must be investigated even with minimal symptoms, such 
as coughing up a little blood. In fact, the Mayo clinic rec-
ommends precaution when prescribing blood thinners 
especially to older patients (>75 years old) who present 
higher chances of GI bleed (Harringa, 2019). On a similar 
note, when treating a patient with factor V Leiden with 
anticoagulation on a long-term basis, one ought to care-
fully monitor the bleeding effect of the prescribed agent. 
Indeed, we can also include female patients with factor V 
Leiden, for which continuous anticoagulation therapy will 
result in heavier menstruations. Although, we previously 
Figure 1: Most common risk factors of Venous Thromboembolism
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argued that the factor V Leiden genotype alone doesn’t 
determine the length of treatment, those patients will 
need long term treatment since the factor V Leiden is a 
genetic component, and by definition cannot just disap-
pear, as opposed to obesity. Therefore, if it is a constant 
risk factor, it will most likely represent a constant threat. 
The next section will present various anticoagulants that 
have been discovered and manufactured.
Different Anticoagulants on the Market
Based on the table above, multiple factors are to be con-
sidered when initiating a patient on oral therapy following 
an acute VTE event, especially when the patient is positive 
for factor V Leiden, and will most likely require long term 
anticoagulation therapy The drug class can be taken into 
account . In this case, both warfarin and the rest of the 
agents called Direct Oral anticoagulants (DOACs) are 
acceptable for treatment of VTE (Milling, Frontera, 2017). 
Furthermore, the daily dosage varies among all AC agents, 
from once a day with Warfarin or Xarelto, to twice a day 
with Eliquis or Pradaxa. Therefore, it raises an obvious 
question of medication compliance. Surely patients would 
be more likely to comply with their medications if only 
they needed to be taken once a day instead of twice a 
day. In that respect, Warfarin or Xarelto seem to be op-
timal options. However, as indicated on the table above, 
the daily dose of warfarin is dependent on a standardized 
international blood test called INR. In fact, patients on 
warfarin need to check their INR blood test quite often 
as their dose of warfarin will be adjusted based upon the 
results. Therefore, the frequent change of coumadin dos-
age undoubtedly will result in patients confused with dos-
age, that is without considering frequent venipunctures 
to test the INR. In addition, warfarin is a vitamin K antag-
onist, which means all foods high in vitamin K will coun-
teract the effect of coumadin; hence, those foods should 
be avoided or eaten in small portions all throughout the 
duration of the treatment with 
warfarin; a factor to consider 
greatly since a lot of greens or 
even garlic can interact with war-
farin (Mayo Clinic, 2018).  
The next component of the 
table includes the creatinine 
clearance, representing a poten-
tial risk of certain DOAC agents 
such as Xarelto, on the renal 
function. Although it doesn’t di-
rectly concern a DVT or a PE, 
certain patients who present 
with blood clots events, may also 
suffer from other medical condi-
tions such as renal disease, which 
in this case can render the choice 
of AC more challenging. 
The last component of the 
table indicates the possibility 
to reverse AC agents due to 
overuse or excess bleeding for 
example as a result of hypovo-
lemic shock or major trauma. 
Warfarin’s reversal agent is Vitamin K. Moreover, a rever-
sal agent became approved by the FDA for both Eliquis 
and Xarelto this year, by the name of Andexanet Alfa 
(Cuker et. al., 2019).
Besides for the factors indicated on the table above, it 
is essential to also mention the potential risks of bleeding 
and consequent serious medical conditions such as GI 
bleed and intracranial hemorrhage. According to mul-
tiple trials, it appears that DOACs have a lower risk of 
intracranial hemorrhage or even GI hemorrhage than 
warfarin and therefore should be used as a first choice, 
if all contraindications have been carefully considered 
(Garcia, Crowther 2019).
Additionally, considerations must be made for female 
patients who are pregnant, because all the above-men-
tioned agents, whether Warfarin or DOACs are not indi-
cated during any of the stages of pregnancy. Alternatives 
Table 1: Oral Anticoagulant comparative table
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will need to be used as needed for treatment of a VTE 
during pregnancy or even as a prophylactic agent; those 
will be contemplated in the family planning section. 
The duration of anticoagulation treatment varies with 
the unprovoked versus provoked status of a VTE, in pa-
tients with either Factor V Leiden genotype, heterozygous 
or homozygous. A blood thinner treatment is designed to 
treat the current thrombosis, and even more importantly 
to prevent recurrence. The nature of the AC agent will 
depend on the availability of a reversible agent, the pa-
tient’s current renal status and the level of compliance a 
provider attempts to achieve, apparently more in favor of 
DOACs due to decreased risk of internal bleeding, com-
pared to warfarin. Recent tendency has it to get tested 
for genetic conditions such as Factor V Leiden, generally 
due to family history of clotting. Therefore, if a patient has 
a Factor V Leiden mutation, there may be some preven-
tative measures to consider in certain cases, even if that 
individual has never experienced a VTE.
Prevention of Venous Thromboembolism for 
Patients with Factor V Leiden
There are several non-genetic risk factors to venous 
thromboembolism (VTE), such as obesity, age, recent sur-
gery or long immobilization states. If we also consider 
the positive Factor V Leiden mutation genotypes, we can 
understand that certain patients are at serious risk for 
developing thrombi, whether from a physiological or ge-
netic standpoint, or both. Moreover, patients who have 
had a VTE can certainly develop another one, hence the 
necessity for treatment, and preventative measures. Let’s 
explore some risk factors and analyze the preventative 
measures that would best benefit those at risk.
First of all, we can raise the question regarding testing 
for genetic mutations such a factor V Leiden for patients 
who have had a VTE or are family members of Factor V 
Leiden. As a matter of fact, knowing that condition exists 
can be part the prevention process. It seems that new-
born or infant screening for Factor V Leiden or testing 
of the population is not recommended, however the rec-
ommendations seem strong for female patients of child 
bearing age with personal or family history of VTE, as well 
as those under 50 years of age with a personal history 
of Thromboembolism (Grody, et. al, 2001). While testing 
family members of Factor V Leiden genotypes carriers is 
important in certain cases, it appears it doesn’t necessarily 
prevent the occurrence of VTE, unless those patients are 
being educated on the mutation. It is especially important 
to educate about VTE risks and implications in different 
aspects of healthcare such as after a surgery, while on oral 
contraceptive or even during pregnancy (Segal et. al, 2009). 
Regarding the prophylactic interventions using med-
ications, patients undergoing surgery or long-term im-
mobilization following a surgery such as a knee or hip 
replacement, will be offered anticoagulation prevention 
via a low molecular weight heparin (LMWH). The most 
common of those agents is called enoxaparin, with brand 
name “Lovenox”, available as an injectable product, that 
can be self-administered by the patient, but requires sev-
eral calculations to determine proper dosage based on 
weight and monitoring with a blood test called the “Anti 
Xa activity” that calculates its efficacy (Busti, 2015). More 
precisely, the LMWH acts as an inhibitor of a factor Xa, 
one of several proteins involved in the coagulation cas-
cade, which results in clotting formation, either in a nor-
mal ratio or abnormal, with consequences such as VTE. .
Another commonly used agent for prophylaxis, es-
pecially following a surgery, is warfarin, previously men-
tioned. In fact, it may seem undesirable for a lot of pa-
tients to go through daily injections. Although the use of 
prophylaxis Warfarin has been associated with more than 
50 % reduction of VTE post orthopedic surgery, LMWH 
was concluded as a superior alternative for protection 
against thromboembolism post-surgery (Paj, Douketis, 
2019). Moreover, the use of low dose Aspirin has been 
contemplated as well for prevention of VTE but is most 
commonly used for cardiovascular prevention such as 
protection from strokes or myocardial infarctions. 
Although the goal of anticoagulant agents is for pre-
venting VTE, the bleeding consequences are not to be 
ignored. Therefore, hospital settings also offer non-phar-
macological options such as an IPC device, intermittent 
pneumatic compression device, that improves venous 
circulations in upper and lower extremities to prevent 
edema, as well as venous thromboembolism. However, 
since data hasn’t shown the IPC device as a complete 
alternative to medicated options, according to “uptodate” 
latest research(Paj, Douketis, 2019), it is becoming com-
mon practice to start off with IPC devices for patients 
with a high risk of bleeding, and then transition to a blood 
thinner medication agent, as presented by the AHRQ, a 
government agency in charge of research and quality in 
healthcare systems (Maynard, 2016).
Testing for Factor V Leiden is not commonly done with 
the general population but focuses on family members of 
those with the genetic mutation. In regard to prophylaxis 
agents for long term immobility, such as post-surgery, 
different agents are available and will depend on the pa-
tient’s abilities to self-administer daily injections, as well as 
the risk of bleeding, yet it is always important to measure 
the levels of risk, especially for those patients with a 
genetic component such as factor V Leiden mutation. The 
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factor V Leiden genetic mutation was discovered in rela-
tion with increased risks of VTE for female patients on 
oral contraception. Indeed, it appears that an important 
amount of the research regarding Factor V Leiden throm-
bophilia is associated with female individuals and attend 
to pregnancy or contraception related matters. 
Female Patients with Factor V Leiden-Family Planning
Female patients of child-bearing age who are positive for 
factor V Leiden need to be aware that their genotype can 
affect their choices when dealing with contraception and 
family planning.
Contraception
It is believed that oral contraceptives, especially estrogen 
containing agents have the potential to increase the risk 
of VTE; indeed, the estrogen will increase the plasma con-
centration of certain clotting factors and fibrinogen, all of 
which are favorable to clotting formation (Busti, 2015).
 Although several sources have pushed for testing 
patients for Factor V Leiden prior to prescribing oral 
contraceptives, it represents a large population of female 
patients being tested and consequent precautions to be 
taken for life with constant awareness of the genotype, 
when there is no guarantee one of those women will 
ever experience a thrombosis event. Rather, a review 
suggests recording a comprehensive personal and familial 
medical history or VTE when prescribing oral contracep-
tives (OCP) (Rosendaal, Koster, et. al, 1995), which seems 
more appropriate and targeted. 
It is important to understand that the association of 
factor V Leiden and use of oral contraceptives cause great 
thrombosis risk, and has been long studied and concluded 
as such (Choe, Suh, 2019), therefore a female patient 
should always mention it to her doctor before being 
prescribed any oral contraceptives. Luckily, several con-
traceptive options have become available on the market 
to satisfy all preferences and medical conditions, which 
becomes handy for those with a history of VTE or known 
Factor V Leiden. For example, the oral contraceptives 
containing only progesterone have been categorized as 
little to non-affecting coagulation. Therefore, these can 
become an ideal option for those women at higher risk 
of developing VTE, such as those with factor V Leiden 
genotypes. Similarly, Intrauterine devices (IUD) contain-
ing only progestin, such as the Mirena, are an excellent 
alternative to oral contraceptives for those who can’t 
seem to comply to the daily regimen of birth control, 
especially when indicated to be taken at the same time 
every day. It is however essential to bring to light the fact 
that fewer studies were conducted on progesterone-only 
agents, therefore more data may be necessary to fully 
draw the conclusion of its higher grade of safety in terms 
of VTE prevention (Tchaikovski, Rosing, 2010). In addition, 
The Journal of Community Hospital Internal Medicine 
published an article this year warning about the proges-
tin-only IUD, when a female patient in her early 30’s with 
Factor V Leiden suffered a pulmonary embolism while on 
that intrauterine device (Jean, 2019). Therefore, although 
it appeared at first that only estrogen containing oral or 
intrauterine agents were associated with increased risk 
of VTE incidences, we find it questionable whether the 
progestin only agents are truely safe alternative for those 
patients at risk such as the Factor V Leiden genotypes, 
or even those without the genotype but with a history 
of clotting. Luckily for those individuals, there is now 
a non-hormonal intrauterine device available such as 
the Paragard IUD, releasing copper as a contraception 
method, therefore seemingly the ideal option for those of 
at VTE risk. In its mechanism, the copper acts as a toxic 
environment for sperm, which significantly reduces the 
chance for fertilization of the egg (Higginbotham, 2018).
Though it seems like the ideal option, it is interesting 
to present the reported increase of menstrual bleeding 
associated with the Copper Intrauterine device, as well as 
cramping (Galan, 2016). Furthermore, the idea of having 
an internal device can be disturbing for a lot of patients 
and has shown serious medical consequences such as 
ectopic pregnancies or infections, although only shown in 
low percentages. 
To sum it up, it appears that although ample options 
are available on the market for contraception, the choic-
es become limited for patients with Factor V Leiden or 
patients with personal or even a family history of VTE. 
Although intrauterine devices optimize compliance with 
the regimen, they aren’t always the preferred options 
for contraception due to their potential serious conse-
quences. Ultimately, patients at risk of developing VTE 
should resort to using the copper IUD, because it doesn’t 
contain any hormones, despite its potential increase of 
bleeding risk, which can be even more exacerbated for 
those patients who already take daily anticoagulant.
Factor V Leiden plays an important role in a patient’s 
choice for contraception, but also during pregnancy or 
when planning to become pregnant.
Pregnancy
Pregnancy represents a risk factor on its own for Venous 
Thromboembolism. During pregnancy, a patient will be 
considered in a hypercoagulable state, or increased ten-
dency to coagulate, due to higher levels of fibrinogen and 
certain clotting factors, as well as a vascular damage or 
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reshaping that the increase in weight and fluid can cause 
(Gibson, Powrie, 2009). Following that thought process, a 
risk factor should be avoided, or if cannot be, should be 
carefully managed; in this case management of pregnancy 
for patients at risk of VTE. 
Patients with Factor V Leiden and/or those with a 
history of VTE should carefully monitor their cycles as 
to know when to get pregnant because of the high prob-
ability those individuals will need to modify the types of 
AC they take. Multiple studies have examined the optimal 
options for prophylaxis AC in patients who are at high 
risk of developing VTE or those who have a history of 
VTE. It appears that the current recommendations sug-
gest the use of heparin injections throughout pregnancy 
and up to 6 weeks after delivery, because heparin does 
not cross the placenta and is not transmitted via breast 
milk. Therefore, it is considered a relatively safe option 
for both the mother and baby (Gibson, Powrie, 2009). 
However, while Heparin is safe for pregnancy, it is im-
portant to distinguish between unfractionated heparin, 
which has been linked to osteoporosis and thrombocy-
topenia when used long term, and low molecular weight 
heparin (LMWH), with less incidence of the above men-
tioned (De Santis, et., al, 2006). An example of LMWH 
is Lovenox, with the generic name enoxaparin, and has 
demonstrated success as a prophylactic agent against 
VTE in several instances world-wide, one of which was 
reported regarding a young pregnant patient in Nigeria 
with factor V Leiden homozygous who was treated with 
LMWH during her pregnancy due to a DVT (Dogara, et, 
al, 2018). Since pregnancy might occur while on an anti-
coagulant, it is essential for those individuals to be aware 
of their cycles in order to start the appropriate AC agent 
as soon as soon they become pregnant. The use of direct 
oral anticoagulants (DOACs) are still contraindicated 
during pregnancy. In fact, it is due to the lack of data prov-
ing them safe, the few results demonstrating a high rate 
of miscarriage, as well as relatively significant amount of 
fetal abnormalities for patients on DOACs, concluded to 
be directly related to the DOACs, but poorly investigated 
(Lameijer, et, al, 2018). 
Female patients who are aware of a risk factor for 
VTE, usually genetic such as factor V Leiden mutation, can 
evidently be more prepared and educated on the pre-
cautions to take regarding anticoagulation management 
during pregnancy. However, many patients in fact find out 
about their Factor V Leiden mutation during pregnan-
cy, as they experience a DVT or pulmonary embolism, 
requiring emergency treatment with LMWH, or after 
suffering multiple spontaneous miscarriages. Interestingly, 
some studies have compared the rate of first trimester 
miscarriages in patients with known factor V Leiden and 
those with known regular genotype, and the incidence of 
early pregnancy miscarriage doesn’t seem to have a close 
relationship with Factor V Leiden. Rather it does when 
comparing later term miscarriage, possibly caused by 
clotting within the uterine vasculature (Jivraj, et., al, 2009). 
Furthermore, while Factor V Leiden had been thought 
more risky, it doesn’t appear to affect the management 
of pregnant patients for VTE prevention, since several 
studies have yet to discover significant differences in 
clinical pictures between homozygous and heterozygous, 
(Gat, et, al, 2014).
Other forms of prevention for VTE during pregnancy 
include compression stockings however these have re-
ceived a low grade of compliance among those women 
due to discomfort. Moreover, it usually can improve 
blood circulation in lower extremities but are limited to 
lower extremities.
As with all patients, pregnant patients with factor V 
Leiden should in addition keep a healthy lifestyle, combin-
ing a balanced diet and regular exercise, to keep proper 
perfusion, for theirs and their babies’ sake.
Conclusion
The high incidences of VTE has stimulated much research 
to find optimal forms of treatment and preventative 
agents in the forms of Anticoagulants, whether oral or 
injectable, for patients at higher risk of developing Venous 
thromboembolism, such as those individuals with the 
Factor V Leiden genetic mutation. Although the newer 
DOACs have become more popular due to decreased 
necessity for close monitoring, decreased bleeding risk, 
and statistical efficiency in the prevention of thrombosis, 
it appears they still cause issues for pregnant patients, 
and require more extensive research to prove their safe-
ty. Fortunately, low molecular weight heparin injections 
have been used for management of pregnant patients 
since they don’t cross the placenta, and they have been 
utilized often as a post-surgery prophylaxis on a short-
term basis. Regarding the management of patients who 
wish to utilize contraception measures, careful attention 
is to be applied due to the elevated clinical relationship 
between the use of estrogen and episodes of VTE, but 
unfortunately most of the contraceptive options do not 
seem adequate for those high-risk female individuals, 
therefore requiring further research and development. 
Although Factor V Leiden appears to be the most popu-
lar genotype associated with VTE, multiple other genetic 
mutations have close relationships with increased risk 
of thrombosis. Since the pregnancy represents a high 
risk factor on its own, perhaps the thought of prenatal 
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testing with a thrombophilia panel doesn’t seem inade-
quate, although the question remains about a reasonable 
response to the screenings in terms of prophylaxis, that 
would be beneficial to patients’ physical health without 
being detrimental to their mental health, once aware that 
an important genetic mutation is present, especially at 
sensitive times such as during pregnancy.
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Anemia of chronic disease (ACD) is the result of altered iron metabolism, blunted erythropoiesis, and shortened red blood cell 
survival caused by inflammatory cytokines. Hepcidin plays a key role in anemia of chronic disease by inducing endocytosis of 
the iron exporter ferroportin. Iron is trapped in enterocytes, hepatocytes, and macrophages, and is unavailable for hemoglobin 
synthesis. When treating the underlying disease is not an option, or anemia is severe, ACD should be treated.  While oral iron 
supplementation is not suitable for ACD, intravenous iron may be effective. Erythropoiesis stimulating agents are a common ap-
proach to treating ACD, but a large percentage of ACD patients are refractory to ESAs. Additionally, there are many safety issues 
associated with ESA therapy. Concomitant IV iron supplementation increases patient response to ESAs and may reduce safety 
concerns as well. Several new, more targeted approaches to ACD treatment are being studied. Isocitrate supplements have been 
shown to improve ACD by minimizing the iron restriction response to increase erythropoiesis. Antibodies such as infliximab and 
tocilizumab, which neutralize the inflammatory cytokines TNF-α and IL-6, respectively, decrease hepcidin expression and improve 
hemoglobin levels. Finally, antibodies and speigelmers that target hepcidin directly are being developed. These new therapies, alone 
or in combination with IV iron or ESAs, show promise in alleviating anemia of chronic disease.
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Introduction 
Iron is an essential element for life. From the smallest 
microbes to the most complex of organisms, all require 
this vital nutrient to survive. As such, one of our bodies’ 
many host defense mechanisms is to limit the amount of 
iron available to pathogens. Inflammatory cytokines cause 
an increase in the expression of hepcidin, a liver protein 
that is a key regulator of iron metabolism. Hepcidin binds 
to ferroportin, the only known exporter of cellular iron, 
and causes it to be internalized and degraded (Nameth 
et al., 2004a). Thus, iron is trapped inside the cells, out of 
reach of bacteria, cancer cells, or other pathogens.
When inflammation becomes chronic, however, this 
innate defense mechanism becomes counterproductive. 
Too much of the iron from senescent red blood cells is 
sequestered within macrophages, rather than recycled 
for erythropoiesis. Patients with chronic inflammation 
often develop a unique form of anemia, known as the ane-
mia of chronic disease (ACD). ACD is the second most 
common type of anemia, caused by some cancers, chronic 
infections such as HIV, autoinflammatory diseases such 
as rheumatoid arthritis, and other diseases that feature 
chronic inflammation such as inflammatory bowel disease 
or heart disease. While treatment for these patients must 
focus primarily on curing the underlying disease, treat-
ing the anemia may greatly improve the patients’ quality 
of life. Because of the unique mechanism by which the 
anemia develops, treatment of ACD can be complicated. 
Treatments often used to treat other forms of anemia, 
such as iron deficiency anemia, may be ineffective, or 
even detrimental. This paper examines several possible 
approaches for treating anemia of chronic disease, given 
its unique pathogenesis. 
Methods
The information in this article was compiled by review 
and analysis of articles located using PubMed, ProQuest, 
and Google Scholar. Access was provided by the Touro 
College Library system. Emphasis was placed on origi-
nal studies, although review articles were also used. 
References cited in the articles provided further read-
ing. Articles discussing anemia of chronic kidney disease 
(ACKD), a related but different disorder were not includ-
ed in this review.
Discussion: 
Pathogenesis of Anemia of Chronic Disease
Hepcidin is a small peptide containing multiple disulfide 
bonds that is secreted by the liver. It was first isolated 
from human urine (Park et al., 2001). Initially recognized 
for its anti-microbial properties, it soon became clear 
that hepcidin is a key regulator of iron metabolism. Iron-
overloaded mice overexpress mRNA coding for a peptide 
closely homologous to human hepcidin. Additionally, iron 
depletion results in a decrease in hepcidin expression 
(Pigeon et al., 2001). Genetically modified mice overex-
pressing hepcidin were born with pale skin and died soon 
after birth. Those that survived had severe microcytic 
iron deficiency anemia (Nicolas et al., 2002a). 
A 2004 study by Nameth et al. provided a break-
through toward understanding the role of hepcidin in 
iron homeostasis. Using in vitro cells expressing fer-
roportin (Fpn) labeled with green fluorescent protein 
(Fpn-GFP), they demonstrated the effect of hepcidin on 
ferroportin. Hepcidin binds directly to Fpn, inducing its 
endocytosis. Upon addition of hepcidin, Fpn-GFP disap-
pears from the cell surface, and is localized in intracellular 
vesicles. (Nameth et al., 2004a). Hepcidin binds directly 
to ferroportin and induces rapid ubiquitination of several 
lysine residues of ferroportin. This tags ferroportin for 
internalization (Qiao et al., 2012). Ferroportin is subse-
quently degraded by lysozymes.  
Ferroportin (also called MTP-1) is an iron transporter 
located at the surface of cells involved in iron metabolism, 
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including duodenal enterocytes, hepatocytes, macrophages, 
and placental cells. It is structurally similar to the DMT1 
class of metal transporters (Abboud and Haile, 2000). 
Ferroportin acts as an iron exporter, releasing iron into 
the bloodstream. Fpn null/null mice are not embryonically 
viable. Inactivation of ferroportin at birth results in severely 
anemic mice with accumulation of non-heme bound iron 
in enterocytes, macrophages, and hepatocytes (Donovan 
2005). In vitro, cells expressing ferroportin only in the pres-
ence of an inducer, accumulate ferritin when ferroportin is 
inactive. Induction of ferroportin results in a clearance of 
ferritin from the cell (Nameth et al., 2004a). 
There are no known cellular iron exporters other 
than ferroportin. The removal of ferroportin from the 
cell surface inhibits transport of iron to the serum. Iron 
is trapped within the cell and stored as ferritin. Hepcidin 
levels, and thus ferroportin levels, are modulated by 
serum iron levels. Iron overload activates a BMP (Bone 
Morphogenetic Protein)/ SMAD signaling pathway which 
causes increased hepcidin expression. Hemojuvelin, a pro-
tein that is mutated in juvenile hemochromatosis patients, 
plays an important role in this pathway as a coreceptor of 
BMP (Babbit et al., 2006).  Hepcidin expression is down-
regulated in response to anemia and hypoxia, allowing the 
iron necessary for erythropoiesis to be released into the 
plasma (Nicolas et al., 2002b). 
Hepcidin also increases as part of the acute phase 
response to inflammation. The inflammatory cytokine 
Interleukin-6 (IL6) is the primary inducer of inflammatory 
upregulation of hepcidin mRNA expression. In vitro, the 
increase of hepcidin stimulated by inflammation is inhib-
ited by the addition of anti-IL6 antibodies. IL-6 infusion 
in humans causes an increase in urinary hepcidin, along 
with a decrease in serum iron and transferrin saturation 
(Nameth et al., 2004b).  IL-6 activates a JAK/STAT signal 
transduction pathway. The immediate -165 base pairs 
of the hepcidin promoter are necessary for hepcidin 
induction by IL-6. Deletion of the STAT binding motif 
within this promoter fragment inhibits IL-6 activation. 
In particular, the transcription factor STAT3 is required 
(Falzacappa et al, 2007). Chronic inflammation results in 
increased hepcidin and anemia in WT mice, but not in 
STAT3 knockout mice (Sakamori et al., 2010).
In patients with chronically elevated IL-6, hepcidin is 
persistently elevated. The resulting lack of ferroportin 
causes iron to be retained within the cells. Dietary iron is 
not absorbed into the plasma. Iron stored in hepatocytes 
of the liver is not released. Most significantly, iron from 
senescent erythrocytes is sequestered in macrophages 
in the spleen. Rats with ACD had higher levels of ferritin 
in the spleen than healthy controls, with less iron being 
released from macrophages (Theurl et al., 2010).  The re-
sulting hypoferremia limits the amount of iron available for 
erythropoiesis. 
In addition to the functional iron deficiency induced by 
hepcidin-mediated iron sequestering, inflammatory cyto-
kines have been shown to have other effects which contrib-
ute to anemia of chronic disease. Specifically, Interferon-γ 
(IFN-γ) has been shown to suppress erythropoiesis. 
Inflammation inhibits the wave of reticulocytosis normally 
seen in cells treated with erythropoietin (Epo) in vitro. 
Neutralization of IFN-γ reverses this effect. Treatment of 
mice with anti-INF-γ antibodies prevents inflammatory 
suppression of erythropoiesis (Thawani et al., 2006). This 
blunting of erythropoiesis may explain why ACD is often 
normocytic and normochromic. Other anemias caused by 
inappropriately high hepcidin levels, such as iron refractory 
iron deficiency anemia, are severely microcytic and hypo-
chromic. IFN-γ suppression of erythropoiesis seems to 
compensate for the lack of bioavailable iron by producing 
fewer normal RBCs, rather than many abnormal ones 
(Nameth & Ganz, 2014).
Further contributing to anemia, erythrocytes have a 
moderately shortened life span in inflammatory conditions. 
Biotin labeling of erythrocytes in mice showed a complete 
RBC turnover by day 15 in mice with inflammation, com-
pared to day 36 in control mice (Thawani et al., 2006). In 
humans, erythrocyte life span in patients with rheumatoid 
arthritis (RA), often used as a model for ACD, is significant-
ly shorter than in healthy controls. Red blood cells from 
these patients transfused into healthy individuals showed 
normal survival. This indicates that the shortened survival 
was not caused by defects in the red blood cells. Rather, 
inflammation causes a decrease in erythrocyte life span 
by some extrinsic mechanism (Freireich et al., 1957). The 
premature destruction of erythrocytes is likely the result 
of increased macrophage activity in the spleen in response 
to various cytokines (Nameth & Ganz, 2014). 
Tumor Necrosis Factor (TNF-α) and Interleukin-1 
(IL-1) were among the earliest inflammatory cytokines 
to be implicated in anemia of chronic disease. However, 
the mechanisms involved are still unclear. Both TNF-α 
and IL-1 reduce hepcidin expression in vitro (Song et 
al., 2013). It seems that their role in ACD is indirect, via 
regulation of other cytokines. Cytokine-cytokine interac-
tions are complex, and researchers still have a lot to learn 
before the pathogenesis of ACD can be fully understood.
Treating Anemia of Chronic Disease
Anemia of chronic disease is a secondary effect of an un-
derlying illness. ACD is usually mild. As such, the major 
focus of treatment protocols for ACD patients must be on 
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curing the primary disease. As the inflammation caused by 
the disease subsides, inflammatory cytokine levels return 
to baseline. Consequentially, the anemia will be resolved 
without the need for anemia-related treatment. However, 
often the underlying disease is not curable. Anemia may 
also have a profound negative impact on the patient’s 
quality of life. The most common complaint of patients 
with ACD is fatigue, which can be debilitating. In such 
cases, direct treatment of the anemia of chronic disease 
is recommended. As with any medical intervention, the 
benefits of treatment must be weighed carefully against 
any possible risks. It is important to note that anemia in 
chronically ill patients is often multifactorial. Anemia of 
chronic disease may occur in conjunction with true iron 
deficiency anemia, or anemia of another cause. It is nec-
essary to correctly diagnose the cause of anemia before 
deciding on a treatment option. Finally, certain treatments 
may not be suitable for certain patients, depending on 
which underlying disease is causing the inflammation.
Oral iron supplementation, the obvious solution for 
iron deficiency anemia, is not appropriate for anemia 
of chronic disease. The removal of ferroportin from the 
basolateral surface of duodenal enterocytes prevents 
oral iron from being adequately absorbed into the plas-
ma. Much of the minimal iron that is absorbed will be 
diverted into hepatocytes (Weiss & Goodnough, 2005). 
Intravenous iron therapy may be effective in treating ane-
mia of chronic disease, because parenteral administration 
allows it to bypass the “mucosal block” in the duodenum. 
Indeed, several trials have shown that IV iron therapy is 
beneficial for anemia of chronic disease in cancer patients. 
A pilot study showed a significant increase in hemoglobin 
levels in cancer patients with non-iron deficiency anemia 
in response to weekly doses of ferric hydroxide sucrose 
(Abdel-Rezeq et al, 2013). A single dose of ferric carboxy-
maltose improved hemoglobin levels in chemotherapy pa-
tients with ACD. This improvement was maintained for a 
minimum of 8 weeks. (Hedenus et al., 2014).  A large study 
comparing the efficacy of IV iron and oral iron supple-
mentation in cancer patients found that both treatment 
options induce a similar increase in hemoglobin levels, 
although the response time was faster for IV iron. IV iron 
also caused less side effects than oral iron. The efficacy 
of oral iron seen in this study is surprising, as it conflicts 
with many other studies. However, this study included pa-
tients with iron deficiency anemia (Birgegard et al, 2016). 
Trials that were specific to patients with functional iron 
deficiency showed IV iron to be superior. 
Several concerns have been raised regarding the safety 
of iron supplementation. Iron overload is associated with 
oxidative stress and cardiovascular events. Additionally, 
iron sequestering is an innate host defense mechanism. 
Iron supplementation may increase the risk of infections 
and tumor growth. (Weiss & Goodnough, 2005). Although 
the trials reported here have indicated that intravenous 
iron is safe for cancer patients, these trials only followed 
patients for short periods of time. Long-term studies 
are necessary to establish whether IV iron is truly safe 
for patients with anemia of chronic disease (Rodgers & 
Gilreath, 2019). Most of the research regarding efficacy 
of IV iron monotherapy for anemia of chronic disease has 
been in chemotherapy patients. Further experimentation 
is necessary to assess whether parenteral iron is useful in 
cases of ACD caused by illnesses other than cancer. 
Among the earliest treatment options available for 
anemia of chronic disease are Erythropoiesis Stimulating 
Agents (ESAs). This category includes recombinant human 
erythropoietin (rHuEpo) and its derivatives, Epoetin-α 
and Darbepoetin-α. ESAs target the blunted erythropoie-
sis characteristic of ACD and should minimize the iron-se-
questering effect of hepcidin as well.  Pharmacological lev-
els of erythropoietin cause a dose-dependent decrease 
in hepcidin expression in vitro (Pinto et al., 2008). In 
another study, pretreatment with erythropoietin partially 
prevented the increase in hepcidin normally induced by 
inflammation in mice. This effect was dose dependent. 
Pharmacological doses of Epo were effective, but the 
endogenous increase in erythropoietin in response to 
hypoxia was insufficient to reduce hepcidin expression. 
IL-6 levels were similar in Epo-treated and control mice. 
However, STAT3 phosphorylation decreased significantly. 
Suppression of STAT3 is likely the mechanism by which 
erythropoietin decreases IL-6 induced hepcidin expres-
sion (Huang et al., 2009). Erythropoiesis stimulating agents 
have been proven effective for ameliorating anemia of 
chronic disease in humans. In a placebo controlled double 
blind trial, normal hemoglobin levels were achieved in 
94% of rheumatoid arthritis patients with ACD treated 
with rHuEpo. Interestingly, rHuEpo also reduced disease 
activity in RA patients (Peeters et al., 1996).  ESAs are 
likewise used to treat anemia of chronic disease in cancer 
patients. 
Unfortunately, there are serious safety concerns re-
garding ESAs. Although few side effects were reported 
in early trials of ESAs for rheumatoid arthritis patients 
(Peeters et al., 1996, Nordström et al., 1997), ESA treat-
ment is associated with numerous adverse effects, es-
pecially in cancer patients. In a meta-analysis of 53 trials 
including close to 4,000 patients, mortality increased by 
17% in cancer patients with anemia treated with ESAs 
compared to controls (Bohlius et al., 2009). In 2007, 
the FDA issued a black box warning stating that “ESAs 
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increase the risk of death, myocardial infarction, stroke, 
venous thromboembolism, thrombosis of vascular ac-
cess, and tumor progression or recurrence [in cancer 
patients]”. Venous thromboembolism is one of the most 
prevalent adverse effects of ESAs. This may be because 
ESAs induce iron-deficient erythropoiesis (IDE), by in-
creasing erythropoiesis despite the lack of bio-available 
iron caused by ACD. This results in elevated platelet 
counts, which increases the risk for thrombolytic events 
(Henry et al., 2011).
Aside from increased safety concerns, the functional 
iron deficiency of ACD limits the efficacy of ESAs. Many 
patients do not respond to ESA treatment. Response 
rates vary from trial to trial. One study, in RA patients, 
reported that only 14.6% of patients achieved target 
hemoglobin levels. Decreased iron levels and more severe 
inflammation were predictive of a poor response. In an 
extension to the study, four out of five initial non-re-
sponders who were now given iron supplementation 
in addition rHuEpo treatment did show significant im-
provement in hemoglobin levels (Nordström et al., 1997). 
Hemoglobin does not increase significantly in response to 
ESAs in mice overexpressing hepcidin (Sasu et al., 2010). 
In another study, rats with higher pre-treatment levels of 
hepcidin, which correlates to lower iron availability, were 
shown to respond poorly to ESA treatment. Although 
ESAs decrease hepcidin expression somewhat, and thus 
decrease splenic iron retention, this effect is inadequate. 
Serum iron remains low, and ESA treatment does not 
effect an increase in hemoglobin in rats with very high 
hepcidin levels (Theurl et al., 2014). 
The limitations of iron-deficient erythropoiesis to ESA 
treatment has led researchers to investigate whether 
concomitant iron supplementation could improve the 
safety and efficacy of ESAs. Indeed, many studies have 
shown positive results when erythropoiesis stimulating 
agents are combined with intravenous iron. Parenteral 
iron administration is preferable to oral supplements, as 
oral iron is not well absorbed by patients with ACD.  IV 
iron could correct ESA-induced iron-deficient erythro-
poiesis and improve response to rHuEpo in rheumatoid 
arthritis patients with anemia of chronic disease (Arndt 
et al., 2005). Encouraging results were seen in cancer 
patients with ACD as well.  Patients receiving supple-
mental iron intravenously achieved higher hemoglobin 
levels in response to epoetin-α than patients receiving 
epoetin-α with oral iron or epoetin-α alone. Response 
rates were significantly improved in the IV iron group 
as well. In the IV iron group, 73% of patients responded 
to the ESA treatment, compared to only 45% and 41% 
in the oral and no iron groups, respectively (Henry et 
al., 2007). Auerbach et al. similarly reported that cancer 
patients who received combination of darbepoetin-α 
and IV iron were more likely to reach target hemoglo-
bin levels, with more rapid and significant improvement 
than patients who did not receive IV iron. Interestingly, 
the incidence of adverse effects, including thrombolytic 
events, was similar in both groups (Auerbach et al., 2010). 
By contrast, post-hoc analysis of data from the first study 
showed that IV iron decreased the likelihood of elevated 
platelet counts and venous thromboembolism (Henry et 
al., 2011). One trial failed to show a significant difference 
between chemotherapy patients receiving darbepoetin 
and intravenous ferric gluconate versus oral iron or oral 
iron placebos. Additionally, many adverse events were 
reported among those patients receiving parenteral iron 
(Steensma et al., 2010). However, this study had several 
limitations. The overall iron dose was lower than in other 
studies, potentially limiting the benefit of IV iron. By con-
trast, the individual doses of iron administered were 50% 
above the recommended dosage, which may explain the 
excessive number of adverse events. Finally, the study was 
terminated early, with few patients completing the study 
(Steensma et al., 2010 & Aapro et al., 2011). Nevertheless, 
the high incidence of adverse events in this study high-
lights the need for additional studies as to the safety of 
parenteral iron. 
Experimental Treatment Options
Another option for targeting the blunted erythropoiesis 
of ACD which is currently being studied is isocitrate sup-
plements. Aconitase is a Krebs’s cycle enzyme responsible 
for converting citrate into isocitrate. Insufficient iron lev-
els result in decreased aconitase activity, to produce less 
isocitrate. Aconitase activity is used by the body as an “iron 
sensor”. Decreased isocitrate results in downstream inhi-
bition of erythropoiesis by sensitizing erythroid progeni-
tor cells to the inhibitory effects of IFN-γ (Richardson, et 
al., 2013). This is known as the iron restriction response. 
Supplementation of exogenous isocitrate inhibits the iron 
restriction response via a PKC mechanism (Bullock et al., 
2010).  Isocitrate does not change serum or stored iron 
levels, nor does it alter erythropoietin levels (Kim et al., 
2016). Rather, it seems to “fool the system” into increas-
ing erythropoiesis despite hypoferremia.
Low doses of isocitrate supplementation reversed 
anemia of inflammation in a model of rat arthritis by 
preventing the iron restriction response (Richardson et 
al., 2013). However, later studies found that much higher 
doses were necessary to achieve even transient results 
in mice. Administration of high doses of isocitrate caused 
increased inflammation in these mice (Kim et al., 2016). 
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The necessity of such high doses to improve anemia of 
chronic disease may limit the efficacy of isocitrate as 
a treatment for ACD in humans. Recent research has 
shown that treatment with a combination of isocitrate 
and fumarate is effective in curing anemia of chronic 
disease in a murine model, even at low doses (Goldfarb 
et al., 2019). Further research, including human trials, is 
necessary to determine whether isocitrate may be a clin-
ically appropriate treatment for ACD. It seems reasonable 
to assume, however, that isocitrate treatment may have 
limitations similar to those seen with ESAs, as bypassing 
the iron restriction response would lead to iron deficient 
erythropoiesis. As with ESAs, supplementation with IV 
iron may be beneficial. 
ACD is caused by the result of the interaction of 
various cytokines. Recent research has focused on in-
hibition of these inflammatory signals using humanized 
antibodies as a target for treating anemia of chronic dis-
ease. Inhibition of Tumor Necrosis Factor-α (TNF-α) is 
a common treatment option for the auto-inflammatory 
disease Rheumatoid Arthritis. Treatment with infliximab, 
an anti-TNF-α antibody, reduces hepcidin levels and im-
proves blood parameters in RA patients. TNF-α alone 
actually decreases hepcidin mRNA expression in vitro. 
Paradoxically, TNF-α also upregulates IL-6 production, 
resulting in the downstream upregulation of hepcidin. 
Inhibition of TNF-α reduces IL-6, thereby indirectly re-
ducing serum hepcidin levels, albeit not as effectively as 
direct inhibition of IL-6 (Song et al., 2013). 
Tocilizumab, an IL-6 inhibitor used to treat multi-
centric Castleman’s disease (MCD) and rheumatoid ar-
thritis, effectively reduces anemia of chronic disease in 
these patients. Tocilizumab is a humanized anti-IL6 recep-
tor antibody. It binds to the IL-6 receptor and prevents 
IL-6 binding (Mihara et al., 2011). Tocilizumab completely 
inhibits IL-6 induction of hepcidin expression in vitro. 
Short-term treatment of MCD patients with tocilizumab 
results in decreased hepcidin and amelioration of anemia. 
These results continue when Tocilizumab was given over 
a longer period of time. Hepcidin expression keeps de-
creasing until normal serum hepcidin levels are reached 
and hemoglobin increases. Other iron-related parameters 
improve as well (Song et al., 2010). Tocilizumab decreases 
serum hepcidin and improves iron related blood parame-
ters including hemoglobin, serum iron, ferritin, and MCV 
in rheumatoid arthritis patients as well (Song et al., 2013). 
In monkeys with anemia of chronic disease, IL-6 blockade 
with tocilizumab caused a rapid decrease of serum hepci-
din. Hemoglobin levels and RBC improvement was dras-
tic at first, then slowed and gradually continued until they 
returned to pre-inflammation levels (Hashizume 2010). 
The amelioration of anemia by tocilizumab seems to be 
due to inhibition of IL-6 induction of hepcidin. However, 
as IL-6 plays a role in the pathogenesis of MCD and RA, 
and tocilizumab reduces disease symptoms, it may be that 
the improvement of the underlying disease plays a role in 
decreasing anemia as well. 
A major concern with tocilizumab treatment is its 
immunosuppressive effect and increased risk of infection. 
Additionally, since tocilizumab suppresses biomarkers 
of infection, it is necessary to observe patients closely 
for symptoms that may indicate infection (Mihara et al., 
2011). The STREAM study, which followed RA patients 
receiving tocilizumab monotherapy over a period of five 
years showed the drug to have a good safety profile. The 
majority of the adverse events reported were mild, and 
the benefits of the drug on patient quality of life out-
weighed these events (Nishimoto et al., 2009). It remains 
to be seen whether tocilizumab and other anti-cytokine 
antibodies are safe and effective for treating ACD caused 
by other diseases. 
Perhaps the most targeted approach to treating ACD 
is direct inhibition of hepcidin activity. Monoclonal anti-
bodies (mAbs) and speigelmers which bind to hepcidin 
and prevent its interaction with ferroportin are promising 
developments. A Phase-1 study of the anti-hepcidin mAb 
LY2787106 in humans showed that the antibody was safe 
and well-tolerated in cancer patients with few serious 
adverse effects reported. However, the drug elicited only 
a transient increase in serum iron, which did not translate 
into improved hepcidin, serum ferritin, and TSAT levels 
(Vadhan-Raj et al., 2017). While ineffective alone, this 
antibody may be useful in treating ACD in combination 
with other drugs. 
As an alternative to antibodies, Noxxon Pharma of 
Germany has developed an anti-hepcidin speigelmer 
called Lexaptepid Pegol (Nox-H94). Speigelmers are oli-
goribonucleotides with L-stereochemistry which bind to 
the target protein and inactivate it in a manner similar to 
antibodies. The advantage of a speigelmer over antibodies 
is that it does not elicit an immunological response in 
patients. Its L-stereochemistry prevents the development 
of anti-drug antibodies (ADAs) and also makes it nuclease 
resistant (Schwoebel et al., 2013). Indeed, patients receiv-
ing lexaptepid did not form antibodies specific to the 
drug (Boyce et al., 2016), while some patients receiving 
the mAb LY2787106 did develop ADAs (Vadhan-Raj et 
al., 2017). In vitro, lexaptepid inhibits the hepcidin-in-
duced decrease in ferroportin expression. In monkeys 
with ACD caused by IL-6 injection, lexaptepid pegol par-
tially improved reticulocyte hemoglobin levels, hemato-
crit, and erythrocyte counts (Schwoebel et al., 2013).  A 
34
Sarit Fischer
placebo controlled double blind study of lexaptepid pegol 
in healthy humans showed a dose-dependent increase 
in serum iron, transferrin saturation, and serum ferritin. 
Reticulocyte hemoglobin did not increase in healthy vol-
unteers but would be expected to increase in patients 
with ACD (Boyce et al., 2016).  Lexaptepid temporarily 
prevents the inflammation-induced hypoferremia caused 
by endotoxin injection in heathy individuals (van Eijk et 
al., 2014). While the results have been promising in trials 
involving healthy individuals, further trials in ACD patients 
are necessary in order to know whether Lexaptepid can 
be clinically useful. 
One aspect which may limit the effectiveness of both 
anti-hepcidin antibodies and speigelmers is the relatively 
high production rate of hepcidin. High doses of these hep-
cidin-binding ligands are necessary to keep up with pro-
duction of new hepcidin (Fung & Nameth, 2013). Further 
experimentation, particularly in patients with anemia of 
chronic disease, will show whether this indeed limits the 
clinical value of such treatments.  Even if these drugs are 
ineffective alone, they may be useful in combination with 
other treatments. Low dose antibody neutralization of 
hepcidin was shown to increase responsiveness to ESAs 
in mice with ACD. The combination of the antibody and 
darbepoetin-α completely corrected anemia in these 
mice (Sasu et al., 2010).  If this is shown to be the case 
in humans as well, these drugs could take the place of 
parenteral iron, thereby eliminating the potential safety 
hazards associated with IV iron. 
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Abstract
Scientific and pharmaceutical advancements have revolutionized medicine. Many once- debilitating or fatal diseases can now be 
managed with medication. However, the search for a cure for the inevitable aging diseased state remained futile until recently. 
Rapamycin has been studied for its possible longevity effects, providing promising results for the development of anti-aging therapies. 
This paper evaluates the benefits and risks of rapamycin use. While rapamycin cannot be supported as a safe anti-aging drug, 
rapamycin studies have elucidated parts of the aging pathway, providing a breakthrough for anti-aging research.
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Introduction 
Hutchinson-Gilford Progeria Syndrome (progeria) is a 
rare genetic disease caused by a mutation on the LMNA 
gene which encodes for the Lamin-A protein. This causes 
a modified form of Lamin-A, known as progerin, which has 
an internal deletion of fifty amino acids (Graziotto et al. 
2012). Wild-type Lamin A is the scaffolding of a cell, which 
holds the nucleus together. Researchers believe the variant 
Lamin-A leads to an unstable nucleus that causes the symp-
toms of progeria (The Progeria Research Foundation).
Children with progeria show early signs of aging, which 
include loss of body fat and hair, growth failure, stiffness of 
joints, aged looking skin, hip dislocation, cardiovascular dis-
ease, stroke, and generalized atherosclerosis. The lifespan 
of children with HGPS is fourteen years, with the common 
cause of death atherosclerosis (The Progeria Research 
Foundation). 
The Progeria Research Foundation is currently con-
ducting a clinical research trial to test a possible cure for 
Progeria. The trial is testing the combined use of Lonafarnib 
and Everolimus on HGPS patients. Lonafarnib is a farnes-
yltransferase inhibitor. By inhibiting the attachment of a 
farsenyl group to progerin, the progerin is unable to in-
hibit the cell function (The Progeria Research Foundation). 
Everolimus, a derivative of rapamycin, promotes the auto-
phagy of the progerin (Graziotto et al. 2012).
Increased levels of progerin have been found in the 
skin and arteries of normal, aged individuals (McClintock 
et al. 2007, Olive et al. 2010). The correlation between 
increased progerin and the physiology of aging is seen in 
the rapid aging of HGPS patients with high levels of pro-
gerin and the decrease in age-associated symptoms upon 
autophagic degeneration of progerin. Thus, the correla-
tion between HGPS and normal aging suggest rapamycin 
as a possible drug to promote longevity in the general 
population (Graziotto et al. 2012).
In 2009, a study showing that rapamycin extends the 
lifespan of mice was published.  This was the first study to 
realize the anti-aging properties of rapamycin on mam-
mals (Harrison et al. 2009). Since then, rapamycin has 
been explored as a possible anti-aging drug for humans. 
Method
Articles sourced in this paper were obtained by searching 
Touro’s database and Google Scholar. Some articles were 
referenced in review articles and the original articles 
were retrieved. Additionally, data was obtained from the 
Progeria Research Foundation and the lecture of Michael 
Hall who discovered and studies TOR.
Discussion  
The Mechanism of Rapamycin
Rapamycin is a macrocyclic lactone secreted by the bacte-
rium streptomyces hygroscopicus which was discovered 
on the Easter Island (Tee 2018). Is was originally intended 
for use as an antifungal. However, its immunosuppressive 
and anti- proliferative properties rendered it unsuitable 
as a safe antifungal treatment. Instead, these properties of 
rapamycin led to its development for other purposes, and 
rapamycin along with its derivatives are FDA approved 
for use as immunosuppressants and an anticancer agent 
(Lamming 2016).
Rapamycin combines with FKBP to inhibit the activity of 
the mechanistic target of rapamycin (mTOR), which is part 
of the phosphatidylinositol 3-kinase-related kinases family 
(Hall 2016). The mTOR protein forms two protein kinase 
complexes - mTORC1 and mTORC2, both balancing cell 
growth and metabolism with degradation.  The mTOR 
pathways responds to favorable growth conditions, such 
as adequate nutrition, resources, and growth factors by 
stimulating anabolic processes (Kennedy, Lamming 2016, 
Laplante, Sabatini 2009). Conversely, stressful conditions 
in the cell inhibit the mTOR pathway, thereby inducing 
catabolic processes (Laplante, Sabatini 2009). 
The two mTOR complexes have some shared compo-
nents. They both contain the mTOR core, the regulatory 
protein Deptor, and mLST8/GβL to ensure complex as-
sembly and stability (Kennedy, Lamming 2016).
In mTORC1, the mTOR protein kinase interacts 
with the scaffold protein Raptor, and the AKT substrate 
PRAS40 (Kennedy, Lamming 2016). As shown in in Figure 
1, MTORC1 controls many processes, including protein 
synthesis, lipid synthesis, autophagy, mitochondrial metab-
olism, and biogenesis (Laplante, Sabatini 2009).  Many of 
the functions of mTORC1 are inhibited by acute exposure 
to rapamycin which causes a decrease in biosynthesis and 
an increase in biodegradation (Tee 2018, Hall 2017). 
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MTORC2 contains the scaffold protein Rictor, the 
protein subunits mSIN1 and Protor-1/2 (Laplante 2009). 
Prolonged rapamycin use inhibits mTORC2 by binding to 
free mTOR and preventing it from forming the mTORC2 
complex (Johnson et al. 2013, Sarbassov et al. 2006, Tee 
2018). MTORC2 is stimulated by IGF-1, insulin, and leptin 
(Kennedy, Lamming 2016).  MTORC2 regulates mTORC1 
via the phosphorylation of AKT. AKT phosphorylates 
TSC2, which is part of the TSC complex. TSC2 promotes 
the conversion of Rheb-GTP, which activates mTORC1 
to Rheb- GDP. Therefore, the phosphorylation of TSC2 
inhibits this conversion process, allowing the Rheb-
GTP complex to remain in its active form and activate 
mTORC1 (Manning, Toker 2017). AKT also phosphory-
lates PRAS40It, which is an inhibitor of mTORC1 in its 
unphosphorylated form (Sancak et al., 2007). The other 
regulatory functions of mTORC2 include regulating cell 
survival, metabolism, proliferation, and 
cytoskeleton organization (Laplante, 
Sabatini 2009). The pathways involving 
mTORC2 are outlined in Figure 2.
What Anti-Aging Effects does 
Rapamycin have on the Body?
MTORC1 controls many processes linked 
to aging. Therefore, the inhibition of these 
processes by rapamycin contribute to 
the drug’s anti-aging effects (Johnson et 
al. 2013). The suggested mechanisms of 
reduced aging by mTORC1 inhibition are 
discussed in this section. 
MTORC1 inhibition promotes autophagy, 
which is the recycling of amino acids and 
degradation of damaged macromolecules 
and organelles.  Autophagy in the cells 
declines with age, and it is proposed that 
the accumulation of damaged particles 
contribute to cellular dysfunction of aged 
individuals (Cuervo 2008).  MTROC1 in-
hibition promotes autophagic mediated 
longevity, as supported by studies on yeast 
and invertebrate (Johnson et al 2013).
Regulation of mRNA translation is an-
other process that may contribute to the 
anti-aging benefits of rapamycin. Under 
favorable growth conditions, mTROC1 
promotes mRNA translation and protein 
synthesis. Inhibition of mTORC1 reduces 
translation, and studies on yeast, nema-
todes, fruit flies, and mice provide evidence 
that regulation of mRNA translation in-
creases lifespan (Kaeberlein, Kennedy 2011). A main rea-
son for the increased lifespan accompanying global mRNA 
translation reduction is the differential protein translation 
of specific mRNA. Molecular evidence is seen in yeast; 
when mTORC1 is inhibited Gcn4 is preferentially trans-
lated and increased translation of Gcn4 increases lifespan. 
Similar mechanisms are seen in studies of nematodes and 
fruit flies (Johnson et al 2013).
Another function possibly contributing to the anti-ag-
ing benefit of rapamycin is reduced inflammation through 
mTORC1 inhibition. Hyperactivation of mTORC1 causes 
inflammation which is present in many age-related dis-
eases such as kidney disease, vascular inflammation after 
angioplasty, atherosclerotic plaques, and lung infection. 
Therefore, rapamycin use reduces inflammation associated 
with these diseases. (Johnson et al 2013).
Additionally, studies on yeast link mTORC1 inhibition to 
Figure 1. Diagram of the pathways involving mTORC1 (Kennedy, Lamming 2016)
Figure 2. Diagram of the pathways involving mTORC2 (Kennedy, Lamming 2016)
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the activation of a stress response pathway. The increased 
stress resistance promotes lifespan extension. Also, regu-
lation of mitochondrial function and enhanced stem cell 
function seem to contribute to the longevity effects of 
rapamycin (Johnson et al 2013). 
Rapamycin Studies on Mammals
The 2009 study conducted by Harrison et al. on 1,901 mice 
provides evidence for the longevity effects of rapamycin on 
mammals. In comparison to the control group, rapamycin- 
fed female mice had a 13% lifespan extension, and male 
mice had a 9% lifespan extension. The average age of the 
mice was 600 days, which is the equivalence of 60 years in 
humans. Thus, the study demonstrates rapamycin’s effec-
tiveness when started late in the lifespan. 
In 2019 Sills et al. studied the safety of rapamycin on 23 
middle-aged marmosets who were fed rapamycin for nine 
months. The marmoset showed no significant side effects 
and only minor effects on hematological markers.  Since 
marmosets are biologically similar to humans, the study 
suggest similar outcomes would occur in humans. 
Rapamycin Side Effects in Humans
Although rapamycin has been found to increase the lifes-
pan of flies, mice, and marmosets, few studies have tested 
its anti-aging effect on humans (Graziotto et al. 2012). This 
section will review negative side effects of rapamycin treat-
ment and the evidence to support the drug as an anti-aging 
therapy for humans. 
Many studies on rapamycin have been conducted on im-
munocompromised patients. Side effects of renal and heart 
transplant patients taking rapamycin for its immunosup-
pressive property include delayed wound healing, intersti-
tial pneumonitis, anemia, high cholesterol and triglyceride 
levels, infection, edema, and gastrointestinal symptoms. 
(Baur et al. 2011, Ekberg et al. 2010, Graziotto et al. 2012). 
Long term side effects of rapamycin include glucose intol-
erance, decreased insulin sensitivity, and increased risk of 
new onset diabetes (Johnston et al. 2008, Lamming 2016). 
While these reported side effects may seem to outweigh 
the potential benefits of rapamycin, it is important to con-
sider that the adverse effects may be influenced by the 
patients’ underlying condition or drug interactions (Kraig 
et al. 2018).
A small-scale study found that short term everolimus 
treatment boosted the immune response of normal, elderly 
individuals to the flu vaccine. This suggests that rapamycin 
improves immunosenescence, one characteristic of aging. 
Since rapamycin is also known for its immunosuppressive 
properties, its effects on the immune system seem to be de-
pendent on disease, age, and/or antigen (Mannick et al. 2014).
 Another small-scale study of a similar population found 
rapamycin use safe for elderly individuals with stabilized 
medical conditions. This population did not show a signifi-
cant change in plasma glucose, insulin, and insulin sensitivity, 
which contrasts with the increased risk of diabetes seen 
with transplant patients. Additionally, there was no significant 
elevation in triglyceride levels, which was also a concerning 
side effect seen in previous studies. The side-effects report-
ed in the study group were limited to a facial rash and GI 
symptoms. However, the study did not reveal any change 
in cognitive functioning, physical performance, or immune 
parameters. While these results do not support the anti-ag-
ing benefits of rapamycin, the limited side-effects on normal 
individuals support the safety of rapamycin use for further 
clinical testing (Kraig et al. 2018). 
Despite the promising results of life extension seen in 
mammals, only a limited number of clinical trials with small 
sample sizes were conducted on humans. Therefore, rapa-
mycin must undergo further studies to determine its efficacy. 
Conclusion/Further Research
The substantial side-effects associated with rapamycin 
use in transplant patients makes it difficult for it to be 
approved as a preventative aging treatment. However, 
the discovery of life extension by inhibiting mTOR pro-
vides a basis for the search of other anti-aging treatments 
that work by a similar mechanism. One suggestion is 
MTORC1 specific- inhibition, which is sufficient to extend 
lifespan and may have reduced side effects. Studies have 
demonstrated the importance of mTORC2 in human 
physiology and metabolism (Lamming et al. 2016). For 
example, mTORC2 plays an important role in B-Cells, 
T-cell and macrophages (Byles et al. 2013, Festuccia et al. 
2014). Additionally, prolonged ex-vivo exposure to rapa-
mycin inhibits lipogenesis in rat hepatocyte which can be 
attributed to the disruption of mTORC2 (Brown et al. 
2007, Kennedy, Lamming 2016). 
Kennedy and Lamming found that while chronic expo-
sure to FKBP12-rapamycin complex inhibits mTORC2, 
chronic exposure to the rapamycin-FKBP51 complex 
does not inhibit mTORC2. The binding affinity of rapa-
mycin with FBPK51 has an inverse relationship with the 
inhibition of mTROC2. Therefore, a rapamycin analog 
with a strong affinity for FKPB51 should be studied as a 
mTORC1 specific inhibitor (2016). 
Another possibility, which is not well-studied, is to har-
ness the benefits of rapamycin by eating a low-protein 
diet. Amino acids are one of the stimuli for mTORC1, 
but not mTROC2 (Lamming 2016). Studies show leucine 
consumption affects mTORC1 activity in humans, and a 
short-term protein-free diet reduces mTORC1 signaling 
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(Moberg et al. 2014, Harputlugil et al. 2014). The branch- 
chain amino acids - leucin, isoleucine and valine – enhance 
the mTORC1 activity in skeletal muscle, liver, pancreas 
and adipose tissue in rodents. Therefore, a diet with lim-
ited proteins or specific amino acids may provide a more 
natural approach to reduce aging (Lamming 2016).
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Immunotherapeutic agents have been researched for many decades as an alternative treatment for cancer. Current research 
demonstrates that immunotherapy is safer than radiotherapy or chemotherapy. This is attributed to immunotherapy’s mechanism 
of utilizing the body’s own defense system, as opposed to absorbing harmful chemicals. Two forms of immunotherapy that have 
been effective in curing cancer without the added danger of chemical toxicity are PNC-27 and PNC-28. These peptides were cre-
ated by a supercomputer at SUNY Downstate Medical Center in New York in 2000. PNC-27 and PNC-28 work with the MDM2 
-P53 tumor suppressor complex. It acts as a competitive inhibitor for binding, increasing the half-life of P53 in the cell and assisting 
with the elimination of cancer cells (Sarafraz-Yazdi E, Bowne WB, et al 2010). These immunotherapy agents also have the ability 
to bind to the cell membrane and lyse the cell. The clinical trials for PNC-27 and 28 were successful, and the drug is currently in 
use outside of the United States. Although this form of immunotherapy does come with some side effects, research illustrates that 
this form of immunotherapy can be a successful strategy in eliminating the cancer and ensuring that a relapse does not occur.
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Introduction
Cancer is one of the three leading causes of death across the 
globe. Although researchers have been discovering cures for 
many diseases, the cure for cancer still eludes them. There 
are over 240 different forms of tumors that currently exist, 
and each type comes with a unique mechanism that can 
help it evade treatment. Tumors are caused by the ongoing 
replication of a cell that does not adhere to cell regulations 
for replication (Vassilev A, DePamphilis, 2017). Due to the 
fact that tumors arise from our own cells, in order to cure 
cancer, researchers have to come up with a treatment that 
exclusively destroys malignant cells, keeping the healthy cells 
intact. While there are many cures being evaluated in cur-
rent research that target all cells,PNC-27 and PNC-28 have 
the ability to target cancer cells only.
There are millions of cells in the human body. In order for 
cells to thrive, the cells need to be replicated to ensure con-
tinuity. New cells are constantly being created as old cells are 
dying. Cells are converted to tumor cells when the check-
points that are responsible for monitoring the division do not 
proceed as expected. (Chao et al., 2017) When the cell me-
tastasizes and travels to another region within the body, the 
tumor is transformed into a potentially lethal cancer.
When a cell goes through the division process, it repli-
cates all of its chromosomes and sends an identical copy 
to the new version of the cell that was formed. The pro-
cess by which this is done is called mitosis. The cell has 
three phases that ensure that cell replication is proceeding 
correctly. These three checkpoints that ensure the legit-
imacy of DNA are known as the M Phase (Mitosis), G1 
Phase (Gap 1), and the G2 Phase (Gap 2). At the G1 phase, 
the accuracy of the DNA is evaluated before proceeding. 
At G2, the chromosome duplication is assessed. (Veron, 
2017) After these checkpoints, the cell goes on to pro-
duce identical daughter cells. In a normal, healthy cell, if a 
cell does not pass these checkpoints successfully, the cell 
is destroyed. These checkpoints are the main regulators of 
replication and ensure a low rate of errors in the DNA.
The process of mitosis guarantees perpetuation of life, 
but it can prove lethal if it proceeds unchecked. Genetic 
mutation (regardless of whether it was caused by carcino-
gens or through random errors during DNA replication) 
takes place in cells throughout the lifetime of an organism 
(Ahluwalia, 2009). When one of these mutations results in 
the breakdown of cell cycle regulation, it gives rise to an 
“unregulated proliferating descendant clone of that par-
ticular cell’’ (Cooper, 2000). This clone of cells can form 
a tumor. Tumors arise with significant frequency, but most 
tumors pose slight risk to their host cell due to tumor 
cell localization. These tumors are known to be benign tu-
mors. It is generally evident when a tumor is benign since 
the cells bear a close resemblance and role comparable to 
normal cells. (Mims, et al. 2015).
One of the most significant stages in the diagnosis of 
cancer patients is the series of events leading to the de-
velopment of tumor cell invasion and metastasis. Cancer 
metastasis is the dispersion of cancer cells to tissues and 
organs outside the original site of the tumor. Once a tumor 
has left its original source, it travels and forms additional 
tumors in other organs. This process occurs in three main 
developments: invasion, intravasation, and extravasation.
Metastasis occurs due to a loss of cell to cell adhe-
sion. Initially, the malignant tumor cells isolate from the 
main mass at the original source. Subsequently, the cells 
proceed to invade the surrounding stroma. This devel-
opment causes the secretion of substances to degrade 
the basement membrane and extracellular matrix of the 
organ it has invaded (Shields JA, Shields CL, 2016). The 
secretion of substances helps express the proteins that 
mediate the control of the tumor’s motility. In addition to 
the tumor’s ability to migrate to other organs, there is a 
process called angiogenesis. The process of angiogenesis 
is necessary for the tumor to exist and keep itself satiat-
ed. Angiogenesis is the development of new blood vessels 
that aid with local diffusion. This helps the cell sustain 
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itself with nutrients, oxygen and transporting metabolic 
wastes (Nowak-Sliwinska P, 2018).
After invading other organs, the tumor then goes 
through the introversion stage. Introversion allows for 
the tumor to make pathways throughout the blood so it 
can travel through the body and settle in another location. 
The tumor networks with the endothelial cells through 
biochemical interactions. This process is regulated by a 
carbohydrate-carbohydrate reaction.
Adhesion to the endothelial cells creates more solid 
bonds to penetrate the endothelium and the basement 
membrane (More SK, Vomhof-Dekrey EE, Basson MD., et 
al 2019). Through this process, the new tumor reproduces.
As mentioned previously, the common driving force 
behind cancer is a genetic mutation, but there are many 
distinctions in how cancer can evolve. There are different 
mutations that can alter the genes standard structure and 
function. It is generally not possible to determine what 
the underlying cause of the mutations. However, research 
has linked different risk factors to an increased probabili-
ty of cancer. Carcinogens and viral or genetic factors have 
all been linked to cancer. For example, exposure to the 
environment plays a role in how genes will be transcribed. 
The atmosphere and our food contain many toxins that 
can cause mutations. UV radiation that is induced by ex-
posure to the sun without ensuring proper protection 
causes thymine dimers, which researchers believe causes 
skin cancer. Smoking is also a significant cause of cancer.
Chemicals in tobacco smoke harm the cleansing system 
that the body employs to remove toxins. Thus, smok-
ers are not as capable of handling toxic chemicals as 
those with healthy lungs and blood (O’Keeffe LM 2017). 
Moreover, smoking damages DNA, and generates potent 
carcinogens which not only affect the trachea, bronchial 
system and lungs, but also permeate the entire system.
Methods
Data was collected using ProQuest and PubMed data-
bases, and the National Library of Medicine. The images, 
graphs, and diagrams are in the research articles refer-
enced. Additional materials were found in the SUNY (State 
University of New York) Downstate research library.
Radiation Therapy Mechanism:
Treatment of cancer originally involved surgical removal 
techniques alone. Over the previous centuries, radiation 
therapy has been discovered as an alternate treatment. 
Radiation therapy treats cancer by focusing beams of in-
tense energy on a specific part of the body to eliminate 
cancer cells. Some of these forms of energy typically in-
cludes X-rays, but can also use high-energy particles or 
waves, such as gamma rays, electron beams, or protons. 
The larger the amount of energy involved in the therapy, 
the more penetration is accomplished by the ionizing ray 
into the cancer tissue (Orth M, Lauber 2014). The ioniz-
ing ray kills the cells that are actively dividing. Although 
radiation is effective for preventing division of rapidly di-
viding cells, it can cause only minimal breaks in the DNA. 
Nevertheless, these breaks stop cancer cells from repli-
cating and producing, activating their elimination. It can 
be used to shrink early stage cancer, or treat advanced 
symptoms of cancer.
Radiation therapy attempts to strike a balance by elim-
inating the harmful dividin cells and minimizing damage to 
the normal cells around the tumor site. Normal cells can 
often repair much of the damage caused by radiation. The 
majority of people with cancer receive radiation therapy 
as part of their treatment plan, along with a combination 
with other treatments.
Physicians prescribe radiation therapy to treat all forms 
of cancer, including benign tumors. Although radiation 
therapy is effective, research shows that radiation therapy 
has a large number of side effects. These include tooth 
decay, third degree skin burns, and difficulty breathing 
(Murphy, et al. 2019). Radiation therapy is rationed, and 
there is a limit to the amount of radiation people can 
safely receive. Depending on how much radiation an 
organ has received during the first round of treatments, 
the body may not have the ability to receive radiation a 
second time.
The major lethal side effect of radiation therapy is the 
relapse of the cancer. Because radiation therapy damag-
es healthy cells, these damaged cells can metastasize to 
other locations and cause a recurrence of the cancer. 
Most types of leukemia cancer, including acute myelog-
enous leukemia (AML), chronic myelogenous leukemia 
(CML), and acute lymphoblastic leukemia (ALL) are all 
forms of cancer that originate from radiation exposure. 
Myelodysplastic syndrome (MDS), a bone marrow cancer 
that may evolve into leukemia, has also been associated 
with previous radiation exposure” (Cidon,EU 2016). Not 
all cancers may return immediately after radiation thera-
py. Research shows that solid tumors take much longer to 
develop, and don’t come back quickly. Most of these can-
cers are not spotted for years after the radiation therapy 
has caused the damage, and some are diagnosed more 
than a decade later. We may be inevitably perpetuating 
the disease itself by using radiation therapy as an option.
C Hemotherapy Mechanism:
A common form of treatment that is currently in use 
is chemotherapy. Chemotherapy is a systemic treatment, 
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and travels through the bloodstream. The treatment is 
often given to the patient for a specific time, ranging from 
6 months to a year. In cases where there is no possible 
cure, chemotherapy may be given to extend the patient’s 
life, or relieve painful symptoms. The drugs are usually 
given by IV or orally. Chemotherapy has a lower probabil-
ity of damaging cells that are at rest, such as most normal 
cells. Physicians can prescribe the treatment after surgery 
was performed to remove the original tumor, in order to 
eliminate the individual cancer cells that may have metas-
tasized before they are able to form a tumor.
The mechanism of chemotherapy is to eliminate cancer 
cells by targeting different cells at different phases of the 
cell cycle in order to halt the replication. The chemother-
apy damages the genes inside the nucleus of cells, and 
attack cells that are at the point of splitting. Some dam-
age the cells while they are replicating their gene before 
they split (Johnstone RW, 2016). Some chemotherapeutic 
agents attack the DNA of the cell by adding a methyl 
group, in order to prevent them from producing addition-
al clones of the cancer cell. These are known as alkylat-
ing agents, and they attach to DNA, RNA, and proteins 
through covalent bonding.
Alkylating agents will attack at any point in the cell 
cycle. There are many types of alkylating groups, such as 
nitrogen mustards, nitrosoureas, and aziridines. The mol-
ecules bind to the DNA and change the DNAs confor-
mation. DNA is composed of a double strand, and the 
molecules may either bind two times to one strand of 
DNA (known as a “intrastrand crosslink”) or may bind 
once to both strands (called a “interstrand crosslink”)” 
(Figure 1). If the cell attempts to replicate or fix cross-
linked DNA during cell division, the DNA strands break 
(Cancer Chemotherapy and Biotherapy, 2005). This leads 
to a form of programmed cell death called apoptosis.
Another chemotherapy drug that interferes with tran-
scription and translation is a topoisomerase inhibitor. 
When the DNA double-strand helix is unwound during 
DNA replication or transcription, the adjoining DNA 
(that has not been opened yet) is wound up extremely 
tightly. The topoisomerase inhibitor produces single- or 
double-strand breaks into DNA, reducing the tension in 
the DNA strand ahead of the replication point (Figure 
2) This allows the normal unwinding of DNA to hap-
pen during replication or transcription. Inhibition of to-
poisomerase does not allow either of these processes 
to continue (Nitiss JL, 2007). Other chemotherapy drugs 
interfere with cell metabolism. This blocks off nutrients 
and oxygen supply, which causes growth arrest.
Research has shown that chemotherapy has many side 
effects. Some of these side effects include fatigue, hair 
loss, infection, fertility problems, weight loss, damage to 
lung tissue, heart problems, kidney problems, and nerve 
damage (Uzun, 2019).) Studies show that one of the pri-
mary drawbacks is that chemotherapy does not achieve 
remission. One reason is that the original treatment is 
not successful in eliminating all the cancer cells. The re-
maining cancer cells that are left in the organ grew into 
a new tumor. Another reason that chemotherapy is not 
successful in achieving remission is that some cancer cells 
have metastasized to other parts of the body and started 
forming a new tumor in the new location. Cancer cells 
may also develop a mechanism that makes it become re-
sistant to treatment when it relapses, thereby blocking a 
possible cure (Stadlr, WM, 2014).
Immunotherapy
Researchers have discovered that one of the best methods 
(Figure 1) The figure illustrates two DNA bases that are cross-
linked by a nitrogen mustard (Siddik ZH 2005
(Figure 2) Topoisomerase I and II Inhibitors (Huda W. 2016)
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for treating cancer is immunotherapy. Immunotherapy is a 
biological therapy that utilizes substances made from living 
organisms to treat cancer. Some immunotherapy treat-
ments use genetic engineering to improve immune cells’ 
cancer-fighting capabilities and are commonly referred to 
as gene therapies. Many immunotherapy treatments for 
preventing, managing, or treating different cancers can 
also be used in combination with surgery, chemotherapy, 
radiation, or targeted therapies to aid their overall effec-
tiveness (Yang, Wang, Wang, 2019).
Immunotherapy boosts the immune system’s ability to 
identify, target, and remove cancer cells. While many cells 
replicate naturally, this behavior is tightly regulated by an 
assortment of factors, including the genes within cells. 
When growth is not required at certain points, cells are 
instructed to halt growth. Cancer cells acquire defects 
that cause them to ignore these inhibitive signals, and 
their replication proceeds in an unregulated and rapid 
manner. Because cancer cells grow and behave through 
abnormal methods, this can alert the immune system of 
a potential threat, which can recognize and eliminate can-
cer cells through a process called immunosurveillance.
Immunosurveillance is an extremely effective method 
for eliminating pathogens from the body, but the process 
isn’t always successful when it pertains to cancer. Even 
though the immune system can prevent or slow cancer 
growth, cancer cells have ways to evade destruction by 
the immune system. For instance, cancer cells may have 
genetic changes that make them appear less discernible 
to the immune system, have proteins on their surface that 
turn off immune cells, or change the normal cells around 
the tumor so they interfere with how the immune system 
responds to the cancer cells (Pardoll D. 2015).
Cancer cells develop ways to evade and escape the im-
mune system, which allows them to continue to thrive 
and metastasize to other organs (Prendergast GC, Jaffee 
EM, 2007).
Therefore, immunotherapies are designed to enhance 
the cancer-fighting capabilities of immune cells and utilize 
the body’s own protective measures to fight the tumors.
NC-27 and PNC-28 Peptides
PNC-27 and PNC-28 are synthetic peptides designed to 
specifically target and destroy cancer cells. Therapeutic 
peptides have the ability to treat an extensive range 
of diseases and cancers and contain a large number of 
advantages over proteins or antibodies. They are easily 
synthesized in a lab and are not toxic to the human body. 
They are manufactured to have a very specific affinity for 
the targeted cell. PNC-27 and PNC-28 were created using 
a super computer by Dr. Matthew Pincus and Dr. Joseph 
Michl of SUNY Downstate Medical Center. The peptides 
were created with a specific fold that only interacts with 
a particular structure present on cancer cells. It can be 
administered by nebulizer, vaginal or rectal suppository 
or intravenously at the tumor site. Many patients travel 
to foreign countries to receive this treatment. PNC-27 
and PNC-28 have been used with exceptional results, 
and over 500 patients have had a high success rate with 
the drug since 2007. PNC-27 and PNC-28 peptides have 
been shown to be highly effective in specifically targeting 
a large variety of different cancers. These peptides have 
had high success rates with breast cancer, leukemia, mela-
noma, and pancreatic cancer lines. It has proven to be the 
most effective when taken simultaneously with immune 
system boosters, proper hydration, and a diet that avoids 
excess sugars and red meat.
P 53 Mechanism for PNC-27 AND PNC 28
TP53 or ‘’tumor protein 53’’ is a gene that is located on 
the seventeenth chromosome of humans. It codes for a 
protein that regulates the cell cycle and hence functions 
as a tumor suppressor. P53 has been described as “the 
guardian of the genome”, referring to its role in keeping 
the cell stable by preventing genome mutation (Uehara 
2018). TP53 has 4 domains that are responsible for acti-
vating transcription factors, tetramerization of proteins, 
recognizing DNA sequences, and checking damaged 
DNA (Sabapathy et al 2019).
The p53 tumor suppressor has a very significant role in 
growth arrest, DNA repair, and apoptosis, and it causes a 
response to different attacks on the cell. Rapid induction 
of high p53 protein levels by various stress types prevents 
inappropriate propagation of cells carrying potentially 
mutagenic, damaged DNA (Zhang et al., 2014). In normal 
cells, p53 is an extremely unstable protein that has a half-
life ranging from 5-30 minutes. The p53 protein is present 
at very low levels in the cell, due to continuous degrada-
tion. This continuous degradation is primarily regulated 
by MDM2. Research over the past decade has assigned 
MDM2 as the central controller of p53 by regulating the 
p53 tumor suppressor function (Carotenuto, 2019).
A mutation of the p53-MDM2 complex during the in-
duction of p53 can lead to the accumulation of active 
p53 in the cell (Figure 3). Consequently, p53 half-life ex-
tends from minutes to hours. This can aid p53 in stopping 
cancer. Both PNC-27 and PNC-28 were tested as agents 
that would competitively block p53 from interacting with 
HDM-2. By acting as a competitive inhibitor, the peptides 
would prolong the half-life of p53 in cancer cells. This 




Mechanism through Membrane and Affinity to HDM2
The PNC-27 and PNC-28 cancer peptides are substanc-
es that causes the death of cancer cells only. PNC-27 
and PNC-28 accomplish this due to their affinity for 
binding to a protein called HDM-2. Cancer cells have 
high levels of HDM-2 present in their cell membranes. 
(Ehsan Sarafraz-Yazdi, Wilbur B. Bowne, 2010). Dr. Ehsan 
Sarafraz-Yazdi (Sarafraz-Yazdi E et al 2015) explains in de-
tail how the PNC-27 and PNC- 28 cancer peptide mani-
fests themselves, and what their mechanisms could mean 
for progress in the field of cancer research. The study 
points out that the peptide’s mechanism hinges on the 
fact that there are formations of oligomeric pores in the 
plasma membrane of tumor cells. (American Association 
for Cancer, 2010) The oligomeric pores are present exclu-
sively in cancer cells. Additionally, the observations illustrat-
ed that PNC-27 and PNC-28 were capable of distinguishing 
between cancerous and non-cancerous cells.
In a 2009 study, researchers discovered that the ’’ 
three-dimensional structure of PNC-27’s and PNC-28’s 
p53 residues of its amino acids may be superimposable 
onto the structure for the same residues bound to HDM-
2.” This discovery alerted researchers to the fact that that 
PNC-27 and PNC-28’s could target HDM-2 in cancer cells’ 
membranes (Pincus, et al (2011)).
Upon further research, it was discovered that by “insert-
ing untransformed cells that are not prone to PNC-27 and 
PNC-28 with HDM-2 containing a localized membrane 
signal, these cells then became inclined towards PNC-27 
and PNC-28”. This research established that the PNC-27 
peptide was able to exclusively mark HDM-2 in the mem-
branes of cancer cells and destroy them through mem-
branolysis, while at the same time leaving the healthy cells 
alive (Sookraj, et al (2010). Additional research established 
that PNC-27 and PNC-28 uses the entire peptide when 
destroying cancer cells, as opposed to fragments. (Cancer 
chemotherapy and pharmacology, 2010).
“The PNC-27 peptide has an HDM-2 binding domain 
that has the same residues 12-26 of p53 and a transmem-
brane-penetrating domain (Sarafraz-Yazdi, et al, 2010). 
PNC-28 is a p53 peptide from its HDM2-2-binding do-
main (residues 17-26), which contains the penetratin se-
quence enabling cell penetration on its carboxyl terminal 
end. This domain is connected to a transmembrane-pen-
etrating sequence, also referred to as the 
membrane residency peptide (MRP). When 
p53 binds to the HDM-2 protein through the 
12–26 amino acid sequence, HDM-2 causes 
ubiquitination of p53 that targets it for pro-
teolysis in the proteasome. Both PNC-27 and 
PNC-28 peptides , which contains a sequence 
that is identical to that of PNC-27 but lacks 
the first six amino acid residues of PNC-27 
(i.e., p53 residues 17-26), are highly toxic to a 
wide variety of cancer cells with IC50 values 
that range from around 75 ug/ml (18.6 uM) to 
200 ug/ml (50 uM).” “While PNC-27 and PNC-
28 are toxic to cancerous cell, neither peptide 
affects normal cells that are in culture, even at 
the highest doses (around 500 ug/ml) tested”. 
This discovery illustrates that both peptides 
would not be toxic to the human body, in con-
trast to the effects of many chemotherapeutic 
agents (Davitt K, Babcock BD, 2014).
In a newer study that was analyzed in 
2014 and published in Annals of Clinical & 
Laboratory Science, researchers conclud-
ed that “the anti-cancer peptide, PNC-27 and PNC-28, 
induces tumor cell necrosis of a poorly differentiated 
non-solid tissue mammalian leukemia cell line that de-
pends on expression of HDM-2 in the plasma membrane 
of these cells.” (Davitt, et al (2014). Studies based on in-
formation discovered in earlier experiments illustrated 
that the PNC-27 and PNC-28 peptides were able to de-
stroy solid tissue tumor cells through the mechanism of 
binding to HDM-2 proteins in their cell membranes, an 
effect which was an effect that was different from the p53 
activity in those cells.
The scientists wanted to determine whether PNC-27 
(Figure 3) A chart of the disruption of mdm2 and the p53 complex (Hashimoto N, 
Nagano H, 2010)
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peptide would also be effective against non-solid tissue 
tumor cells (Davitt et al., 2014). Their study determined 
whether the non-solid tissue tumor cells expressed 
HDM-2 in their membranes in the first place (solid tis-
sue cells were found to do so), and find if PNC-27 could 
cause these cell’s death by the HDM-2 binding. The re-
searchers observed that these non-solid tumor cells do 
express HDM-2 in cell membranes.
They also noted that the PNC-27 peptide could cause 
cell destruction through membranolysis through the 
same HDM-2 binding mechanism as it did in the solid 
tissue tumor cells, independent of the p53 pathway. The 
research established that the peptides are successful for 
both solid and non-solid tumors, making it a valuable drug 
that could treat a variety of cancers.
Studies and Trials on PNC-27 and PNC-28
Electron microscopy was utilized to observe the levels of 
HDM2 in the cell membrane (Wang, et al 2010). Parts of 
the membrane were isolated, and whole cell lysates from 
several different cancer and untransformed cell lines are 
shown in the figure below. The cells were blotted for 
HDM-2 (Figure 4). “In the lower section in the table, it can 
be seen that all whole cell lysates had positive results for 
the blotting procedure for HDM-2. On the upper section 
for the blots shown in the figure, the membrane fraction of 
each cancer cell line (lanes 4–7) is seen to contain signifi-
cant levels of HDM-2. In contrast, the three untransformed 
cell lines (lanes 1–3) were discovered to contain low 
levels of HDM-2 in the region22 of the membrane. The 
percentage of whole cell lysate of HDM-2 present in the 
membrane fractions of the cell lines is shown in the lower 
section of the bar graph.” (Safaraz-Yazdi E, Bownwe WB, 
2010) The graph illustrated that the fractions of HDM2 
present in the membranes of the cancer cell lines have an 
increased level of four-fold to nine-fold.
When the PNC-27 peptide was tested, researchers 
noted pain levels drop in the average time of a week. 
Three weeks following the administration of the peptide, 
the subjects sometimes developed flu-like symptoms. 
This is an indicator that the immune system had the abil-
ity to recognize and react to the death of cancer cells 
(Sookraj, Ka, Bowne WB 2010). Additionally, when the 
cancer killing peptide PNC-27 was administered after 
tumor growth had occurred at a different site from the 
original tumor, the tumor decreased in size, followed by 
a gradual increase in tumor growth that was “significantly 
slower than growth in the presence of control peptide.” If 
the cancer killing peptide is immediately senttouro to the 
tumor, researchers concluded that the peptide would be 
successful in treating cancer. (Prendergast, Jaffee, 2007). 
At six weeks, the researchers noted an increase in lactate 
dehydrogenase and bilirubin levels.
At ten weeks, a large amount of tumor breakdown is 
noticeable. At the same time, the tumors become softer 
and pliable. In addition, some increase in the size of the 
tumor itself occurred simultaneously. However, this can 
often be attributed to inflammation because of immune 
system response. At about three months, researchers 
saw that the subjects of the study exhibited better ener-
gy levels and less cancer-related symptoms.
A study published in the International Journal of Cancer 
(2006) writes that researchers discovered that PNC-28 
was able to reduce the rate of cancer cell growth in an 
organism at a quicker pace. Research tested PNC-28 to 
analyze its function to halt the replication of cancer cells. 
When PNC-28 was given over a two-week timeframe, 
the PNC-28 caused complete destruction of these tu-
mors. (Science Daily, 2006) When administered simulta-
neously with tumor implantation, PNC-28 blocked the 
tumor growth entirely in the duration of the two-week 
period of administration, as well as two weeks after treat-
ment, followed by weak tumor growth that leveled off at 
(Figure 4) “Blots of whole cell lysates (Lower) and membrane 
fractions (Upper) for H (M) DM-2 in different cell lines as follows: 
Lane 1, MCF-10-2A; lane 2, BMRPA1; lane 3, AG13145 fibroblasts; 
lane 4, TUC-3; lane 5, MIA-PaCa-2; lane 6, MCF-7; lane 7, A-2058. 
The first three cell lines are untransformed; the remainders are 
different cancer cell lines. Each bar graph shows the percentage 
of HDM-2 in whole cell lysate that is present in the membrane 
of each cell line listed above. The numbers on the X axis of the 
bar graphs correspond to the lane numbers shown in the blots.” 
(Safaraz-Yazdi E, Bownwe WB, 2010)
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low tumor size (Bowne WB, Sookraj KA, 2015). The trials 
on both drugs supported the theory that immunotherapy 
is able to eliminate cancer cells without causing damage 
to the human system.
 All methods and studies in this paper have been com-
pleted, and the drug is currently being sold out of the 
United States. It is in trial stages to be sold in the United 
States as well. PNC-27 and PNC-28 are novel drugs that 
bring much promise to the field of cancer research, and 
promises an alternative to the other harmful treatments 
being used today. However, larger studies should be con-
ducted to reduce the side effects that are experienced 
by patients taking the drug. There were no attempts in 
proving that PNC-27 is harmful for ingestion, unless 
contaminated by an outside source. There are multiple 
factors involved in creating immunotherapeutic peptides 
as treatment to cancer. Other approaches to improving 
the drug would be to further elucidate the mechanism 
by studying various models of the disease. By examining 
different models, this will hopefully give a deeper per-
spective and aid the efforts for a cure.
Conclusion
Cancer is a disease that has caused an upward trend in 
mortality rates. Although some progress has been made in 
cancer research for a cure, there are many drawbacks to 
the current treatments available. The current treatments 
are chemotherapy and radiation. While both of these treat-
ments can successfully eradicate tumors and cancer cells, 
they also tend to damage healthy cells. There is also poten-
tial for a relapse because not all cancer cells are targeted 
during treatment, as some cancer cells may drift to other 
organs and rebuild there. As a result, many cancer patients 
succumb to the toxic effects of cancer treatments rather 
than the cancer itself. With wealth of evidence in support 
of immunotherapy, this alternative treatment shows great 
promise because it does not adversely impact healthy cells. 
This is because the underlying concept of immunotherapy 
is to invest the body’s healthy cells with resources to be 
able to naturally combat the cancer cells. This is done by 
PNC-27 and PNC-28 peptides. Through research and study 
on animal subjects, the PNC-27 and PNC-28 peptides have 
been shown to be highly effective in selectively targeting 
a wide variety of specific forms of cancer, including pan-
creatic cancer, breast cancer, leukemia, melanoma, and ad-
ditional cancer lines. Since PNC-27 is non-toxic, patients 
can get rid of the cancer in a healthy manner, while aiming 
to follow a lifestyle based on holistic health and wellness. 
When properly administered, PNC-27 and PNC-28 puts 
cancer on the defensive, resulting in outcomes that include 
significant pain reduction and, in many cases, lengthening of 
life. This research supports the evidence that PNC-27 and 
PNC-28 are one of the most effective ways to treat cancer.
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One of the most revealing parts of the human body is the eye. In fact, systemic conditions and diseases are commonly manifested 
in the eye and display pathology that reflect disorders. An example of a chorioretinal vascular condition that can present itself in 
the eye is diabetes mellitus, which if left uncontrolled can damage the eyes and a person’s vision. Age related macular degeneration 
is specific to the eye, potentially leading to irreversible loss of central vision. Intravitreal injections containing vascular endothelial 
growth factor inhibiting agents appear to be the leading lines of defense against diabetic retinopathy and macular degeneration 
progression, helping to reduce both the pathological and visual manifestations of these chorioretinal vascular diseases.
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Background
Diabetes is the fourth leading cause of health complica-
tions, making many people susceptible to diabetic reti-
nopathy. In fact, the prevalence of diabetes is expected 
to increase by 7.7% by 2030, leaving many people at risk 
(Abbas et al., 2017). Age related macular degeneration is 
another neovascular condition of the eye which can re-
duce visual acuity to 20/800 in a patient’s better eye by 
60%, resembling a patient who “is bedridden with a cata-
strophic stroke” (Folk & Stone, 2012). These diseases are 
capable of impairing the daily functioning of a patient if 
they are not treated and monitored. Most ocular diseas-
es can be identified with a dilated eye exam. Treatments 
with delivery of vascular endothelial growth factor inhib-
itors to the retina via intravitreal injection has gradually 
become the first line of treatment for ocular conditions 
such as diabetic retinopathy and macular degeneration. 
Pan-retinal photocoagulation (PRP) is a laser treatment 
that can also be used in controlling these conditions and 
preventing the progression of vision loss. Research is cur-
rently being done on both of these methods in an effort 
to determine their use in ocular disease.
Hypothesis
In most circumstances, vascular endothelial growth factor 
inhibiting medications can be implemented in a treatment 
plan to alleviate both the visual complaints and the patho-
logical findings associated with chorioretinal vascular 
conditions. In some cases, however, this treatment option 
may not be appropriate due to potential risks and anoth-
er treatment may be indicated.
Methods
Research for this paper was conducted with the use of Pro-
Quest, EBSCO, and Pub-Med databases. Figures used through-
out include corresponding sources from research articles.
Diagnostic Methods
Conditions such as age-related macular degeneration 
and diabetic retinopathy can be diagnosed with a prop-
er exam. Ophthalmic tropicamide, a mydriatic, is used in 
order to give the clinician a proper view of the fundus. 
Imaging methods such as optical coherence tomography 
(OCT), fluorescein angiography, and wide field fundus 
imaging may also be used for future comparison during 
treatment. Diagnostic guidelines have been established to 
aid in classifying the type and severity of ocular disease. 
Findings, diagnostic methods, visual complaints, and prog-
nosis of these conditions will be discussed in the following 
sections. Popular treatment options will also be outlined.
Diabetic Retinopathy
Diabetic retinopathy (DMR) is a complication resulting 
from diabetes mellitus Type 1 or 2. It appears to be one 
of the leading causes of blindness in patients aged 20-65 
(Stewart, 2012). Currently, 336 million people suffer from 
diabetes and are therefore at risk of developing diabetic 
retinopathy, otherwise known as DMR (Abbas et al., 2017). 
Diabetic damage to the eye is a result of macular edema, 
which in more advanced cases, can lead to intraocular 
bleeding, detachments of the retina, macular ischemia, and 
retinal neovascularization. Possible risk factors for DMR 
include hyperglycemia, elevated blood pressure, and ele-
vated serum levels (Buffolino & Park, 2019). Patients can 
usually control risk factors with lifestyle modifications 
including diet and exercise, yet it is important to note 
that specific patient demographics can predispose people 
to diabetic retinopathy. 
Firstly, individuals diagnosed with diabetes at an earlier 
age tend to be more vulnerable to developing the condi-
tion. DMR becomes more prevalent as the age of diabetes 
onset is younger. “What is hitherto unknown is whether 
the increased prevalence of complications associated with 
early-onset disease is simply a consequence of the lon-
ger duration of disease, a consequence of a more severe 
metabolic phenotype, or in fact something specific to the 
diabetic milieu in younger patients that makes tissues more 
inherently susceptible to hyperglycemic damage” (Wong 
et al., 2008). Long-term exposure to elevated blood glu-
cose levels seems to lead to oxidative stress on the eyes 
(Stewart, 2012). By the same token, retinopathy is not 
common in the first five years of a Type 1 diabetes onset, 
and diabetic retinopathy tends to be present after 20 years 
of having Type 2 diabetes (Cook et al., 2008). 
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Secondly, in addition to patient age, ethnicity is also 
associated with DMR. African Americans, Hispanics, and 
South Asians are especially prone to diabetic retinopathy. 
African Americans seemingly have reduced glycemic con-
trol, which can lead to retinal complications due to higher 
A1C values. The internationally recognized mark differ-
entiating safe and unsafe A1C values is 7% (Long et al., 
2017). A study showed that over a six-year period, 72% 
of African Americans with Type 1 diabetes mellitus devel-
oped retinopathy (Buffolino & Park, 2019). Furthermore, 
the combination of male sex, African American ethnicity, 
duration of standing diagnosis, and value of hemoglobin 
A1C, were “positively associated with retinopathy severi-
ty” (Long et al., 2017).
Before any signs of diabetic damage appear on the 
retina, choroidal vessels may constrict due to hypoxia 
and vascular changes can develop. Furthermore, it is im-
portant to note that in the early stages of damage to the 
retina, the patient may not be able to discern changes 
in visual acuity; the condition is usually diagnosed in a 
later stage of diabetic retinopathy (Wang & Tao, 2019). 
About 50% of patients with diabetes do not come for 
yearly screening visits (Buffolino & Park, 2019). The first 
markers of diabetic damage in the eye are the results of 
swelling and leakage of blood vessels because of poorly 
controlled blood sugar levels. The natural synthesis of 
vascular endothelial growth factors (VEGF) results in 
the disruption of the blood-retina barrier that leads to 
the spread of serum proteins leading to edema (Stewart, 
2012). Bleeding near the macula can noticeably blur the 
patient’s vision. According to Mayo Clinic’s webpage on 
diabetic retinopathy (n.d.), the patient may also complain 
of fluctuating vision. This can occur because of uncon-
trolled blood sugar levels that cause the lens to swell and 
alter the refraction of light in the eye. Two other common 
visual complaints are impaired color vision and floaters 
(Vien, n.d.). Over time, the body may begin to generate 
new blood vessels in order to properly supply the eye 
with oxygen, which severely impacts the patient’s vision 
and everyday functioning. Other lesions associated with 
diabetic retinopathy such as microaneurysms, hemor-
rhages, cotton wool spots, and hard exudates can be seen. 
Diagnosis and Prognosis of Diabetic Retinopathy
Diabetic retinopathy is classified into either proliferative 
or nonproliferative diabetic retinopathy (PDR/NPDR) 
and then further broken down into mild, moderate, and 
severe. This classification considers the degree of damage 
present on the retina. The job of the clinician is not an 
easy one to classify the stage of diabetic retinopathy. With 
the help of wide field fundus imaging, the ophthalmologist 
is able to document and compare any changes to the ap-
pearance of the retina. The wide field images below can 
demonstrate the classifications of diabetic damage to the 
retina based on any associated findings.
Additionally, optical coherence tomography (OCT) is 
used to provide cross-sectional scans of the retina which 
can also help in determining the presence and degree of 
edema or cotton wool spots. Layers of the retina such as 
the RPE and choroid may also be altered. 
Age-Related Macular Degeneration
Age related macular degeneration (AMD) is the most 
common cause of blindness in patients older than age 65. 
In industrialized countries, blindness due to AMD had a 
reported 1.47% prevalence and affected 1.75 million peo-
ple in the United States alone (Eng, et al., 2019). The depo-
sition of yellow, extracellular material underneath the 
retinal pigment epithelium that form drusen, indicative of 
photoreceptor cells that are degenerating is a key com-
ponent of AMD (Virgili et al., 2015). The RPE must reuse 
materials in order to help revitalize photoreceptors. A 
defect in the cycle suggests the poor quality of enzymes 
that are responsible for breaking down those materials 
(Sarks et al., 1994), leading to degeneration of the RPE 
as drusen evolve into geographic atrophy. Extracellular 
deposits or atrophy of the RPE near the retina can lead 
to significant loss of central vision. As the drusen degen-
erate, they give a white appearance to the retina with 
“irregular margins and foci of calcification before disap-
pearing to leave a focal patch of atrophy” (Sarks et al., 
1994). Most patients complain of blurred or distorted 
vision or a scotoma (Cook et al., 2008). Risk factors for 
AMD include smoking, hyperlipidemia, and hypertension. 
Age-related macular degeneration is also strongly tied to 
a genetic predisposition to the point that children and sib-
lings of patients with AMD are automatically considered 
suspects for the condition. Many sources rank genetics 
as an important contributor to the likelihood of devel-
oping age-related macular degeneration. Various studies 
show that people of African descent have a reduced risk 
for AMD, than does the Caucasian population (Delcourt, 
n.d.). Smoking increases the risk of AMD as well. 
Although much about AMD and its pathogenesis is still 
unknown, studies show “that the largest single genetic 
factor contributing to AMD is a variant of codon 402 in 
the gene encoding complement…[that] strongly supports 
the long-held belief that the immune system is an import-
ant contributor to AMD” (Folk & Stone, 2012). In some 
observed cases of AMD, inflammatory mediators and 
other molecules have been found at the macula, indicating 
that there is indeed a connection between the condition 
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and inflammation. Furthermore, the release of excess ac-
tivated macrophages in chronic inflammatory diseases is 
linked to cellular damage at the macula. Electron micros-
copy and immunohistochemistry methods were used to 
detect the presence of inflammatory biomarkers at sites 
of atrophy and neovascularization in patients with AMD 
(Cachulo & Costa, 2017).
Prognosis and Classification of AMD
Age-related macular degeneration is diagnosed with 
a dilated retinal examination. Evaluating a case of AMD 
requires paying attention to changes at or near the mac-
ula. Age-related macular degeneration begins with the 
dry form, characterized by the presentation of drusen. 
Number, size, and location of drusen are helpful in de-
termining the progression of the condition. Additionally, 
drusen with indistinct borders seem to be indicative of 
the advancement of AMD (Cachulo & Costa, 2017). 
As AMD progresses, the retinal pigment epithelium 
layer begins to show signs of atrophy. A case of AMD is 
characterized as wet or neovascular once new blood ves-
sels begin to grow over or underneath the RPE (Folk & 
Stone, 2012). The generalized term “late AMD” refers to 
two specific presentations on the macula with exudates 
which can either be geographic atrophy or vascular AMD. 
Progression from dry to wet AMD occurs for 15% of 
patients complaining of severe loss of central vision and 
presenting with geographic atrophy that develops (Eng et 
al., 2019). Patients may notice visual distortion of straight 
lines. Ten percent of patients with AMD suffer from this 
more advanced form. More than 200,000 patients in the 
United States alone are diagnosed per year, accounting 
for 90% of all severe vision loss (Stewart, 2012). In a large 
study done, “the prevalence of large drusen increased 
from about 1.5% in Caucasians aged 40-49 years, to more 
than 25% in those aged 80 years or more” (Delcourt, 
n.d.). This statistic is important to consider because it 
indicates that Caucasians appear to be more at risk for 
developing AMD than people of other demographics such 
as Hispanic American, African American, and Chinese 
(Delcourt, n.d.). Of course, as the name of the condition 
suggests, the likelihood of developing AMD increases ex-
ponentially with age.
VEGF in Ophthalmology
Angiogenesis is a process that can be both lifesaving 
and necessary, yet in some cases can be detrimental. 
Throughout the body, the natural process for generating 
new blood vessels is crucial for maintenance related to 
growth (embryonic or otherwise) and repair. Yet in cir-
cumstances of hypoxia and inflammation, it allows the 
growth of tumors and is linked to the destruction of tis-
sue (Stewart, 2012). Angiogenesis is also important when 
neovascularization is required such as after myocardial 
infarction. However, in ophthalmic cases, the generation 
of new blood vessels can lead to hyperpermeability that 
can harm vision by leading to retinal detachments and 
edema between the retinal layers. The primary molecule 
that is associated with angiogenesis is vascular endothelial 
growth factor. “Within the posterior segment of the eye, 
VEGF is produced by retinal pigment epithelial cells, neu-
rons, glial cells, endothelial cells, ganglion cells, Muller cells, 
and smooth muscle cells” (Stewart, 2012). The primary 
cells of interest leading to the harms from AMD and DMR 
however, are vascular endothelial cells. Generally, the syn-
thesis of VEGF is triggered by tissue hypoxia that can ei-
ther be caused by “primary vascular occlusive disease or 
anaerobic tumor metabolism” (Stewart, 2012). The mech-
anism leading to the proliferation of vessels is complex 
but it results in mitosis and swelling of the endothelial 
cells, as well as vasodilation, helping new blood vessels 
develop. Specifically, VEGF works to encourage growth 
along the endothelial cells and dissolve the spaces be-
tween them, leading to the breakdown of the blood-reti-
nal barrier that makes capillaries leak and new, potentially 
detrimental, blood vessels form (Stewart, 2012). VEGF-A, 
a subfactor of this molecule, is linked to growth and 
permeability of newly-developing blood vessels. VEGF 
inhibitors block the receptors that natural VEGF would 
bind to, preventing angiogenesis. “Long-term blockade of 
VEGF-A [receptor] causes shrinkage and maturing of the 
vessels so that they no longer leak. The accumulation of 
fluid within and beneath the retina dissolves, and the pho-
toreceptors reattach to the underlying retinal pigment 
epithelium” (Folk & Stone, 2012). By using a medication 
that reduces the permeability of the retinal vessels and 
stopping their growth, leakage is also reduced, preventing 
swelling in order to bring the patient’s visual acuity back 
to baseline (Folk & Stone, 2012). It is interesting to note 
that these drugs are capable of resolving findings asso-
ciated with two very different conditions in that one is 
systemic and can target multiple parts of the body, while 
the other is localized in the eye.
VEGF Inhibitors: A Comparison
Although all VEGF inhibitors prevent neovascularization, 
there are several subclasses of this drug. Their generic 
names aflibercept, bevacizumab, and ranibizumab will be 
used throughout this paper (Folk & Stone, 2012). The ef-
ficacy of the medications as they compare to each other 
is still being studied.
Bevacizumab received approval from the Food and 
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Drug Administration for the treatment of colon cancer. 
Bevacizumab also binds to VEGF-A, which led clinicians to 
think that the drug may also be effective in treating neo-
vascularization and exudates on the retina. Although there 
is no FDA approval for its intravitreal use, bevacizumab is 
proving itself effective (Folk & Stone, 2012). When com-
pared to other medications in its class, bevacizumab has 
a longer half-life. One dose of the drug can reduce levels 
of natural VEGF in the blood by 117 times in just one day 
and when measured after one month, still maintained a 
four-fold reduction (Stewart, 2012). Furthermore, many 
clinicians recommend this drug because of its vast dif-
ference in cost compared to others. Being prepared in 
larger doses than is necessary for the eye means that the 
medication can be divided for multiple doses (1.25 mg. 
on average), reducing the cost even further. Whereas a 
dose of ranibizumab costs $2000, bevacizumab, although 
regarded as off label therapy, costs $75 per treatment 
(Folk & Stone, 2012). 
Ranibizumab was developed specifically for use in the 
eye by fragmenting the bevacizumab molecule for higher 
affinity by five to twenty times more than bevacizumab 
(Stewart, 2012). A study looking at regular monthly treat-
ment with ranibizumab shows that the first five years of 
treatment produce the best results in terms of visual acu-
ity, but then results seem to approach baseline levels over 
time thereafter (Nishikawa et al., 2019). For treatment with 
ranibizumab, the MARINA study attempted to determine 
effective dosage of the medication. At random, 716 pa-
tients with neovascular AMD were treated with monthly 
0.3mg or 0.5mg injections of the drug, or sham treatment 
for 24 months. Results showed that 92% of patients that 
were treated with 0.3mg of ranibizumab and 90% treated 
with 0.5mg lost less than 15 letters when being tested for 
changes in visual acuity. Furthermore, 26.1% of patients 
that were treated with 0.3mg and 33.3% with 0.5mg treat-
ment had a 15-letter improvement or greater. 
When aflibercept is compared to the other drugs, its 
increased binding affinity to VEGF-A receptors combined 
with its larger molecular size allows for a higher efficacy 
and hence, less frequent treatment. When used on a two-
month basis after three monthly consecutive loading doses, 
results compared to monthly treatment with ranibizumab 
(Stewart, 2012). Patients with neovascular AMD who were 
treated with aflibercept intraocular injections were able to 
sustain improved vision for four years. Even though after 
one year some regression was present, 94.5% of patients 
still had improved vision. “Thus, visual gain [of aflibercept] 
in the first year is generally favorable, but long-term out-
come is not as promising” (Nishikawa et al., 2019).
Conclusively, visual acuity was shown to improve with all 
three classes of treatment, but specific data was shown by 
a study conducted by DRCR.net in which 600 Americans 
with diabetic edema participated. The average age was 61 
and most people had diabetes for over 15 years. Visual 
acuity before the study was 20/32 or worse and patients 
were administered either of the three drugs at random 
and monitored on a monthly basis in the first year of the 
study. When comparing the visual acuity of patients after 
treatment, those on aflibercept for two years were able 
to read 3.5 more lines compared to ranibizumab patients 
who read 3, and bevacizumab patients read 2.5 (Wells, 
2016). Aflibercept showed better efficacy after the one- 
and two-year mark. “By two years, 41 percent of partic-
ipants in the aflibercept group received laser treatment 
to treat their macular edema, compared with 64 percent 
of participants in the bevacizumab group and 52 percent 
in the ranibizumab group.” Ultimately, with treatment in-
volving any of the three drugs, visual acuity was improved 
to 20/32 and 20/40. There were even studies showing the 
efficacy of bevacizumab in improving patients’ visual acui-
ty from 20/235 to 20/172. The results of the study suggest 
that there is a slight difference between the frequencies 
at which the drug must be readministered depending on 
the specific type of medication chosen. According to the 
DRCR study done, there was no significance to using one 
medication over another for treatment of mild macular 
edema when visual acuity is 20/40 or better. However, 
in cases of 20/50 or worse vision it has been shown that 
Eylea (aflibercept) performed better than ranibizumab 
and bevacizumab (Wells, 2016).
Risks
Although this modality of treatment is usually the first 
line of defense against further damage to the retina, exist-
ing risks should be considered. Firstly, for all the subclass-
es of intravitreal injections used for treating chorioretinal 
disorders, the risk for eye infection and inflammation is 
the same. These are consequences of the administration 
and not the drug itself (Wells, 2016). Injection into the 
vitreous chamber also raises the risk for endophthalmi-
tis, retinal tear or detachment at the area of injection, 
and vitreous hemorrhage because of penetrative trauma 
(Pershing et al., 2013). These risks must be kept in mind 
when developing a treatment plan for a patient suffering 
with other kinds of ocular disease as well. Furthermore, 
because additional fluid is added to the vitreous cavity 
when the medication is given, an elevation in intraocular 
pressure from increased volume in the eye can result.
A study was done spanning academic centers Stanford 
University Hospital & Clinics and Mayo Clinic. Patients 
who received anti-VEGF injections between January 1, 
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2006 and December 31, 2010 participated in order to 
determine the relationship between administration of 
the drug and intraocular pressure elevation taking place 
within 60 days of the injection. Intraocular pressure 
asymmetry between the eyes by a value of more than 
3mm Hg was also considered. Those with a history of 
glaucoma or elevated IOP in the past did not qualify to 
participate. “A total of 11,828 bevacizumab injections and 
10,354 ranibizumab injections were administered during 
the study period at the two clinical sites. In this series, 21 
eyes of 18 patients developed elevated IOP of 24mm Hg 
of higher within 60 days of previous injection” (Pershing 
et al., 2013). Most patients were Caucasian females who 
received treatment for wet AMD and presented other 
pathology related to elevated IOP, such as narrow ante-
rior chamber angles on gonioscopy. Most of the 21 eyes 
needed treatment for elevated pressure, 76% required 
prolonged treatment, and 19% resolved with no treat-
ment. It was found that a risk of increase in IOP persisted 
even later in treatment after multiple injections to the 
eye. This risk was reported regardless of the subclass of 
anti-VEGF used, however a higher chance of IOP eleva-
tion in ranibizumab treatment was reported (Pershing et 
al., 2013). This risk is especially important to consider if 
the patient in question has glaucoma or is a glaucoma 
suspect, as a subtle rise in intraocular pressure may be 
detrimental. In such a case, the drug should be adminis-
tered and the patient carefully monitored for changes in 
IOP that may lead to an acute attack of glaucoma.
Additionally, receiving anti-VEGF drugs alongside having 
coexisting cardiovascular conditions may lead to adverse 
effects. The SUSTAIN trial showed that although there is 
no link to myocardial infarction, a 10% incidence of stroke 
was found in patients with previous cerebrovascular dis-
ease that were also being treated with VEGF inhibiting 
medications (Stewart, 2012). In patients receiving regular 
treatment with ranibizumab, there was a higher incidence 
of heart attack, stroke, or death from cardiovascular or 
unknown conditions (Wells, 2016).
Finally, the nature of this treatment option for AMD/
DMR is that frequent, monthly follow up visits are re-
quired to monitor and readminister the drug, render-
ing compliance of treatment more difficult to upkeep. 
Inherent drawbacks to the use of VEGF inhibiting agents 
are its cost and frequency of treatment as it relates to 
burden on the patient. Perhaps lowering the overall cost 
of the treatment (medication and visit) while creating a 
medication with a longer half-life or efficacy will allow 
more patients to undergo long term treatment, prevent-
ing blindness (Baek et al., 2019). In some cases, the use 
of a laser to clear drusen and prevent the furthering of 
neovascularization may be more appropriate, as will now 
be discussed. 
Use of Pan Retinal Photocoagulation
Although traditional cases of diabetic retinopathy and 
macular degeneration now indicate treatment with in-
travitreal injections, this has not been the case for long. 
In the past, the first line of defense was treatment with 
blue-green Argon laser in order to create lesions around 
the area of retinal neovascularization and promote the 
regression of abnormal blood vessels and drusen. This 
option to help DMR and AMD is called pan retinal pho-
tocoagulation. In this technique, a beam of light from the 
laser is focused onto the retina using a special lens. The 
strength of the laser now used is usually weaker, with 
studies trying to determine the efficacy of subthreshold 
laser treatment to avoid applying more energy than nec-
essary. Up to 300 lesion spots may be delivered, with each 
one between 100μm and 200μm in size. “Subthreshold 
photocoagulation delivers light energy with very short 
impulses that are absorbed by the RPE only, aiming to 
spare the neurosensory retina”. Adjusting the strength, 
pulse duration, and frequency of the laser makes the 
treatment effective yet more gentle on the choroid in 
an attempt to reduce potential photoreceptor loss. 
Although the mechanism of treatment is not fully known, 
some ideas explain its efficiency. 
Firstly, the laser may help in clearing remnants left by 
phagocytic cells and macrophages along the choroid. It is 
hypothesized that the accumulation of these cells leads 
to the development of drusen. Another train of thought 
is that the laser may precipitate the RPE layer to release 
cytokines and growth factors that are able to “modify the 
biochemical processes underlying the clinical manifesta-
tions of the retinal disorder, rather than simply destroying 
drusen, and may also act on the drusen remote from the 
site of laser energy application” (Virgili et al., 2015). Also, 
the laser energy is capable of causing the temperature of 
the retina to rise slightly, leading to the release of heat 
shock proteins. They “act as chaperones for refolding mis-
folded proteins in aging cells, thereby rejuvenating retinal 
pigment epithelium (RPE) cells and restoring their cellular 
function” (Eng et al., 2019).
A study included patients with extrafoveal neovascular 
presentation with drusen. Patients were 50 years of age 
or older and visual acuity either was 20/100 or worse 
(Silva, 2011). The laser used was a conventional blue-
green Argon laser. Energy was set to be powerful enough 
to create the necessary lesions or controlled burns on 
neovascular areas. In this study, attention was not paid 
to maintaining sub-threshold energy. By using pan retinal 
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photocoagulation, the likelihood to stabilize the visual 
acuity of a patient doubled for those eyes, showing a 58% 
reduction in the risk to have severe vision loss. 
Highlights from the Macular Photocoagulation Study 
Group (Silva, 2011) are shown here:
A. Five years after treatment, average visual acuity 
was 20/125 in the group treated compared to 
20/200 in patients not treated with PRP.
B. Within the five-year span of treatment, 54% of 
patients had signs of recurring severe vision loss, 
with the majority of cases taking place within two 
years of treatment.
C. Smoking after PRP treatment was linked to accel-
erated recurrence of severe vision loss, as 85% of 
patients smoked more than 10 cigarettes per day 
compared to 51% in the non-smoking population.
An additional analysis of 12 studies of 2,481 eyes that 
were treated with subthreshold pan retinal photocoagu-
lation showed similar results. This study included treat-
ments done with 514nm and 810nm lasers. Conclusions 
of the review showed that pan retinal photocoagulation 
treatment is effective in reducing drusen count and 
thereby improving visual acuity in patients with dry AMD 
with the 810nm laser being consistently more effective. 
However, the study mentions that in order to obtain a 
significant improvement in visual acuity, the treatment 
must clear a substantial amount of drusen. Additionally, 
the study found that among the eyes that were treated, 
there was “no significant change in the risk of develop-
ing choroidal neovascularization or geographic atrophy” 
(Eng et al., 2019) and that more research would need 
to be done to conclusively confirm the efficacy of the 
810nm infrared diode laser compared to the 514nm laser. 
Comparing the treated patients with the observed 
patients in the study, the following data was obtained in 
regard to the relationship of diminishing drusen and treat-
ment with pan retinal photocoagulation (Eng et al., 2019): 
1. In five out of the 12 studies in which visual acuity 
was measured, it was determined that there was 
no difference in visual acuity in the groups who 
had and had not received treatment. Yet, the re-
maining studies showed a correlation between 
receiving treatment and improved visual acuity. 
This indicates that although pan retinal photoco-
agulation may be effective in clearing drusen from 
the retina, perhaps more research is necessary to 
conclude the effectiveness of the laser in improv-
ing the visual outcome for the patient.
2. In regard to the development of choroidal neo-
vascularization (CNV), three of nine studies that 
followed up on this mentioned that there was no 
development of CNV. An additional three howev-
er noted that eyes treated with subthreshold pan 
retinal photocoagulation were slightly more likely 
to develop CNV.
3. Geographic atrophy was also monitored in this 
series of studies. It was reported that two studies 
showed GA in treated eyes, while another study 
showed that although the incidence of developing 
geographic atrophy in treated eyes was 3.9%, the 
likelihood was higher in eyes that were not treat-
ed, at 14.0%.
After five years, following up on patients showed 64% 
of eyes that were not treated with the laser developed 
more severe vision loss compared to 46% of patients that 
had treatment with PRP. Yet, the recurrence rate of vision 
loss was 54%, with 75% of those recurrences taking place 
in the first year (Cook et al., 2008).
Conclusion
Currently, there are a number of available treatment 
options to reduce visual complaints and pathological 
findings in patients with chorioretinal vascular condi-
tions. Interventions such as subthreshold pan retinal 
photocoagulation and vascular endothelial growth factor 
inhibiting agents are still undergoing various studies, yet 
they do appear to be effective and promising options for 
patients battling age related macular degeneration and 
diabetic retinopathy. There are reasons why a clinician 
may choose one over the other in hopes of achieving 
the maximum benefit for the patient, depending on cost, 
compliance, and coexisting conditions. Although vascular 
endothelial growth factor inhibiting agents have become 
the first line of defense against neovascularization and 
other such complications of ocular disease, there are still 
reasons why they may not be the appropriate treatment 
option for a given patient as there are associated risks. 
Furthermore, some clinicians believe that using alterna-
tives such as PRP may be a better option altogether. On 
the other hand, an advantage of VEGF inhibiting agents 
over pan retinal photocoagulation is “prompt regression 
of neovascularization and the preservation of peripheral 
and night vision” (Buffolino & Park, 2019). Undergoing 
treatment with VEGF inhibiting medications for patients 
with severe vision loss may not be recommended as the 
drug may not be able to restore vision (Baek et al., 2019), 
however in most circumstances, VEGF inhibiting drugs can 
and perhaps should be implemented to alleviate both the 
visual complaints and the pathological dangers associat-
ed with chorioretinal vascular conditions. Potential risks 
previously discussed such as IOP elevation, inflammation, 
visual and pathological damage, and coexisting conditions 
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may need to be considered on a case by case basis, ne-
cessitating another modality of treatment. Nevertheless, 
it should be stressed that without a proper dilated exam, 
very little can be observed and treated; imaging methods 
can also be used to monitor the stability or progression 
of these diseases.
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Abstract
Crohn’s disease and ulcerative colitis are the two most prevalent inflammatory bowel diseases (IBDs) in Jewish and Caucasian popu-
lations, affecting as many as one in 250 individuals. Nevertheless, the underlying causes of both disorders are not yet fully understood 
and remain unknown. However, current evidence suggests that the exaggerated inflammatory response, more commonly referred 
to as IBD, is believed to arise from dysregulation of the gastrointestinal (GI) immune system in genetically predisposed individuals 
who are exposed to environmental triggers. Recent advances have identified multiple IBD susceptibility genes; however, only a few 
environmental determinants of IBD have been consistently identified. The difficulty in understanding the etiology of IBD is in part 
due to the complex interactions between genes and the environment. Additionally, autoimmune mechanisms are believed to play 
a role in the development of IBDs, but the target antigens and the underlying pathways have not been sufficiently characterized 
and identified. IBD is commonly referred to as an “idiopathic disease;” a disease with an unknown cause (Health &Medicine, 2016; 
Sartor, 2006). This paper examines the possible causes of IBD, specifically highlighting Crohn’s disease.
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Crohn’s Disease (CD) is a chronic autoimmune disease 
mainly affecting the gastrointestinal (GI) tract extending 
from the mouth to the anus; however, it’s most com-
monly found in the ilium, leading to the alternate name 
ileitis (Newman & Siminovitch, 2003). It’s characterized 
by thickened areas of the GI wall with inflammation 
extending through all four layers including the mucosa, 
submucosa, muscularis externa, and serosa (Politics & 
Government week, 2017; Ruthruff, 2007). The inflam-
mation is somewhat similar to that of ulcerative colitis, 
and commonly leads to abdominal pain, diarrhea, vom-
iting, weight loss, anemia and fever (Torres et al. 2017). 
However, some patients may experience mouth and skin 
sores along with joint stiffness and swelling (Creek, 2017). 
Unfortunately, patients suffering from CD are at a higher 
risk of developing other autoimmune disorders such as 
osteoporosis, thyroid disease, as well as colorectal can-
cer (Baumgart & Sandborn, 2012; O’Sullivan, 2009; Bae 
et al. 2014). Symptoms range from mild to severe and 
treatment varies depending on the severity of the disease. 
Typically, a doctor will perform a series of tests before 
confirming CD. These tests may include a physical exam, 
lab tests, stool samples, CT scans, MRI, endoscopy and 
a colonoscopy (Baumgart & Sandborn, 2012), in which 
a small flexible camera is inserted through the rectum 
to distinguish abnormalities. Together, these tests detect 
abnormalities which may exist throughout the intestinal 
track thus indicating IBD.
While there is currently no known cure for CD, treat-
ment options are available (Akobeng, 2008; Michail et al. 
2013). It is estimated that roughly ten percent of patients 
who undergo surgery will have prolonged clinical remis-
sion (Baumgart, 2012; D’Incà & Caccaro, 2014). The goal 
of treatment is to reduce inflammation and to improve 
the prognosis by limiting complications (Newman & 
Siminovitch, 2003). Noninvasive treatment options in-
clude anti-inflammatory medication, antibiotics, and im-
munosuppressant drugs. Anti-inflammatory medication 
controls and suppresses inflammation, thereby decreasing 
the frequency of flare ups. With proper treatment over 
time, periods of remission can be extended, and flare ups 
can be reduced. Alternatively, immunosuppressant med-
ications, such as corticosteroids, aid by suppressing the 
immune system, thus allowing the intestinal tissue to heal. 
However, in some instances, more invasive treatment 
plans are required. Despite significant progress in treat-
ments for CD, it’s estimated that as many as seventy-five 
to ninety percent of patients suffering from the disease 
will undergo surgery to relieve symptoms at some point 
during the patient’s life.  (Politics & Government Week, 
2017; Liu et al. 2017). At times, CD creates complications 
that are deemed a medical emergency, such as a bowel 
abscess, a fistula (which may result from an unaddressed 
abscess), uncontrolled bleeding, or intestinal blockage, in 
which case surgery may be required. As an aside, patients 
may also require surgery as a result of previous medica-
tions having caused severe side effects, or simply because 
the medications have stopped working as effectively as 
the body adapts and immunizes itself against the medica-
tion (Torres et al. 2017).
 There are several types of surgeries that can be per-
formed, the most common one being a bowel resection. 
This involves the removal of all parts of the damaged in-
testine and is performed when parts of the small bowel 
are diseased or blocked (Simon et al. 2003). A partial 
colectomy is another type of bowel resection in which 
the surgeon removes the damaged parts of the colon. It 
can be performed openly or laparoscopically. When per-
formed openly, the surgeon manually cuts an extensive 
incision; alternatively, the surgeon may prefer to work 
laparoscopically, making several small incisions, thereby 
allowing him to work outside the body. In some instanc-
es, a total colectomy is required in which the surgeon 
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removes the entire colon. This is generally required only 
in severe cases in which the colon is highly inflamed, and 
medication is ineffective (Travis, et al. 2011). A colectomy 
often requires further procedures to reattach the discon-
nected portions of the digestive system, thus permitting 
waste to leave the body. For example, in some instances, 
an ostomy is performed. This surgery is categorized as 
a lifesaving procedure as it is performed when stool is 
unable to be eliminated from the body through the rec-
tum (Travis et al. 2011). In this procedure, the colon is 
removed, and a stoma is created on the abdomen. Wastes 
are then allowed to pass through the surgically created 
stoma into an ostomy bag, a prosthetic bag which holds 
stool and can be emptied regularly.
Common risk factors of these surgeries include bleed-
ing, bowel obstruction, infection and pulmonary embolism. 
Methods
Data was collected using ProQuest and PubMed data-
bases through Touro College’s online library. Among the 
key-phrases used were “Crohn’s Disease”, “irritable bowel 
disorder”, “epigenetics”, as well as “hygiene hypothesis.”
Genetic Factors
There is a significant amount of evidence suggesting that 
genetic factors play a key role in the triggers of IBD. Genetic 
mutations lead to the body’s defective defense against mi-
crobes in the digestive system, allowing the immune system 
to attack the lining of the digestive tract, thereby causing 
inflammation indicating IBD. The genetic analysis of complex 
diseases, such as IBD, is difficult to identify for several rea-
sons. First, the disease isn’t categorized into a single entity, 
but rather into groups of heterogeneous disorders, where 
environmental and genetic factors play a significant role in 
disease expression. Additionally, ethnic differences that may 
exist between patients suffering with IBD are associated 
with different mutations (Bae et al. 2014). Other difficulties 
faced include the relatively low frequency of IBD, about .1-.4 
percent,  amongst populations (Michail et al. 2013); statistics 
showing that only about ten  percent, first-degree relatives 
are affected with the same disorder (Sartor, 2006; Pena, 
1998); as well as the presence of genes with minor genetic 
effects, are some of the difficulties faced with when identify-
ing disease susceptibility. Nevertheless, there is an emerging 
understanding of the inherited aspects that predispose an 
individual to IBD (Newman & Siminovitch, 2003).
The evidence for genetic involvement in IBD comes from 
ethnic e.g., Ashkenazic Jews and family-based studies on 
blood relatives affected with CD, associations of IBD with 
known genetic syndromes, diseases with known genetic 
predisposition such as autoimmune diseases, and more 
recently through genetic marker studies (Barber GE, Yajnik 
V, Khalili H, et al. 2016). Various genetic markers have shown 
different levels of correlation with IBD. Some have failed 
to show a consistent association with IBD, including blood 
groups, secretor status, a 1-antitrypsin, and immunoglobulin 
marker genes. Studies on these markers can be divided into 
those in which a genetic element is proven and those in 
which a genetic predisposition may be present (Pena,1998). 
Several polymorphisms in the genes encoding different cy-
tokines and their receptors have been described and are 
potential candidates to be studied scientifically.
There are currently multiple studies being carried out 
to help identify the genetic mutations, causes, and suscepti-
bility in developing IBD. In addition, technological progress 
in genetic testing and DNA sequencing permitted many 
genome-wide association studies (GWAS), which helped 
identify new single nucleotide polymorphisms (Loddo 
& Romano, 2015). Correspondingly, over the past few 
decades, there have been significant advances in the un-
derstanding of genetic causes linked to IBD. (Newman & 
Siminovitch, 2003). The studies described below are popu-
lation-based studies in areas that extend over a period of 
time, making them most likely to give fair, unbiased results. 
These studies have confirmed the increased prevalence 
of IBD in family members as compared to those in the 
general population. These include studies based on twins, 
families, and the Jewish Ashkenazic ethnic group.
The data derived from studies performed on twins pow-
erfully supports the view that IBD is linked to a genetic 
component. There is a significant increase in the concor-
dance of IBD in monozygotic twins compared to dizygotic 
twins, particularly with Crohn’s disease. Twin studies for 
CD have shown fifty percent concordance in monozygot-
ic twins compared to less than ten percent in dizygotic 
twins (Loddo & Romano, 2015). Environment plays only a 
negligible role in predisposition for CD. Indirect evidence 
supporting the necessity of predisposing genes for the de-
velopment of the disease in the presence of a common 
environment is the low prevalence in spouses of patients 
with IBD. Spouses who both suffer from CD, is deemed as 
a highly unusual occurrence, as frequent as can be expect-
ed by chance alone (Dudley, 1995)
 Family-based studies consist of studying linkage analysis 
in sibling pairs and parental transmission in genome-wide 
screening using microsatellite markers. Microsatellite 
markers, otherwise known as simple sequence repeats 
(SSRs), which can be defined as segments of DNA where 
the nucleotide sequence repeats. Familial aggregation of 
IBD has been well documented in North American and 
European studies. It is well established that first degree 
relatives, particularly siblings, are at much greater risk in 
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developing IBD as compared to those in the general pop-
ulation. For example, if one parent has CD, the child has 
a ten percent increased risk in developing CD; and even 
if both parents suffer from CD, that likelihood increases 
to thirty-five percent (Pena, 1998). It has been shown that 
siblings of patients suffering from CD experience a seven-
teen to thirty-five times greater likelihood of developing 
CD (Akobeng, 2008).
Another significant study performed on ethnic popula-
tions proved that genetic variants are indeed associated 
with CD. People of Ashkenazi Jewish heritage have an in-
creased risk and a higher prevalence in developing CD 
as compared to non-Jews (Baumgart & Sandborn, 2012; 
Newman & Siminovitch, 2003). Several studies have prov-
en that CD is two-to-four times more prevalent among 
individuals of Jewish decent compared to non-Jewish 
Europeans living in the same area (NewsRX Health & 
Science, 2012). Currently, there are seventy-one genet-
ic variants that have been identified in Ashkenazi Jewish 
ancestry that increase an individual’s risk of developing 
CD. (Baumgart & Sandborn, 2012). In a study performed 
examining over six thousand individuals whose Jewish an-
cestry was confirmed by a large number of genetic mark-
ers, several variants were detected that are associated 
with the increased risk of CD. The involvement of twelve 
recognized CD risk variants in Ashkenazi Jews was con-
firmed and identified in novel genetic regions, as opposed 
to in non-Jewish European populations (Kenny et al. 2012). 
Further studies of these regions may aid in the discovery 
of biological pathways affecting susceptibility to CD and 
lead to the development of innovative and more effective 
treatments. This study not only proves the genetic origin 
of CD, but also demonstrates the value of genetic studies 
in secluded ethnicities, such as the Ashkenazim. Jewish 
heritage is an independent risk factor for developing CD. 
Genetic anticipation is the earlier onset of a disease in 
the offspring of parents with the disorder; a phenomenon 
featured in other genetic diseases, it has now been iden-
tified in Crohn’s (Polito et al. 1996).
While genetic studies have been highly successful at 
identifying the genetic risk factors for CD, these studies 
have proven virtually nothing about why one person will 
exhibit only mild symptoms of CD while another patient 
may require surgery to treat their condition. However, a 
familial link is often noticed in the symptoms of related 
patients. Researchers recognize that family members with 
CD often tend to have similar progress through treat-
ments (NewRX, 2017). Furthermore, researchers looked 
at the genome of two thousand seven hundred patients 
who shared similar symptoms and severity of CD. By com-
paring these patient’s DNA, the researchers discovered 
four genetic variants including FOX10, IGFBP1, MHC, and 
XACT that influence the severity of a patient’s condition. 
Strikingly, none of these genes have been shown to affect 
the risk of developing CD. This fact suggests that it is likely 
that genetics not only plays a role in the diagnosis of CD, 
but in the patient’s prognosis as well (Obesity, Fitness & 
Wellness Week, 2017).
Environmental Factors
Although the precise cause for CD is unknown, it’s be-
lieved that environmental factors also play a role in 
the development of the disease. Several environmental 
risk factors, such poor diet, as well as the side effects 
of breastfeeding, smoking, stress, and drugs, are believed 
to trigger inflammation. Additionally, childhood exposure 
towards an overly hygienic environment, seem to allow 
CD to manifest in predisposed patients.
Food is believed to promote the maintenance of gut 
integrity. Although the direct cause and effect relationship 
between the gut microbiota and IBD is unclear, targeting 
the intestinal microbiota allows for prevention of disease, 
as well as potential research concerning new treatments. 
Diet plays a significant role in a patient suffering from 
CD, as the body is unable to digest and absorb food ap-
propriately, thereby causing malnourishment in patients 
with CD (O’Sullivan, 2009). Furthermore, many patients 
with CD are anemic, as well as deficient in vitamin D, folic 
acid and vitamin B12 (Torres et al. 2017; Creek, 2017). 
Patients are recommended to avoid certain foods such as 
raw fruits and vegetables, dairy, fatty, greasy, spicy, and high 
fiber foods, as these foods are more difficult for the body 
to digest and absorb, and commonly irritate the bowel 
(Livie et al. 2006). While it has not been proven that a 
poor diet is a direct cause of CD, research has shown a 
common thread, that a proper diet is helpful in several 
ways by reducing one’s predisposition to developing CD. 
Moreover, diet has also been used as a treatment option 
for CD (Akobeng, 2012). Similar research has proven that 
maintaining a healthy diet is equally as effective in putting 
a patient in remission as corticosteroid treatments, par-
ticularly in the case of children (BMJ, 1997). Nutritional 
repletion is effective both by affecting the gut mucosa 
as well as by decreasing intestinal permeability. There is 
some evidence that the enteral diet has a direct effect on 
the gut mucosa by reducing cytokine production and the 
accompanying inflammation, thus leading to decreased 
intestinal permeability (Hanaway, 2006).
Breastfeeding promotes colonization with microbiota 
such as Bifidobacteria by providing them with the HMOs 
(human milk oligosaccharides) they require to thrive. 
According to one study, when specific HMOs, GOSs 
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(short-chain galactooligosaccharides) and FOSs (long-chain 
fructooligosaccharides), were fed to infants in the first six 
months of life, they later had fewer incidences of autoim-
mune reactions linked to gut microbiota, including recur-
rent wheezing, and allergic urticaria. Accordingly, Crohn’s 
which is an autoimmune disease, may be affected similarly 
by breastfeeding (Torres, et al. 2017). Maternal secretory 
IgA, a component of breast milk has been proven to af-
fect the composition of intestinal microbiota and the ex-
pression of genes associated with intestinal inflammation. 
Additionally, a negative correlation has been found between 
infants’ exposure to breast milk and the development of 
early onset IBD, suggesting breastfeeding has a preventative 
effect on IBD development (Stiemsma et al. 2015).
While cigarette smoking is notorious for initiating 
health risks such as lung cancer and heart disease, it is 
believed to play a role in the development of IBD as well. 
Although the pathogenesis for IBD is unclear, cigarette 
smoking is associated with IBD outcomes as it exacer-
bates the condition. Analysis of multiple studies has con-
firmed that active smokers are at increased risk for ac-
quiring CD (Newman & Siminovitch, 2003). Furthermore, 
smoking has repeatedly been proven to worsen the prog-
nosis of CD as it promotes a fistulizing phenotype, aggra-
vates disease course, and produces a decreased response 
to medical treatment. (Ole et al. 2009). Interestingly, while 
smoking has negative ramifications for Crohn’s sufferers, 
it may have a protective effect on those with a genetic 
disposition towards UC. Active smokers were proven to 
be at a lower risk for developing UC in comparison to 
those who never smoked and those who quit smoking. 
This phenomenon may be linked to nicotinic acetylcho-
line receptors, which are present in mucosal epithelial 
cells of the bowel, as well as on T cells. However, clinical 
trials of nicotine replacement in IBD have only yielded a 
modest benefit at best; thus, nicotine alone may not be 
the driving factor (Ole et al. 2009).
Despite the significant consequences of smoking asso-
ciated with patients suffering from IBD pathogenesis, the 
highest incidence of CD occurs in countries with a low 
prevalence of smoking such as United States and Canada 
(Rook, 2012). Furthermore, the majority of patients with 
CD are not current smokers and the majority of smokers 
do not develop CD, proving that smoking or lack thereof 
likely plays a role in the pathogenesis of only a subset of 
IBD patients (Torres et al. 2017). These studies display little 
correlation between smoking and IBD. Nonetheless, all IBD 
patients should be encouraged to quit smoking due to the 
deleterious negative health effects associated with smoking. 
The role of psychological distress and personality as 
predisposing factors for the development of CD remains 
controversial. The debate concerning this matter has 
been ongoing for over eighty years without reaching a 
common ground, as attempts to investigate the role of 
psychological factors have unveiled conflicting results. 
However, over the past several years, it has become evi-
dent that psychological stress is at least associated with 
CD. However, that stress may be the result rather than 
the cause of chronic and longstanding CD. Unpredictable 
flare-ups and changes in body image can also lead to addi-
tional stress. This stress may precipitate an exacerbation 
of the disorder, thus continuing a vicious cycle of flare ups. 
Multiple theories have been presented suggesting ex-
planations on the unknown environmental exposures 
that may interact with the immune system and result in 
abnormal inflammatory intestinal response. However, the 
most predominant theory is the hygiene hypothesis, which 
explains the link between exposure to specific microbi-
al allergies and the prevention of certain diseases. This 
hypothesis theorizes that when one’s childhood has had 
excess hygiene and a lack of exposure to enteric patho-
gens; the child may not develop sufficient immunity to-
wards pollution and environmental contamination. Thus, 
it will inevitably impair microbial competence of the GI 
immune system and its ability to recognize new antigens, 
thereby predisposing children to immunologic disorders 
further on in life (Sabe et al. 2017). While the effect of 
lack of exposure is believed to be most profound during 
early childhood, the ideal timing and degree of exposure 
required remains unclear. The hygiene hypothesis also 
theorizes that multiple childhood infections and poor hy-
giene protects and prevents an individual from developing 
Crohn’s disease by allowing the host to develop tolerance 
or immunity to agents that may trigger Crohn’s disease 
later on in life (Stiemsma et sl. 2015). Additionally, it is 
entirely probable that the impact of various exposures 
are not mutually exclusive; such that disease development 
depends on the dose-response interactions between ex-
posures, and this reflects how strongly one’s exposure 
may protect or increase the risk conferred by CD sus-
ceptibility mutations) (Sabe et al. 2017).
Interestingly, the first Crohn’s disease gene identified, 
CARD 15(caspase-activation recruitment) also referred 
to as the NOD2 (nucleotide oligomerization domain 
gene), found within IBD1 locus is involved with the in-
nate immune system and the response of monocytes 
upon perceiving a bacterial encounter. The abnormal 
and unconstrained inflammatory response that may 
occur in individuals with NOD2/CARD15 mutations is 
likely to be involved with the pathogenesis of Crohn’s 
disease. Polymorphisms in the CARD15/NOD2/IBD1 
locus have been associated with the highest risk for CD 
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development. Recent evidence shows that polymorphisms 
cause reduced functionality of the immune system and 
exacerbated phenotype (Newman & Siminovitch, 2003). 
Counterintuitively, countries with poor sanitary condi-
tions such as Africa and the Middle East reportedly have 
a relatively low frequency of Crohn’s disease (Torres et 
al. 2017), while more developed countries such as Canada 
and the United States have the highest rates of CD. It is 
believed that endemic parasitic infections may favorably 
affect the immune system as to prevent disease by stim-
ulating T-helper type2 (Th-2) cells, which in turn down-
regulate Th-1 cells and prevent the exaggerated Th-1 re-
sponse associated with Crohn’s disease. Building on this 
theory, the ova of Trichuris suis (eggs of a pig whipworm), 
have been successfully used to treat Crohn’s disease 
patients, as the intake of these parasites elicit Th-2 cells 
thereby suppressing Th-1 cells from activating (Guarneret 
et al. 2006; Summers, et al. 2005).
Many physicians treating patients with IBD do not be-
lieve that stress or diet are direct causes of IBD. Yet, due 
to the lack of understanding of the etiology of IBD, no 
known direct cause and cure exist for the disease. The 
Crohn’s and Colitis Foundation and medical researchers 
suggest that foreign substances found in the environment 
or external agents such as bacteria may interact with a 
weak immune system, thereby producing an immune re-
sponse of inflammation which the body is unable to stop 
(McGovern, Gardet, Törkvist, et al. 2007).
Epigenetics
It has become apparent that epigenetics plays a significant 
role contributing to the development of CD. Epigenetics 
can be defined as mitotically heritable changes in gene 
expression without shifting the DNA. Gene expression 
can be altered by changes to the structure and function of 
chromatin. Different cells in the body are characterized by 
different functions and different levels of gene expression 
despite each sharing the same genetic code. This variation 
in gene activity from cell to cell is achieved by mecha-
nisms and processes that are collectively termed epi-
genetics. The main epigenetic mechanisms include DNA 
methylation, histone modification, RNA interference, and 
the positioning of nucleosomes. These epigenetic mecha-
nisms, in particular DNA, allow the onset and reactivation 
of disease that’s triggered by environmental factors that 
rapidly break the mucosal barrier, thus stimulating an im-
mune response or altering the balance between beneficial 
and pathogenic enteric bacteria. Different genetic abnor-
malities can lead to similar disease phenotypes; these 
genetic changes can be broadly characterized as causing 
defects in mucosal barrier function, immunoregulation 
or bacterial clearance. These new insights will help de-
velop better diagnostic approaches that identify clinically 
important subsets of patients for whom the natural his-
tory of disease and response to treatment are predict-
able. Methylation appears to be of great importance in 
the interaction between genome and the environment. 
Variation in DNA methylation is a well-recognized cause 
of human disease and is likely to play a pivotal role in the 
cause of complex disorders such as CD.
Discussion and Conclusion
Inflammatory bowel disease is sectioned into two divisions, 
CD and UC. Both are complex multifactorial disorders 
characterized by chronic relapsing intestinal inflammation. 
However, the etiology of both diseases remains largely 
unknown as it is characterized as an idiopathic disease 
(Sartor, 2006). Understanding the causes and molecular 
mechanisms of CD and UC is a leading challenge in gas-
troenterology research, due in part to the relatively low 
frequency of these disorders. Although significant effort 
has been made to help identify genetic and environmental 
factors that may increase the risk of IBD, little is known 
about IBD-specific factors.  Recent research has suggested 
that IBD is caused by a complex interplay between genetic 
predispositions of various genes, combined with an abnor-
mal interaction with environmental factors as a result of 
a perceived threat. Epidemiological evidence for a genetic 
contribution is made apparent by twin and family studies 
of CD patients. Genetic variants that stimulate IBD have 
a substantial effect on gene function. These variants are 
so rare in allele frequency, that the genetic signals aren’t 
detected in genome-wide association studies of patients 
with IBD. With recent advances in sequencing techniques, 
roughly fifty genetic disorders have been identified and 
associated with IBD such as osteoporosis as well as thy-
roid disease. Monogenic defects have been found to alter 
intestinal immune homeostasis through many mechanisms. 
Candidate gene resequencing should be carried out in ear-
ly-onset patients in clinical practice.  
The evidence that genetic factors are the prime contrib-
utors to disease pathogenesis confirms the insignificant 
role of microbial and environmental factors. Epigenetic 
factors can mediate interactions between environment 
and genome. Epigenetic mechanisms could affect develop-
ment and progression of IBD. Epigenomics is an emerging 
field, and future studies could provide further insight into 
the pathogenesis of IBD. 
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Autism spectrum disorder (ASD) is characterized as a developmental disability caused by abnormalities in brain function. Studies 
link ASD with various physiological abnormalities, such as cerebral hypoperfusion, oxidative stress, inflammation, and mitochon-
drial dysfunction. Studies show that diminished blood flow to the brain demonstrates a connection between several core autistic 
behaviors, and the hypoperfusion generally worsen with age, growing more prevalent in older children. Although hyperbaric oxygen 
therapy (“HBOT”) is not yet approved by the United States Food and Drug Administration ) (“FDA”), several studies performed 
internationally have proven its efficacy in treating people with autism. Even so, the FDA does approve of its use for other medical 
conditions such as decompression sickness (the bends) experienced by divers, treatment of air or gas embolism, carbon monoxide 
poisoning , and thermal burns. Hyperbaric oxygen therapy chambers expose the patient to 100% oxygen (unlike the 21% oxygen 
found in the air we breathe) by increasing the air pressure in the chamber up to three times higher than normal air pressure of 
1 atm. This allows the lungs to take in more than the expected amount of oxygen and thus be distributed throughout the body 
to the cells that are deprived of oxygen. This paper examines the effectiveness of HBOT in children with ASD, by reviewing the 
available research.
Is Hyperbaric Oxygen Therapy Effective For Treating Autism?
Malky Meyer
Malky Meyer graduated in January 2020 with a Bachelor of Science degree in Biology. She will attend Touro 
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Introduction
Autism spectrum disorder (ASD) is a neurodevelopmen-
tal disorder characterized by “persistent deficits in social 
communication and social interaction across multiple 
contexts and restricted repetitive patterns of behavior, 
interests, or activities,” (APA, 2013). ASD includes autistic 
disorder, pervasive developmental disorder, and Asperger 
syndrome. Approximately 1 out of 110 people in the 
United States are currently affected by ASD (Rice, 2006). 
The cause of ASD is unclear. Although several genetic 
syndromes, such as Fragile X and Rett syndromes, have 
been linked with ASD, the majority of ASD cases are not 
due to a simple single gene or chromosomal disorder; 
studies have estimated that genetic syndromes only ac-
count for 6-15% of ASD cases (Schaefer & Mendelsohn, 
2008). Recently, research and clinical studies in ASD have 
linked physiological abnormalities, such as cerebral hy-
poperfusion, inflammation, oxidative stress, mitochondrial 
dysfunction and immune dysregulation (Rossignol & Frye, 
2012). With this perspective, ASD may consist of physio-
logical irregularities rather than merely a CNS disorder 
(Herbert, 2005). Treating ASD is not a simple matter; 
there are a limited number of treatments. The behavioral 
aspects of ASD are manageable with the help of behavior-
al therapies. Applied behavioral analysis (ABA), specifically, 
has been proven to lead to advances in certain children 
with ASD. In two years, ABA brought about remarkable 
improvements in the IQ and behavioral issues of several 
children with ASD (Lovaas, 1987). After four years, ABA 
researchers at the Wisconsin Early Autism project found 
analogous results of improved IQ and behavior (Sallows 
& Graupner, 2005). Conversely, researchers in Norway 
found that eclectic therapy (a form of psychotherapy) 
was successful in the treatment of children with ASD 
who were observed for only one year. The results proved 
to supersede the effective outcomes of ABA (Eikeseth, 
et al., 2002). When it comes to  cognitive and behavioral 
transformations in children with ASD, behavioral thera-
pies are not an ideal approach, as they are quite time de-
manding. Additional treatments for ASD that aim to treat 
physiological irregularities have been conveyed, yet, a 
majority of these forms of treatments have not been crit-
ically assessed. However, many studies were performed 
to test the effects of HBOT to treat the physiological ab-
normalities possessed by people with ASD, many of which 
have shown promising results.
Methods
The research incorporated in this paper was retrieved 
from original research papers and scholarly articles ob-
tained through Touro College’s library of databases, such 
as ProQuest and EBSCO. Google scholar, and PubMed 
were also used to acquire data. The articles chosen were 
critically assessed, compared, and analyzed to evaluate if 
hyperbaric oxygen therapy is effective for treating autism
History of Hyperbaric Chambers
Hyperbaric air or “air under pressure” is a medical treat-
ment that dates back over 150 years.  In 1662, a British 
physician created a sealed chamber in which the air was 
compressed and decompressed using valves and oxygen. 
This was extraordinary;it preceded the  discovery of 
oxygen and was utilized as a treatment for respiratory 
diseases (Clarke, 2008). The idea of employing pressur-
ized environments developed further in 1879, when the 
French surgeon, Fontaine, built a pressurized mobile op-
erating room. He observed that inhaled nitrous oxide 
had greater efficacy when used under pressure. Patients 
treated in an increased pressure environment were 
not as cyanotic as those treated in standard conditions. 
Additionally, his patients experienced improved oxygen-
ation (Fontaine, 1879). In the early 1900’s, Dr. Orville 
Cunningham, a professor of anesthesia, found a greater 
improvement in heart disease victims when they resided 
66
Malky Meyer
closer to sea level than when they were living at higher 
altitudes. Later, hyperbaric chambers were utilized by the 
military, in the 1940’s, to treat deep-sea divers who expe-
rienced decompression sickness. In the 1950’s, physicians 
first used HBOT during lung and heart surgery, which 
steered to its use for carbon monoxide poisoning in the 
1960’s. Since then, over 10,000 clinical trials and case 
studies have been achieved for several other health-relat-
ed purposes, with the great majority reporting successful 
outcomes (Ohnishi, et al. 2000).
Hyperbaric oxygen therapy (HBOT)
Hyperbaric oxygen therapy (HBOT) is the medical use 
of oxygen in a pressurized environment, and involves 
breathing 100% oxygen while inside a hyperbaric cham-
ber that exhibits pressures greater than sea level (1 at-
mosphere). The increased pressure permits oxygen to 
dissolve and saturate the blood plasma (autonomous of 
hemoglobin), which yields an extensive array of valuable 
physiological and cellular outcomes. This noninvasive 
therapy is the most reliable way to provide ample oxygen 
to all organs of the body. The standard treatment lasts 
for 60-90 minutes, during which the patient lies down 
and breathes regularly (Feldmeier, 2003). The use of hy-
perbaric oxygen treatment (HBOT) was implemented 
as a treatment method for numerous clinical disorders. 
It has been proven in several clinical studies to enhance 
the body’s inherent ability to regenerate and repair. It is 
used as a therapy to facilitate the healing process in both 
chronic and acute disorders. Decompression sickness, 
stroke victims, arterial gas embolism, healing of wounds, 
severe carbon monoxide poisoning and smoke inhalation 
are only some of the common uses of HBOT. However, 
in 2005, researchers began to consider using HBOT to 
improve behavioral and physiological abnormalities found 
in individuals with ASD (Leach, et al. 1998).  This paper will 
evaluate the current data on treating ASD with HBOT. 
First, the effects of HBOT on physiological irregularities 
in children with ASD will be evaluated. Then, the effects 
on autistic behaviors will be examined. Finally, the appar-
ent contrary effects of HBOT in ASD and restrictions of 
studies will be assessed.
Cerebral Hypoperfusion in ASD and the Effects 
of HBOT
Cerebral hypoperfusion is characterized as insufficient 
blood flow in the brain and is one of the common physi-
ological abnormalities possessed by individuals with ASD. 
Positron emission tomography (PET) and single-photon 
emission computed tomography (SPECT) were used in 
studies to discern hypoperfusion exhibited in the brains of 
people with ASD versus normal healthy brains (Bjørklund, 
et al. 2018). Both PET and SPECT scans are types of nu-
clear imaging tests that utilize radioactive tracers to cre-
ate three-dimensional images. However, they differ in the 
radiotracers used. Studies have proven these scans to be 
a reliable measure of cerebral blood flow in observing 
what areas of the brain are receiving more blood flow. 
(Amen, et al. 2011; NIH CC, 2002). Common autistic 
behaviors such as need for consistency (Ohnishi, et al. 
2000), habitual behaviors (Starkstein, et al. 2000), disability 
in processing emotions and facial expressions (Critchley, 
et al. 2000), and delayed language development (Wilcox, 
et al. 2002), are linked to hypoperfusion. Moreover, hy-
poperfusion is related with increasing age in children with 
ASD (Wilcox, et al. 2002). It is possible that HBOT could 
improve cerebral hypoperfusion in ASD. Numerous stud-
ies were completed that evaluated the effects of HBOT 
to treat various neurological disorders, such as chronic 
brain injury and traumatic brain injury. The results of the 
SPECT scans were evaluated before and after the deliv-
ery of HBOT at low pressures (1.3 to 1.5 atm). These 
studies showed significant results (Harch, et al. 2012), 
(Golden, et al. 2002). Histograms correlated to the pre 
and post SPECT scans were analyzed with a widely used 
medical images software called Osirix DICOM. Results 
from both scans showed significant pattern differences 
beneath the cerebral cortex in the central area of white 
matter, known as the centrum ovale. The pre-HBOT im-
ages displayed a larger array of counts in the histograms 
than in the post-HBOT. The narrower range of counts in 
the post-HBOT corresponded to the increase of perfu-
sion to the lacking areas. The effectiveness was studied 
through many areas in addition to SPECT: physical exam, 
symptoms, and psychological measurement (Harch, et al. 
2012). Moreover, numerous case studies have reported 
enhancements in cerebral perfusion after HBOT treat-
ment. One study involved a child with ASD who received 
one hour of HBOT at 1.3 atm and 24% oxygen per day for 
ten days (Heuser, et al. 2002). The SPECT scans revealed 
increased perfusion. However, the effects of ten treat-
ments only lasts several months. For longer lasting effects 
(6-18 months) more treatments are necessary (20-60 
treatments). Behavioral improvements were detected in 
this child including cognitive and memory functions. The 
child became sympathetic, started to point and articulate, 
and interact with others. Another child with ASD, who 
received 40 treatments of HBOT at 1.3 atm and 24% 
oxygen, also presented behavioral improvements, such 
as, improvements in speech and communication and fine 
motor skills (Rossignol, 2008).
Another study involved 108 children with ASD who 
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experienced decreased perfusion in their temporal lobes 
as measured by SPECT scans (Kinaci, et al. 1970). They 
received HBOT at 1.5 atm with 100% oxygen for an hour 
a day for 50 days. After their treatments, SPECT scans 
revealed that 82.40% showed improvements in their 
temporal lobes, 85.26% in their frontal lobes, and 75.75% 
in other areas. Furthermore, clinicians did an Autism 
Treatment Evaluation Checklist (ATEC) on 54 of the in-
dividuals and significant improvements were noted: 85.5% 
in Sociability, 79% in Speech/Language/Communication, 
75.2% in Health/Physical/Behavior, and 87% in Sensory/
Cognitive Awareness. This study revealed major improve-
ments in the physical, behavioral and cerebral perfusion of 
children with ASD after HBOT (Kinaci, et al. 1970). This 
study is reliable due to the large sample size, unbiased 
SPECT imaging, and therapist assessments.
Oxidative Stress in ASD and the Effects of HBOT
Oxidative stress is defined as an imbalance between the 
production of reactive oxygen species (free radicals) and 
antioxidant defenses. Some children with ASD experience 
oxidative stress. Some researchers believe that HBOT in-
directly causes an increase in oxidative stress due to the 
amplified production of reactive oxygen species (“ROS”) 
from the elevated oxygen levels (Alleva, et al. 2005). 
Therefore, they are reluctant to use HBOT on children 
with ASD, since some of them already have elevated oxi-
dative stress levels (Rossignol, et al. 2007). A contributing 
factor to their increased oxidative stress levels might be 
due to the excessive amounts of oxygen supply to their 
cell’s mitochondria, which can escalate the production of 
ROS. In contrast, HBOT has proven to upregulate antiox-
idant enzyme production that can aid with detoxification 
issues found in children with ASD such as glutathione 
peroxidase, superoxide dismutase (Gulec, et al. 2004), 
and catalase (Nie, et al. 2006). The antioxidant enzyme 
level increase can protect against harm initiated by ROS 
(Rossignol, 2007). Additionally, minor elevations in ROS 
created by HBOT can be advantageous, as they increase 
mitochondrial biogenesis (Gutsaeva, et al. 2006). 
Two studies have observed the influences of HBOT 
on oxidative stress in children with autism (Audhya, 
2007; Rossignol, et al. 2007). The first study included ad-
ministering HBOT at 1.3 atm daily to 48 children with 
autism. Catalase, glutathione peroxidase and superoxide 
dismutase (SOD) levels were screened before beginning 
HBOT and again after day 1 and day 32 of HBOT (Audhya, 
2007). Results demonstrated a 1.9-fold increase of the 
original catalase levels after the first day and a 90% im-
provement after 32 days. Glutathione peroxidase showed 
a 1.4-fold increase after 1 day and a 1.2-fold increase after 
32 days from the initial HBOT. Finally, a 4.5-fold increase 
of SOD was observed after 1 day and a 4.7-fold increase 
after 32 days of starting HBOT. The results of HBOT on 
antioxidant enzymes can be considered conditioning. 
The second study involved 18 autistic children from 
ages 3-16. This open label, prospective study included ad-
ministering 40 treatments of HBOT, with 24% oxygen, at 
1.3 atm, to 12 children, and 100% oxygen at 1.5 atm to 6 
children. Blood markers were taken before and after 40 
treatments (Rossignol, et al. 2007). Researchers noticed 
dramatic improvements in speech, socialization, GI func-
tion, and strength. The effects persisted months after the 
study was completed. Furthermore, insignificant chang-
es were seen in plasma-oxidized glutathione levels. This 
proves that oxidative stress markers did not worsen be-
cause oxidized glutathione is transported from within the 
cells when intracellular levels surpass the redox capacity 
(Dickinson and Forman, 2002). However, the intracellu-
lar oxidative stress levels in the children with ASD did 
not diminish with the lower HBOT pressures (Rossignol, 
et al. 2007). The open-label nature of this study and the 
two diverse treatment groups (one group who received 
24% oxygen at 1.3 atm versus the other group who re-
ceived 100% oxygen at 1.5 arm), as well as the absence 
of a control group, are some of the limitations of this 
study. Nonetheless, the prospective nature of this study 
strengthens it. 
Inflammation in ASD and the Effects of HBOT
Some individuals with ASD experience inflammation, such 
as neuroinflammation, gastrointestinal inflammation and 
immune dysregulation as supported by recent studies. 
Numerous studies have conveyed atypical inflammatory 
indicators in children with ASD. For instance, increases 
in Tumor Necrosis Factor-alpha (TNF-alpha) (Chez, et al. 
2007), and neopterin (cellular immune system activation 
marker) (Messahel, et al. 1998), were related in studies 
of children with ASD. Additionally, studies showed that 
children with ASD, who reported having gastrointestinal 
inflammation, have analogous symptoms to one suffering 
from inflammatory bowel disease (IBD) (Ashwood, et 
al. 2003). Anti-inflammatory results were reported after 
treatment with HBOT. A decrease in pro-inflammatory 
cytokines (including TNF-alpha, IL-1 and IL-6) (Weisz, et 
al. 1997), and an increase in counter-inflammatory IL-10 
levels were reported after HBOT (Buras, et al. 2006). 
Moreover, improvements in IBD were reported in a 
systematic review that used HBOT (Rossignol 2012). 
A study reported a decrease in production of interfer-
on-gamma by lymphocytes with HBOT at 2.0 atm/10.5% 
oxygen, but an increase in interferon-gamma with 100% 
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oxygen administered at 1.0 atm (Granowitz, et al. 2002). 
Therefore, it is concluded that the result of HBOT on 
reducing inflammation is facilitated through the pres-
sure-related component and not particularly on the de-
livery of oxygen. 
Unfortunately, a series of recurring events can cause 
amplified inflammation which can lead to escalated cere-
bral hypoperfusion. This may cause hypoxia, which leads 
to production of HIF-1a (hypoxia-inducible factor-1alpha) 
which induces inflammation (Nathan, 2003). HIF-1a is 
fundamental in the innate immune system, as it triggers 
inflammation by myeloid cells (Cramer, et al. 2003). 
The effects of HBOT on biomarkers of inflammation 
in children with ASD were inspected in two prospective 
studies. The first study included 12 children who were 
given 40 treatments of HBOT at 1.3 atm/24% oxygen 
and 6 children who were given HBOT at 1.5 atm/100% 
oxygen. Biomarkers were measured before and after the 
treatments by testing the participants’ blood specimens 
taken before and after the treatments (Rossignol, et al. 
2007). Improvements were seen in C-reactive proteins 
(non-specific inflammation markers), as their levels de-
creased in the total study population (p=0.021). The most 
significant decrease was seen in children with the highest 
levels of C-reactive proteins prior to the study. These 
children also showed behavioral improvements. SRS 
(Social Responsiveness Scale), ABC-C (Aberrant Behavior 
Checklist – Community), and ATEC (Autism Treatment 
Evaluation Checklist) were filled out by the parents and 
were used to calculate the scores for each child before 
and after their treatments. 
The second study measured plasma cytokine levels, in-
cluding some related to inflammation prior to and after 
HBOT. Ten children with ASD participated in this 20 week 
study with 80 sessions of HBOT given to them at 1.5 
atm/100% oxygen (Bent, et al. 2012). Although the study 
reported behavioral improvements, negligible modifica-
tions were observed in cytokines. Yet, the authors men-
tioned that none of the children actually had irregular 
cytokine levels prior to the study, so notable variations 
could not be seen. 
In another study, a child with ASD who suffered from 
eczema and bowel inflammation, with a distended abdo-
men, displayed significant improvements after 40 treat-
ments of HBOT at 1.5 atm and 100% oxygen over the 
course of a month (Rossignol 2008).
Mitochondrial Dysfunction in ASD and the 
Effects of HBOT
Mitochondrial dysfunction is observed in some people 
with ASD (Rossignol & Frye, 2011; Frye & Rossignol, 2011). 
HBOT is considered a possible treatment for mitochon-
drial dysfunction, although treatments for this condition 
are minimal (Rossignol & Frye, 2011). The outcomes of 
HBOT on mitochondrial dysfunction were measured in 
various studies. 
In a controlled study HBOT at 1.5 atm and 100% 
oxygen was administered to 69 patients who obtained 
severe traumatic brain injury (TBI), within 24 hours of in-
jury. Significant increases in brain oxygen concentrations 
were seen, as well as increases in cerebral blood flow 
and reduced CSF lactate levels (elevated CSF lactate is 
an indicator of mitochondrial dysfunction). Results also 
showed improvements in mitochondrial function and 
brain metabolism after contrasting both room air treat-
ment of 21% oxygen and 100% oxygen given at normal 
pressure (1 atm) (Rockswold, et al. 2010).
HBOT can make more electron transport chains in 
mitochondria. In 2008, a study was conducted on healthy 
rat tissue (Kurt, et al. 2008). HBOT was done on the rat 
and the tissues were looked at before and after the treat-
ment. Results showed that the mitochondria were work-
ing more efficiently. Mitochondria work more efficiently 
through physical exercise. During exercise, the cells are 
stressed and mitochondria are making more electron 
transport chains. Similarly, with HBOT, the cells are slight-
ly stressed and they make more electron transport chains 
thereby working more efficiently and experiencing less 
oxidative stress. 
Furthermore, a study was conducted in 2006, which 
showed it is possible to increase the number of mito-
chondria in the brain cells of rats. This phenomenon is 
called mitochondrial biogenesis (Gutsaeva et al. 2006). 
This was not demonstrated in humans, because it would 
require risky brain biopsies to be performed on patients. 
This can be one possible mechanism as to why HBOT is 
working. Although these results seem promising, no clin-
ical studies were performed to test the effects of HBOT 
on mitochondrial dysfunction in children with ASD. 
Behavioral Measurements in ASD and the Effects 
of HBOT
Most of the studies performed using HBOT for chil-
dren with ASD have inquired behavioral rather than 
physiological factors. In a current systematic review, 
two double-blind, arbitrary, controlled trials were re-
viewed regarding the use of HBOT in children with ASD 
(Ghanizadeh, 2012). The first study examined the outcome 
of giving 33 children with ASD, 40 treatments of HBOT 
with 24% oxygen at 1.3 atm, which included 2 treatments 
each day for 5 days a week, over the course of 4 weeks. 
This study was performed in comparison to 29 control 
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children with ASD who were given room air that was 
slightly pressurized (1.03 atm/21% oxygen) (Rossignol, et 
al. 2009). Noteworthy improvements were detected in 
the treated children on the ATEC scales (questionnaire 
that measures changes in severity of ASD in response to 
treatment) by the caregiver, as well as on the CGI scales 
(Clinical Global Impression rating scales: measures the 
severity of symptoms, treatment response and the effec-
tiveness of treatments) by the clinicians and parents. The 
results showed improvements in language, eye contact, 
cognitive attentiveness and overall functioning. Strengths 
of this study comprise of the involvement of 6 medical 
centers (which limited possible biases correlated to a 
specific site study), assessments by blinded parents and 
clinicians and the use of a control group.
The second study examined the outcome of giving 18 
children with ASD, 80 treatments of HBOT with 24% ox-
ygen at 1.3 atm, within a 15 week duration. These results 
were compared to 16 children who were treated with a 
placebo, involving air flowing through a chamber at normal 
pressure. Subsequently, ABA therapy was given to both 
groups, yet insignificant changes were observed using var-
ious behavioral scales (Granpeesheh, et al. 2010). These 
undesirable results can be attributed to the fact that rig-
orous ABA therapy was given during the administration 
of HBOT which did not seem successful (Ghanizadeh, 
2012). On the other hand, this study is reliable because of 
the blinded evaluators as well as the control group. The 
contrasting results can be ascribed to the discrepancies 
among the two controlled trials (Ghanizadeh, 2012). For 
example, the age and quantity differences of the partici-
pants, as well as the magnitude of treatments. One study 
delivered 10 hours of HBOT per week (Rossignol, et al. 
2009). While the other study provided 5 hours per week 
(Granpeesheh, et al. 2010). There were also probable dis-
tinctions in ASD severity.
Antagonistic Properties of HBOT in ASD
Among the many studies performed, minimal unfavorable 
outcomes were reported of HBOT usage for people with 
autism. One study stated that “HBOT was safely admin-
istered to autistic children and all participants were able 
to finish 40 HBOT sessions without any major adverse 
events” (Rossignol, et al. 2007). A different study informed 
minor antagonistic effects, including 4 kids with earaches, 
2 kids with otitis media and other individuals who were 
autonomously affected with insomnia, seizures, lethargy, 
amplified vocal sensitivity and hyperactivity (Bent, et al. 
2012). In a controlled study, one of the participants ex-
perienced frequent urination and a skin rash which the 
doctor attributed to yeast as the causing factor. Other 
participants withdrew from the study, specifically one 
child who experienced regressing symptoms of asth-
ma after several HBOT treatments. The physicians did 
not think the two were related, but removed the child 
as a safeguard. Another child withdrew from the study 
before completing it due to anxiety. One participant in 
the control group experienced diarrhea and abdominal 
swelling, yet still completed the experiment. In addition, 
another control group participant experienced wors-
ening of pre-existing eczema. Seizures or barotrauma, 
however, were not detected in neither the treatment nor 
control groups (Rossignol, et al. 2007). In a study per-
formed on the effects of HBOT in Thai autistic children, 
it was reported in the data analysis that “there was no 
serious adverse effect in any case and tinnitus was a mild 
side effect in one case and it went away in one week” 
(Chungpaibulpatana, et al. 2008). 
According to the FDA, “patients receiving HBOT are 
at risk of suffering an injury that can be mild (such as 
sinus pain, ear pressure, painful joints) or serious (such 
as paralysis, or air embolism). Since hyperbaric chambers 
are oxygen rich environments, there is also a risk of fire” 
(FDA commissioner, 2013) .
Restrictions of the Studies Performed
Most of the studies performed contain restraints that 
contribute to the erratic results among them, including 
the retrospective approaches, the absence of control 
participants and the minimal amount of participants. 
Moreover, the open trials increase bias, as both the par-
ticipants and the researchers are aware which treatment 
is being given. However, two of the controlled studies did 
not contain these restraints. Furthermore, other studies 
utilized observational methods which are not efficient 
when analyzing modifications in memory and attentive-
ness (Jepson, et al. 2011). Unfortunately, the long-term 
effects of HBOT are unknown because once the study 
was complete researchers did not follow up on the 
long-lasting effects. Additionally, a majority of the studies 
focused on behavioral modifications rather than physi-
ological modifications. Earlier studies proved that ABA 
therapy in individuals with autism is only effective when 
done over a substantial period of time. For example, ABA 
therapy studies displayed significant behavioral changes 
over a one to four year duration (Lovaas, 1987; Sallows & 
Graupner, 2005). 
It is common for the physiological modifications seen 
in autistic children treated with HBOT to be observed 
before intellectual and developmental enhancements due 
to the intricacies of brain maturation. Studies have found 
significant physiological improvements after a short time 
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in participants who were treated with HBOT, specifically 
modifications with cerebral hypoperfusion. While most 
of the studies noted behavioral enhancements in sever-
al children with autism, the studies only persisted for a 
few months. This short duration of time is not enough 
to determine the influence HBOT has on development. 
Further studies are necessary to investigate the long last-
ing results of HBOT in people with autism. 
Many studies noted behavioral and physiological ad-
vances when treating autistic children using HBOT. Yet, 
noteworthy developments were not found when re-
searchers from a common group performed two studies 
(Granpeesheh, et al. 2010; Jepson, et al. 2011), and insig-
nificant results were noticed in a different minor study 
(Lerman, et al. 2009). The inconsistent outcomes among 
the studies may be attributed to the autistic children’s 
opposing responses to HBOT (Jepson, et al. 2011). To 
illustrate, children who possess certain physiological ab-
normalities such as mitochondrial dysfunction, cerebral 
hypoperfusion and inflammation might be more prone to 
display improvements. Nevertheless, most of the studies 
performed to test behavioral aspects did not analyze the 
chemical aspects such as levels of oxidative stress or in-
flammatory markers. However, one behavioral study did 
analyze alterations in the levels of cytokine, but insignifi-
cant modifications in cytokines were seen because all the 
participants already had regular cytokine levels prior to 
their HBOT treatment (Bent, et al. 2011).
Further investigation is required including participants 
with ASD who possess specific physiological abnormal-
ities and which analyze variations in these physiological 
issues such as cerebral hypoperfusion and inflammation. 
Noteworthy improvements were related in studies which 
administered HBOT sessions more frequently. This also 
seemed true in studies that used HBOT to treat patients 
with traumatic brain injuries, (Harch, et al. 2012). More 
studies, however, are needed to analyze several HBOT 
factors, such as the ideal oxygen and pressure limits re-
quired to treat patients with ASD.
HBOT in Thailand
In 2008, the first study in Thailand was performed to de-
termine the effects of HBOT to treat autistic children and 
whether it is safe or not (Chungpaibulpatana, et al. 2008). 
The study included 7 Thai autistic children who received 
10 sessions of HBOT once a week at 1.3 atm. Before and 
after the treatments, five areas were evaluated: “1. Social 
development 2. Fine motor and Eye-hand coordination 3. 
Language development 4. Gross motor development 5. 
Self - help skills” (Chungpaibulpatana, et al. 2008). Results 
showed advances within these five domains with 75% of 
children who displayed progress while 25% showed no 
reaction to the treatment.
FDA Approval
Although HBOT is currently being used as a treatment 
method to treat various disorders in Thailand such as 
autism, it has not been clinically verified or cleared by 
the FDA to cure or be successful in the treatment of au-
tism, cancer, or diabetes (FDA, 2013). However, the FDA 
did approve the use of HBOT for several other condi-
tions. These include “treatment of air or gas embolism 
(dangerous ‘bubbles’ in the bloodstream that obstruct 
circulation), carbon monoxide poisoning, decompression 
sickness (‘the bends’), and thermal burns (caused by heat 
or fire),” (FDA, 2013).
Disadvantages
Dr. Paul Claus, medical director of Mayo Clinic’s 
Hyperbaric and Altitude Medicine Program, relates risk 
factors of HBOT. The increased oxygen of the chamber 
supports combustion which poses a risk for fires in the 
facility. Therefore, necessary precautions are taken. The 
patients are required to remove their street clothes since 
polyester is fuel for fire. The patients are provided with 
cotton blend clothing instead. Additionally, the treatments 
are quite expensive; they are approximately $1,500 an 
hour in most hospital settings (Claus, 2017). However, 
if more studies are done documenting improvements of 
HBOT, then hopefully the cost will be covered by the 
healthcare system or insurance companies to further 
benefit those with autism. .
Conclusion
“There is no one-answer for many questions but there 
are many answers for one question. Multiple factors are 
the possible causes of autism. The curative factors may be 
from multidisciplinary approaches,” (Chungpaibulpatana, 
et al. 2008). Numerous studies have demonstrated that 
HBOT is an effective treatment for children with autism. 
The pressures utilized during treatment with HBOT (1.5 
atm/100% oxygen maximum) are proven to improve the 
common physiological abnormalities in individuals with 
ASD; such as, cerebral hypoperfusion, oxidative stress, in-
flammation and mitochondrial dysfunction. Furthermore, 
studies that targeted the behavioral measurements in 
ASD also showed positive results even though most of 
those studies did not use control groups. The two studies 
that did utilize control groups however related opposing 
outcomes. However, multiple crucial variations between 
the trials were noted. Taken together, the studies imply 
that the use of HBOT in children with autism correlates 
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with marginal antagonistic effects and is handled well. In 
conclusion, HBOT is a harmless and possibly beneficial 
treatment for kids with autism. However, additional stud-
ies are necessary before it can become an internationally 
accepted treatment method. Future studies should be 
more specific and directed towards the specific physio-
logical abnormalities within the various ASD subdivisions 
and should use control groups as well to promote effi-
ciency and determine which people can gain from HBOT 
treatment. Furthermore, why don’t the hospitals in 
Thailand publish anything regarding their routine HBOT 
usage? They value intellectual property not academic 
publications. If it were not more clinically effective than 
the use of HBOT would not be used regularly and its 
ineffectiveness would spread like wildfire. Based on the 
studies performed, overall, the use of hyperbaric oxygen 
therapy appears to be a promising treatment for children 
with ASD.
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Abstract
With obesity on the rise, and subsequently numerous diseases, many people are looking for newer ways to counter the effects of the 
influx of fatty, high sugar and unhealthy foods they are consuming. The most common and widely used method is a diet plan.  The 
key to both a healthy and effective diet is knowing what the diet does to the body.  There are short term diets which have adverse 
effects if kept for too long and long-term diets which are aimed for a healthy lifestyle.  Every diet is based on the increased and 
decreased consumption of different macronutrients and therefore, each affects the body differently.  The Ketogenic Diet is a high fat 
consumption diet that is gaining credence from its success rate.  However, due to it being a relatively new diet fad, there are not too 
many who understand the long-term adverse effects of a high fat diet. 
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Introduction
We live in a world of instant gratification. Smart phones, 
smart cars and smart homes are the new social norm. 
Another idea of the now world we live in is takeout food. 
Instead of preparing meals, one can be picked up or even 
delivered to your home at minimal charge. This would 
seem to be useful for person who is too busy to cook but 
is leading to a major problem in western culture – obesi-
ty.  With obesity on the rise, many people are looking for 
newer ways to counter the effects of the influx of fatty, 
high sugar and unhealthy foods they are consuming. The 
most common and widely used method is a diet plan.  
The word diet is simply the amount of food or drink 
a person consumes.  When people speak about a diet 
though, they are referring to a special course of con-
trolled or restricted intake of food and or drink for a 
particular purpose. Magazines, websites, and health mo-
guls are promoting new diets and fads almost daily.  It has 
reached a point where weight loss has become a socie-
tal pressure leading people to come up with numerous 
‘quick fix’ diets to lose the ‘excess’ weight so as not to 
deviate from society.
Aside from body image concerns, there are many 
chronic illnesses that are related to obesity.  To name a 
few, hypertension, diabetes, joint pain, and cardiovascular 
diseases, such as an acute myocardial infarction, are all 
largely products of unhealthy chosen lifestyles and poor 
dietary habits. While there are certain diets that are great 
in preventing, or at least not promoting, various diseases 
they are mistakenly used by healthy individuals who are 
possibly harming themselves as they are unaware of the 
side effects.  
The aesthetics of being leaner and thinner have become 
the idol of, and completely overtaken, the views of almost 
every individual today.  It has become such an obsession 
that new diet plans are arising daily.  Some plans are more 
beneficial than others and some are just fads, but they are 
all developed on the same basis of energy expenditure.
To start with, the two biggest fat loss myths must be 
disproven.  First, calorie counting does not work.  For 
those who want nothing more than to hear that they can 
get lean and fit by only paying attention to what they eat 
and not how much, this idea is what they thrive on.  This 
is total fools play since how much you eat is significantly 
more important than what you eat.  For example, John 
Cisna, a science teacher, lost 60 pounds in six months 
eating food bought solely from McDonalds every day.  He 
wanted to burst the lie that people believe about food 
intake.  While his diet plan may not have been too nutri-
tious, it proved that you can lose weight by eating whatev-
er junk food you would like as long as you are minimizing 
your calorie intake (Peterson, 2015).  This kind of plan 
will give the wanted weight loss; however, such an eating 
regimen will slowly affect his visceral health if it is kept 
up. These types of fast foods are high in fat without many 
vitamins which can cause, amongst many other issues, 
high cholesterol levels and high blood pressure due to the 
buildup of plaque and therefore narrowing of the arteries. 
The proper way to diet is to have a plan that is both bal-
anced as well as nutritious.  A balanced plan is consuming 
the proper percentage of both macro and micronutrients. 
Nutritious foods are ones that are rich in those nutrients 
that are needed daily for an organism to uphold its prop-
er functions.  Food is the material we take into our bodies 
to nourish it with the (hopefully) proper nutrients and 
other substances it needs for energy, health, and growth. 
Macronutrients are the substances our bodies require in 
large amounts.  Namely protein, carbohydrates, and fats. 
There are also some minerals needed in relatively large 
quantities, but this paper will focus on fats, carbohydrates 
and protein as most diets pertain to altering the con-
sumption of one of such food groups.  
Secondly, it is important to understand the one most 
important thing about weight loss.  It comes down to 
energy balance which is the correlation between energy 
intake and energy expenditure (Lean, Astrup, & Roberts, 
2018).  Put in more than you take out and you will have 
an excess amount of energy meaning you will gain weight. 
Eat about as much as you burn daily, and your weight 
will stay the same.  Take in less energy than you use and 
there will be a deficit and you will lose weight.  This is 
not some wild un-based theory either.  According to the 
first law of thermodynamics, energy cannot be destroyed 
nor created, but can only change its form within a system. 
Our bodies absorb the food we eat and transform the 
stored energy into energy we can use.  Muscles convert 
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the stored energy for mechanical energy, digestive system 
for body fat (chemical energy) and our organs convert 
energy into thermal energy.   This is evidence how energy 
is never lost, but rather converted to the form each part 
of our body needs based on demand. 
The process of our body transforming the food we in-
take to usable energy is one of the purposes of energy 
expenditure.  Energy expenditure (EE) is the amount of 
energy that a body needs to carry out its physical and 
physiological functions and is measured in calories.  It is 
the combination of a basal metabolic rate (BMR) or stan-
dard metabolic rate (SMR) and their activity level.  Basal 
metabolic rate represents the minimum energy expendi-
ture for a resting and fasting animal at thermoneutrality 
(Nilsson & Nilsson, 2016).  This means BMR is the low-
est sustainable energetic (caloric) cost required to keep 
one’s body functioning at rest.  Activity level is movement 
that requires additional energy aside from one’s BMR. 
Activity level is not only pumping iron five days a week 
at the gym, it is also taking the stairs rather than the el-
evator during the day, mowing the lawn, changing a tire, 
or pushing a shopping cart. The more physical activity a 
person is involved in, also adds to a greater amount of 
energy a person expends and therefore the more s/he 
needs to consume.
Aside from physical activity there are other factors that 
play a role in determining a person’s BMR - gender, body 
mass index, age and yes, even genetics.  Due to these vari-
ous factors, nutritional requirements differ from person to 
person and are therefore evaluated based on kilogram of 
body weight and every person will alter the amount based 
on their energy exertion during both health and disease. 
It should come as no surprise then that consuming less 
energy than your body requires for a couple weeks or 
months would account for less energy in the body and 
therefore a leaner and leaner body type.  Since energy 
balance has been proven to be the basic regulation for 
weight loss and weight gain it is found at the baseline of 
every proper diet plan. 
In addition to dieting, it is both scientifically proven 
as well as seen in people’s success that exercise in syn-
chrony with a healthy diet plan is the most advantageous. 
Individuals who exercise along with being careful with 
what they eat will lose weight.  They expend more calo-
ries than they take in daily and the deficit results in a loss 
of body weight. The Cleveland Clinic agrees and explains 
why exercising without a diet plan is not too effective for 
weight loss (Team, W., 2018).  They state that in order 
to lose weight one of two options must be done; either 
one must burn more calories by working out than s/he 
consumes in one day or take in fewer calories alone than 
one’s body uses daily.  To summarize, putting one’s body 
into an energy deficit will cause weight loss and this is the 
basis for the majority of diet plans.  
The two main types of diets are long-term plans and 
short-term plans.  Long term diets aim to benefit a per-
son’s healthy well-being for the long haul.  The results 
may not be instantaneous, yet the programs are easier to 
follow.  These diets do not restrict a certain food group 
completely which prevents the process from becoming 
too arduous for someone who thinks that diets are re-
straining.  The overall objective is a healthy lifestyle.  
Alternatively, short term diets are the quick fixes. 
These diet plans usually see results within a week of fol-
lowing them.  Diets that fall under this category are ones 
where quick weight loss is desired for aesthetic looks or 
necessary in preventing larger health issues, like cardio-
vascular disease or diabetes.  These usually entail many 
restrictions which aside from making the dieter unwilling 
to stick with the plan, it makes them unhappy to comply 
with the rules.  
One severe version of a short-term diet is known as 
crash dieting.  These diets are severely low total calo-
rie plans and are sustainable for a couple weeks at most. 
They are mostly used by bodybuilders and other profes-
sions before a performance where by eating very mini-
mally, they can accentuate the appearance of their muscle 
hypertrophy.   The problem begins the week after the diet 
is over.  Many people find motivation to continue such 
a restricted diet in the promise of the prize.  The logic 
behind knowing the situation is temporary gives way to 
individuals being able to have greater self-control which 
is a staple in crash diets.  Additionally, in such a case not 
having an end goal also makes such diets extremely diffi-
cult and not very long lasting in general.   
While these diets may help people lose much more 
weight than they would on a gradual diet plan, they are 
worse for the person in the long run.  As an individual 
loses weight rapidly, their metabolism slows down. The 
metabolism lowers because the body tries to preserve 
its energy stores.  This helps the short-term diet process 
by decreasing the ‘hunger’ a person would feel due to the 
body’s adaptation to the caloric decrease.  However, after 
such a severe low-calorie diet is over and an individual 
loses thirty or more pounds, their metabolism does not 
rise back up right away.  At this point, the body requires 
fewer calories due to the decrease of energy metabo-
lized.   Adding much more calories to a metabolism that 
is designed to burn fewer amounts per day will result in 
increased weight and will likely leave the person worse 
off than where s/he started.  
A large example is shown in the weight loss program 
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The Biggest Loser, which is a 30-week weight loss tele-
vision program for bariatric adults.  In 2016 a study was 
done on six men and eight women who participated in 
the show to see if the weight they lost while on the show 
stayed.  Part of the ‘Biggest Loser Study’ found that the 
majority of the show’s contestants regained a significant 
amount of the weight they had lost within six years after 
exiting the show.  A few even ended up heavier than they 
had been before they started the competition (Fothergill 
et al. 2016).  It was as if their bodies were intensifying 
their effort to pull the contestants back to their original 
weight (Oshin, 2020). 
This phenomenon can happen to anyone, not just those 
on low-calories diets. For every kilogram of weight loss 
a person experiences, their metabolism slows down 
around twenty to thirty calories.  But while it is burning 
less, the body also wants to eat more – the appetite of 
someone losing weight increases, making the person want 
to consume about one hundred calories more than they 
were having before.  The process, known as adaptive ther-
mogenesis, serves the purpose of regulating an organism’s 
energy balance after changes in diet. 
The body has a certain amount of fat – a “set point” – 
that it is comfortable with from a survival standpoint and 
wants to maintain. When a person begins vigorous train-
ing combined with a restrictive diet, the body responds 
by thinking it is under threat. The training may increase 
the body’s muscle mass, but when the diet becomes too 
restrictive – which varies from person to person – leptin, 
the satiety hormone, begins to drop, somewhat like a 
starvation alarm.  Leptin manifests itself as hunger and 
you either don’t get as full from your meals, or you can’t 
go as long between meals without getting hungry.  
Nowadays, there are various lauded fad diets.  One 
of which is called the Ketogenic diet,  more commonly 
known as the keto diet. This diet is a short term diet 
based on two main goals.  The primary goal is to greatly 
reduce the number of carbohydrates consumed.  Without 
the  intake of carbohydrates, the body cannot synthesize 
glucose, it’s main energy source, and therefore, will need 
to resort to an alternate fuel.  Secondly, fat consumption 
needs to be increased in order to become the new pri-
mary source of energy.  
To reduce the intake of glucose one must consume 
fewer carbohydrates.  Carbohydrates are the primary 
source of energy production in the body.  When the 
body is deprived of carbohydrates due to reducing in-
take (to about less than 50g per day), insulin secretion 
is significantly reduced and the body enters a catabolic 
state.  Glycogen storage depletes which forces the body 
to go through certain metabolic changes.  Two metabolic 
processes that come into action when there is low car-
bohydrate availability in body tissues are gluconeogenesis 
and ketogenesis. 
Gluconeogenesis is when the body produces its own 
glucose.  This is primarily done in the liver using lactic acid, 
glycerol, and certain amino acids (alanine and glutamine). 
When glucose availability drops further, gluconeogenesis 
is not enough to keep up with the needs of the body and 
ketogenesis begins and provides the body with ketone 
bodies as an alternate source of energy in the form of 
ketone bodies. Ketone bodies synthesized in the body can 
be easily utilized for energy production by heart, muscle 
tissue, and the kidneys.  Even though the brain normally 
uses a large percent of the carbohydrate intake to sustain 
its function, it can learn to use ketone bodies as they are 
able to pass the blood brain barrier as well.  
The ketogenic diet consists of seventy percent fat, 
twenty five percent protein and five percent carbohy-
drates.  The mechanism by which the Ketogenic diet in-
duces weight loss is by minimizing carbohydrate intake, 
which reduces insulin production, and thereby decreases 
the amount of glucose stored as fat in cells.  Digested 
fat does not convert to glucose and thus does not acti-
vate insulin secretion.  The Keto diet emphasizes high fat 
consumption based on the physiological metabolism of 
fat, where it is lysed to energy instead of being stored in 
adipocytes.  Fat calories consumed are not stored.  For 
the body to replace the energy it lacks from glucose, due 
to low carbohydrate intake, the body turns to its current 
reservoir of fat storage, in addition to the fatty foods, 
which in turn facilitates weight loss.  
The basic ketone bodies that accumulate in the body 
during ketogenic diet,  namely  beta-hydroxybutyrate and 
acetone, are formed from the oxidation of fatty acids into 
acetoacetate. This metabolic state is referred to as “nu-
tritional ketosis” and as long as the body is deprived of 
glucose, this ketotic state will remain. 
Since ketone bodies are released only in small concen-
trations and don’t alter the blood’s pH, nutritional ketosis 
is quite safe.  The issue arises when ketones build up in 
the body mainly due to diabetes, especially if combined 
with a disease or severe starvation.  Accumulation of ke-
tone bodies dramatically lowers the pH (increase acidity) 
of the blood which leads to ketoacidosis and if left un-
treated can eventually cause severe dehydration, coma or 
death.  
Why are ketone bodies used as an efficient energy 
source in the body? Ketone bodies produce more ad-
enosine triphosphate (ATP) in comparison to glucose, 
and are therefore used as an efficient energy source to 
the body.  One hundred grams of acetoacetate generates 
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9400 grams of ATP, and 100 g of beta-hydroxybutyrate 
yields 10,500 grams of ATP; whereas, 100 grams of glu-
cose produces only 8,700 grams of ATP. This allows the 
body to maintain efficient fuel production even during a 
caloric deficit (Masood, et. al, 2020).
An increased fat presence in the gastrointestinal tract 
increases satiety by stimulating the secretion of orexigen-
ic hormones, an appetite stimulant, like GLP-1 and CCK. 
These hormones delay gastric emptying and decrease 
motility which allows food to pass through the system at 
a slower rate. This causes an individual to feel satiated for 
a longer period. This may also be the reason why many 
people on the ketogenic diet lose weight. Individuals on 
such a diet consume large amounts of fat which keeps 
them full in between meals.  Therefore, it prevents them 
from snacking throughout the day and eating excessive 
amounts of unnecessary calories. 
Over the past decade, nutrition science has produced 
robust evidence that high-carbohydrate diets contribute 
to obesity and chronic disease, and that very low-car-
bohydrate, ketogenic diets provide a healthy alternative. 
Since then, another study concluded that low-carbohy-
drate diets should be avoided just as much as high carb 
diets because they are both associated with higher over-
all mortality and shorter average lifespans (Bellemare & 
Finaret, 2018). 
Both high and low percentages of carbohydrate diets 
were associated with increased mortality, with minimal 
risk observed at fifty to fifty five percent carbohydrate 
intake. Low carbohydrate dietary patterns favoring ani-
mal-derived protein and fat sources, from sources such as 
lamb, beef, pork, and chicken, were associated with higher 
mortality, whereas those that favored plant-derived pro-
tein and fat intake, from sources such as vegetables, nuts, 
peanut butter, and whole-grain breads, were associated 
with lower mortality, suggesting that the source of food 
notably modifies the association between carbohydrate 
intake and mortality.
The ketogenic diet was originally developed to help 
children with epilepsy.  According to Greene,et al.(2003) 
“…ketones, unlike glucose, may be unable to deliver the 
immediate and large amount of energy necessary to initi-
ate or sustain seizure activity”.  In this way, seizures can be 
decreased as the glucose necessary to sustain such high 
brain activity is not available. Furthermore, seizures would 
subside or become less severe in times of fasting.  Fasting 
prevented seizure spikes.  Researchers further thought 
of what would happen if they were to find a diet with 
similar effects as if one fasted - ketone bodies.  Epileptics 
would be able to control their seizures somewhat possi-
bly and thereby some part of their life for longer periods 
of time.  This led to the high fat, low carb ketogenic diet 
and it worked because like fasting, ketone bodies were 
produced and not taking in excess sugar which also peaks 
the strength of seizures.  For certain people with epilepsy, 
the ketogenic diet should be followed, according to the 
guidelines of a certified professional, as the benefits may 
outweigh the disadvantages for individuals.  The diet reg-
imen may have a higher mortality rate but for them, they 
would rather be in better control of their lives.  
In addition to preventing seizures, the ketogenic diet is 
believed to be related to other long-term effects as well. 
Since it is a relatively new concept, there hasn’t been that 
much long-term time for research but an excess of fat in 
the body has many effects. Although this is the case the 
diet seems to be effective. A study on eighty three obese 
patients, with a body mass index greater than thirty five, 
who took part in a twenty four week ketogenic diet; re-
ported a significant decrease in the body weight, increase 
in high density lipoproteins, and decease of  low density 
lipoproteins (Dashti et al.(2004)  
People have become very interested in this diet due 
to its ability to reduce weight. However, people are not 
aware of the long-term effects this may have on their 
overall health.  An evidence-based case study reported 
that the ketogenic diet can increase the risk for cardio-
vascular disease by twenty six percent each year. This 
statement is backed up by the evidence they found about 
this diet in particular.  The ketogenic diet increases LDL, 
low density lipoprotein, levels because of the increased 
intake of saturated fat ( Dashti, et al. 2004).
LDL is a lipoprotein mainly made from cholesterol, 
which transports lipids from the liver to peripheral tissue 
for it to be stored or utilized as energy. Cells in the body 
have receptors that bind to LDL and engulf it via endo-
cytosis. The cholesterol esters in the LDL can be stored 
or hydrolyzed into cholesterol and fatty acids to be used 
for hormones, bile, or the cell membrane. LDL is known 
as the unwanted cholesterol in the blood because of its 
function. It is undesirable to have stored cholesterol (a 
form of fat) in the organs, tissues, and cells throughout 
the body.
The more fat you eat - and a ketogenic diet requires 
a lot of fat - the more low density lipoproteins are pro-
duced, but when receiving cells are saturated by choles-
terol (lipids) the residual low density lipoproteins remain 
in the bloodstream. This is dangerous as it can cause ath-
erosclerosis - plaque buildup in the arteries which can 
lead to various cardiovascular emergencies.   
Another negative side effect of high fat diets is Biliary 
Disease. Biliary disease is a condition that affects the bile 
duct whose purpose is to pass bile to the small intestine. 
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For example, Cholecystitis, the production of gallstones 
in the gallbladder, which can occur from an overconsump-
tion of fat or increased blood cholesterol. Gallstones can 
block the bile duct thereby prohibiting the passage of bile. 
This will prevent fat from being broken down, digested, 
and absorbed. In theory this may sound great because if 
fat is not absorbed it will pass through our digestive tract 
without increasing the calorie intake. This is true although 
it will cause fatty stool and anal leakage. 
An additional overwhelming issue that will be caused by 
Cholelithiasis (gallstones) is pancreatitis (inflammation of 
the pancreas). The reason why these two issues are con-
nected is because the bile duct from the gallbladder and 
the pancreatic duct merge before entering the intestine. 
Bile from the liver and enzymes from the pancreas both 
pass through this common  duct.  When gallstones are 
lodged in this area, the pancreas cannot release enzymes 
such as proteases, lipases and amylase into the intestine. 
When this happens, a process known as auto digestion 
begins to occur where proteases like trypsin and chymo-
trypsin begin to digest pancreatic tissue instead of being 
released to break down proteins taken in by the body. 
 Other negative side effects of the keto diet include 
edema, swelling catalyzed by fluid buildup, fat necrosis, a 
lump of dead or damaged tissue and pancreatic hemor-
rhage, bleeding in the pancreas.  Another issue that can 
arise from the keto diet is fatty liver, an increased build-
up of fat in the liver.  Non-alcoholic fatty liver disease 
(NAFLD) is asymptomatic and therefore, an individual will 
be unaware of this disease until the condition worsens. 
People on the keto diet consume such large quantities of 
fat that their livers overload.  This is especially dangerous 
if sustained, because their energy stores stem from fat 
consumed being lysed to ketones.  If the liver minimizes 
its bile secretion, less fat will be utilized for ketone bodies 
and thereby, drain the body’s energy stores.  This leads to 
fatigue, dizziness, lack of energy and motivation which in 
turn leads to the people being lax in their health and ex-
ercise - countering the reason they started the diet in the 
first place.  Only once  a fatty liver further manifests into 
hepatitis will these symptoms become prominent will the 
dieter seek medical attention.  
A positive side effect of the ketogenic diet also primes 
us to burn the excess fat that so many of us are carrying 
around our waists. Our glucose levels return to normal, 
we become less insulin resistant, we shed fat, and sig-
nificantly reduce our risk of developing chronic disease. 
Another significant benefit is the production of ketone 
bodies, now the subject of intense scientific investigation 
due to their many health-promoting properties including 
protection of the brain and nervous system, reduction of 
systemic inflammation, the root cause of cardiovascular 
disease, and anti-cancer effects.
Low carbohydrate diets, which restrict carbohydrate in 
favor of increased protein or fat intake, or both, are a pop-
ular weight-loss strategy.  However, the long-term effect of 
carbohydrate restriction on mortality is controversial and 
could depend on whether dietary carbohydrate is replaced 
by plant-based or animal-based fat and protein.  One wide-
ly followed long-term diet that has been proven to be very 
beneficial and effective is the Whole Food and Plant Based 
diet more commonly known as the vegan diet.  
In another study 15,428 adults aged forty five to sixty 
four were evaluated periodically through interviews 
where they filled out semi quantitative food frequency 
questionnaires.  Typical portion sizes were provided as 
reference so that they could estimate their intake of each 
food item consumed.   The results were adjusted for age, 
sex, race, total energy consumption, diabetes, cigarette 
smoking, physical activity, income level, and education. 
In conclusion, the low carbohydrate diets that substi-
tuted the carbohydrates for animal derived fat and pro-
tein sources, such as from lamb, pork, beef, and chicken 
were accompanied by higher mortality.  In comparison, 
the low carbohydrate diets that replaced carbohydrates 
with fat and protein from a plant base such as from vege-
tables, nuts and whole grain were associated with mortal-
ity.  This finding suggests that the source of protein and fat 
in one’s diet can change mortality showing that these two 
things are related. The optimal quantity of carbohydrates 
consumed in a diet should be between fifty to fifty five 
percent of total intake.  For this reason, less than fifty 
percent or more than fifty percent of carbohydrates con-
sumed seems to be ineffective (Seidelmann et al 2018). 
Long-term effects of a low carbohydrate diet with typ-
ically low plant and increased animal protein and fat con-
sumption have been hypothesized to stimulate inflamma-
tory pathways, biological ageing, and oxidative stress. On 
the other end of the spectrum, high carbohydrate diets, 
which are common in Asian and less economically advan-
taged nations, tend to be high in refined carbohydrates, 
such as white rice.  These types of diets might reflect poor 
food quality and confer a chronically high glycemic load 
that can lead to negative metabolic consequences. 
One diet plan based on this philosophy is the vegan 
diet.  A study was aimed clarifying  the association be-
tween vegetarian, vegan diets, risk factors for chronic 
diseases, risk of all-cause mortality, incidence, and mor-
tality from cardio-cerebrovascular diseases, total cancer 
and specific type of cancer (colorectal, breast, prostate 
and lung), through meta-analysis.  This comprehensive 
meta-analysis reported a significant protective effect of 
79
Effects of High Fat Diets
a vegetarian diet versus the incidence and/or mortality 
from ischemic heart disease (-25%) and incidence from 
total cancer (-8%).  A vegan diet conferred a significant 
reduced risk (-15%) of incidence from total cancer (Dinu, 
et. al., 2017).
In conclusion, finding a diet that suits an individual is 
not so simple. According to the International Society of 
Sports Nutrition (ISSN), there are two main positions 
in regard to diets.  The nature of the diet and the way it 
influences the body composition.  Each diet type has its 
own various sub classifications that fall under the main 
eating style.  Therefore, while diets are a good way to lose 
weight, there is a point where they can do more harm 
than good.  The keto diet is a great plan to stick with for 
a short while; however, consuming mostly fat every day, 
takes a toll on the body.  Although the ketogenic diet is 
popular there are many long term diets that are undoubt-
edly safer and healthier for the body.  
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